Institut für Experimentelle Genetik,

GSF-Forschungszentrum für Umwelt und Gesundheit, Neuherberg

Dr. von Haunersches Kinderspital

Functional Characterization of the Human Peroxins PEX3 and PEX19, Proteins Essential for Early Peroxisomal Membrane Biogenesis

Peter Uli Mayerhofer

Table of Contents

Abstract

Abstract

Peroxisomes are single-membrane-bound organelles present in virtually all eukaryotic cells. Their significance in human metabolism is illustrated by the existence of severe inherited diseases caused by the failure of peroxisomal biogenesis (peroxisomal biogenesis disorders; PBDs). Proteins required for peroxisomal assembly are termed "peroxins" and are encoded by at least 23 *PEX*-genes. In most cases, defects in *PEX* genes lead to a disruption of peroxisomal matrix protein import, whereas various peroxisomal membrane components are synthesized and accumulate in peroxisomal membrane remnants ("peroxisomal ghosts"). Since yeast mutants in *PEX3* and *PEX19* have been shown to lack peroxisomal ghosts, these peroxins were expected to be involved in the early stages of peroxisomal membrane synthesis. This work focused on the functional characterization of human PEX3 and PEX19 to gain insights into their role in human biology and disease. PEX19 was shown to interact with three peroxisomal ABC half-transporters (Adrenoleukodystrophy protein ALDP, Adrenoleukodystrophy-related protein ALDRP, and the 70 kDa peroxisomal membrane protein PMP70), confirming its role as a broad specific peroxisomal membrane-protein binding-protein. As a prerequisite for these protein-protein interaction assays, the human *ALDR* gene was characterized. Proteins encoded by two *PEX19* splice variants showed a considerable functional diversity as to peroxisomal membrane protein binding and with respect to induction of peroxisomal formation in *PEX19*-deficient human fibroblasts. Farnesylation of PEX19 was shown not to be essential for these functions. These data provide the first experimental evidence for specific biological functions of the different predicted domains of the PEX19 protein. In order to investigate the molecular details of peroxisomal assembly and to evaluate experimental treatment strategies for the peroxisomal biogenesis disorders, data useful for the future generation of a mouse model with targeted disruption of the *PEX3* gene were presented. The human *PEX3* gene was characterized with the goal to identify a yet unknown human *PEX3*-deficient phenotype. Two inactivating *PEX3* mutations were detected in two PBDs-patients exhibiting a severe and lethal Zellweger syndrome phenotype. They showed a total lack of morphologically recognizable peroxisomal membrane remnants in their fibroblasts. Expression of the wild type *PEX3* cDNA in the mutant cell lines restored peroxisomal biogenesis, establishing PEX3 as a key factor in early human peroxisome synthesis. Taken together, the combined data presented here provide evidence for the essential role of PEX3 and PEX19 in the initial steps of an alternative human peroxisome-formation pathway. In contrast to the theory that peroxisomes can arise exclusively by growth and division of preexisting peroxisomes, this alternative pathway does not require morphologically recognizable peroxisomal membranes.

Zusammenfassung

Zusammenfassung

Peroxisomen sind von einer einschichtigen Membran umgebene Zellorganellen, die nahezu in allen eukaryontischen Zellen vorkommen. Ihre Bedeutung im menschlichen Stoffwechsel wird durch eine Reihe schwerer genetischer Erkrankungen belegt, die durch Defekte der peroxisomalen Biogenese ausgelöst werden (Peroxisomale Biogenesedefekte, PBD). An der peroxisomalen Biogenese sind mindestens 23 Proteine (Peroxine) beteiligt, die durch *PEX*-Gene kodiert werden. Meistens wirkt sich der Defekt eines *PEX*-Gens in einem gestörten peroxisomalen Matrixprotein-Import aus, während peroxisomale Membrankomponenten normal synthetisiert werden und sich in leeren, residualen peroxisomalen Membranstrukturen („peroxisomal ghosts") ansammeln. Für *PEX3*-und *PEX19*-Hefemutanten konnte das Fehlen dieser „peroxisomal ghosts" gezeigt werden. Diese Beobachtung führten zu der Hypothese, dass beide Peroxine an der frühen peroxisomalen Membransynthese beteiligt sind. Das Ziel dieser Arbeit lag in der funktionellen Charakterisierung der humanen Peroxine PEX3 und PEX19, um neue Erkenntnisse über deren Bedeutung in der Humanbiologie und deren Beteiligung an genetischen Erkrankungen zu erlangen. Es konnte gezeigt werden, dass PEX19 mit drei peroxisomalen ABC-Halb-Transportern (Adrenoleukodystrophieprotein, ALDP; Adrenoleukodystrophie-related Protein, ALDRP; 70 kDa peroxisomalen Membranprotein, PMP70) interagiert. Somit wurde die Rolle von PEX19 als allgemeinspezifisches peroxisomales Membranprotein-Bindeprotein bestätigt. Als Vorarbeit für diese Protein-Protein Interaktionsversuche wurde das humane *ALDR*-Gen näher charakterisiert. Für Proteine, die von zwei *PEX19*-Splicevarianten kodiert werden, konnte ein funktioneller Unterschied hinsichtlich peroxisomaler Membranprotein-Interaktion und Einleitung der peroxisomalen Biogenese in *PEX19*-defizienten humanen Fibroblasten gezeigt werden. Es wurde widerlegt, dass die Farnesylierung von PEX19 essentiell für diese Funktionen ist. Dadurch ergibt sich der erste experimentelle Hinweis auf spezifische biologische Funktionen der unterschiedlichen vorhergesagten Domänen des PEX19-Proteins. Um die molekularen Details der peroxisomalen Biogenese zu untersuchen und um Behandlungsstrategien für die PBD zu entwickeln, wurden Vorarbeiten für die spätere Generierung eines *PEX3*-defizienten Mausmodells geleistet. Zum Zwecke der gezielten Suche nach Patienten mit einem *PEX3*-Defekt wurde das humane *PEX3*-Gen näher charakterisiert. Zwei inaktivierende *PEX3*-Mutationen konnten in zwei PBD-Patienten gefunden werden, welche einen schweren letalen Zellweger-Syndrom Phänotyp aufwiesen. Ihre Fibroblasten waren durch das Fehlen von morphologisch sichtbaren peroxisomalen Membranstrukturen charakterisiert. Da nach Expression der wild-typ *PEX3*-cDNA in den mutierten Zellen die peroxisomale Biogenese wieder hergestellt werden konnte, wurde *PEX3* als neues humanes Krankheitsgen mit einer Schlüsselrolle in der frühen peroxisomalen Biogenese etabliert. Zusammenfassend belegen die hier präsentierten Daten die fundamentale Bedeutung von PEX3 und PEX19 in den ersten Schritten eines alternativen Weges der humanen peroxisomalen Biogenese. Im Vergleich zu dem Modell des „Wachstums und Teilens" von Peroxisomen benötigt dieser alternative Syntheseweg keine morphologisch detektierbaren peroxisomalen Membranen.

CHAPTER I:

Introduction

1 Peroxisomes: Morphology and Metabolic Functions

Membrane biogenesis and its regulation is one of the mayor foci in modern molecular cell biology (Schatz & Dobberstein, 1996). Despite their simple architecture, peroxisomes represent a diverse group of organelles, with varied metabolic activities (van den Bosch *et al.*, 1992). Like the Golgi apparatus, they actually constitute a dynamic organelle population consisting of many structurally and functionally distinct compartments that differ in their import competency for various proteins (Titorenko & Rachubinski, 2001b). Therefore, the processes of peroxisomal membrane assembly and maintenance have begun to attract the interest of a broad range of scientists. In addition to the protein import into organelles such as the ER, Golgi apparatus, mitochondria, nucleus and chloroplasts, this would complete the knowledge about highly specific intracellular trafficking systems in eukaryotes that mediate the biosynthesis of the different intracellular compartments.

Figure I-1: Peroxisome morphology. A, Electron microscopy of a yeast (*Yarrowia lipolytica*) cell. B, Indirect immunofluorescence microscopy of a single human fibroblast stained with fluorescein-labeled antibodies specific for the peroxisomal matrix enzyme catalase. Note the peroxisomal punctate pattern indicating the presence of hundreds of discrete peroxisomes. C, Electron microscopy of human liver. D, Electron microscopy of human liver stained cytochemically for catalase. Not the cluster of diaminobenzidine-positive peroxisomes. ER: endoplasmic reticulum; L: lipid droplet; M: mitochondria; N: nucleus; P: peroxisome. A from (Titorenko & Rachubinski, 2001a); C and D from (Lazarow & Fujiki, 1985).

Peroxisomes, the last of the major subcellular organelles to be discovered, are present in virtually all eukaryotic cells. In a morphological study, they were introduced by Rhodin (1954) as small spherical oval bodies in the proximal convoluted tubular epithelium of the mouse kidney (Rhodin, 1954). Because of the lack of functional identity, Rhodin named them microbodies. The biochemical characterization of peroxisomes and their recognition as distinct organelle was established in the 1960's: De Duve and Baudhuin observed that catalase, urate oxidase and d-amino acid oxidase were associated with particles different from lysosomes, microsomes, and mitochondria (De Duve & Baudhuin, 1966). The term 'peroxisome' was introduced by de Duve and Baudhuin because these organelles contain at least one hydrogen-peroxide-producing oxidase and a catalase to decompose the hydrogen peroxide (De Duve & Baudhuin, 1966). Breidenbach and Beevers named the corresponding organelle in plants glyoxysomes because they contained five enzymes of the glyoxylate cycle (Breidenbach & Beevers, 1967).

Peroxisomes have a relatively simple morphology (Fig. I-1): They are small spherical organelles, ranging in diameter from 0.3 to 1.5 µm, delimited by a single unit membrane, containing a electron-dense matrix and occasionally a granular or crystalline core. Their abundance ranges from less than a hundred to more than a thousand peroxisomes per cell.

Peroxisomes show remarkable metabolic diversity (Tab. I-1). Their size, number, protein composition and biochemical function vary depending on the organism, cell type, and/or environmental condition (Geraghty *et al*., 1999; Subramani, 1993; Wanders & Tager, 1998). Most of the enzymes that catalyze these peroxisomal reactions are found within the organelle matrix (lumen). In human, the granular matrix contains more than 50 matrix enzymes that participate in a wide variety of metabolic pathways including the β-oxidation of certain fatty acids and biosynthesis of ether phospholipids, cholesterol, bile acids, and polyunsaturated fatty acids.

Table I-1: Metabolic functions of peroxisomes

	Yeast	Fungi	Plants	Mammals	Humans
Bio-synthesis	• lysine	• penicillin		• ether phospholipids • cholesterol • bile acids • polyunsaturated fatty acids	• ether phospholipids • cholesterol • bile acids • polyunsaturated fatty acids
Degradation	**• decomposition of hydrogen peroxide** • glyoxylate cycle • amino acids • methanol • ß-oxidation of fatty acids	**• decomposition of hydrogen peroxide** • glyoxylate cycle • ß-oxidation of fatty acids	**• decomposition of hydrogen peroxide** • glyoxylat cycle • purines • some reactions of photorespiration • ß-oxidation of fatty acids	**• decomposition of hydrogen peroxide** • amino acids • purines • prostaglandin • polyamines • α-oxidation of fatty acids • ß-oxidation of very long-chain fatty acids	**• decomposition of hydrogen peroxide** • amino acids • purines • α-oxidation of fatty acids • ß-oxidation of very long-chain fatty acids

2 Peroxisomal Diseases

The importance of peroxisomes in mammalian metabolism is illustrated by the existence of severe inherited metabolic diseases caused by peroxisomal malfunction. Single peroxisomal enzyme disorders result from a deficiency in a single peroxisomal enzyme that is not involved in the biogenesis of the organelle. Therefore, one single peroxisomal metabolic pathway is affected whereas the peroxisomes of the patients are of normal number and morphology. Table I-2 lists the single peroxisomal enzyme deficiencies identified so far. On the other hand, disorders associated with peroxisomal assembly are termed "Peroxisomal Biogenesis Disorders" (PBDs). These disorders affect several metabolic pathways of the peroxisome, as they result from a deficiency in the biogenesis of the whole organelle.

Table I-2: Single peroxisomal enzyme deficiencies[a]

Peroxisomal function involved	Disorder	Phenotype	Deficient enzyme/protein identified	Genetic basis resolved
Fatty acid β-oxidation	X-ALD	X-ALD	ALDP	Yes
	Acyl-CoA oxidase deficiency	NALD-like	Acyl-CoA oxidase	Yes
	D-Bifunctional protein deficiency	ZS/NALD-like	D-Bifunctional protein	Yes
	Thiolase deficiency	ZS-like	Peroxisomal thiolase 1	No
	Branched-chain acyl-CoA oxidase deficiency	No patients identified		
	L-Bifunctional protein deficiency	Not existing any longer*		
	Branched-chain peroxisomal thiolase deficiency	No patients identified		
	Racemase-deficiency	Late-onset neuropathy	Racemase	Yes
Etherphospholipid biosynthesis	DHAPAT-deficiency	(Rhizomelic) chondrodysplasia punctata	Yes	Yes
	Alkyl-DHAP synthase deficiency	(Rhizomelic) chondrodysplasia punctata	Yes	Yes
Fatty acid α-oxidation	Phytanoyl-CoA hydroxylase deficiency	Refsum disease	Yes	Yes
Isoprenoid biosynthesis	Mevalonate kinase (MK) deficiency	1. Classical MK-deficiency 2. Hyper IgD/periodic fever syndrome	Yes	Yes
Pipecolic acid degradation	Isolated hyperpipecolic acidaemia	Variable (see text)	No	No
Glutaryl-CoA metabolism	Glutaryl-CoA oxidase deficiency	Glutaric aciduria type 3	Yes	No
Hydrogen peroxide metabolism	Catalase deficiency	Acatalasaemia	Yes	Yes
Glyoxylate detoxification	Alanine:glyoxylate aminotransferase deficiency	Hyperoxaluria type 1	Yes	Yes

*All patients described with presumed L-bifunctional protein deficiency have now been found to be deficient in D-bifunctional protein due to mutations in the D-bifunctional protein gene (see text).

[a] from (Wanders et al., 2001)

2.1 X-Linked Adrenoleukodystrophy: A Peroxisomal Single Enzyme deficiency

X-Linked Adrenoleukodystrophy (X-ALD; OMIM No. 300100) is the most common inherited peroxisomal disorder characterized by the abnormal accumulation of saturated very long chain fatty acids (VLCFAs; ≥C22:0) predominantly in myelin, adrenal cortex, and testis (Moser *et al*., 1995b). The biochemical defect is localized to the level of lignoceroyl-CoA synthesis, a step in the peroxisomal β–oxidation of very long chain fatty acids. The clinical manifestations of X-ALD are highly variable. In the case of the most frequent and severe childhood cerebral form, patients seem unaffected until the age of five to ten years, when there is onset of adrenal insufficiency and progressive neurological dysfunction (Moser *et al*., 1995b). After onset of symptoms the course is rapidly and progressive, leading to an apparently vegetative state within two to four years and to death at varying intervals thereafter (Gärtner *et al*., 1998c). Further phenotypes are ranging from the adolescent and adult onset cerebral form, the Adrenomyeloneuropathy affecting primarily the spinal cord, the Addison only form with isolated adrenal insufficiency, as well as asymptomatic forms. Because the various phenotypes occur within the same kindred, modifying genes and/or environmental factors might contribute to this phenomenon.

The Adrenoleukodystrophy gene (*ALD*), mutated in X-ALD, was identified by positional cloning (Mosser *et al*., 1993) and belongs to the family of ATP-binding cassette (ABC) transporters (Contreras *et al*., 1994; Kobayashi *et al*., 1994; Mosser *et al*., 1994) capable of transporting a wide variety of ligands across biological membranes. The ALD protein (ALDP, synonym: ABCD1), located within the peroxisomal membrane, is an ABC half-transporter composed of one hydrophobic transmembrane domain (TMD) and one hydrophilic nucleotide binding fold (Fig. I-2A). Three other ABC half-transporters have been located within the peroxisomal membrane: The Adrenoleukodystrophy-related protein (ALDRP, synonym: ABCD2) (Holzinger *et al*., 1997b; Lombard-Platet *et al*., 1996), the 70 kDa peroxisomal membrane protein (PMP70, synonym: ABCD3) (Kamijo *et al*., 1990) and the 69 kDa peroxisomal membrane protein (PMP69, synonym: ABCD4) (Holzinger *et al*., 1997a; Shani *et al*., 1997). ABC half-transporters are expected to act as dimers to form functional units. Recently, homo- as well as heterodimerization has been reported to occur between the carboxy-terminal halves of ALDP, ALDRP and PMP70 (Liu *et al*., 1999a). *ALDR-* or *PMP70*-cDNA, if transfected in fibroblast of a patient suffering from X-ALD, have been shown to correct the defect of β–oxidation indicating a functional redundancy of peroxisomal

ABC half-transporters (Braiterman *et al.*, 1998; Kemp *et al.*, 1998). Because ALDRP is the closest homologue of ALDP (Fig. I-2B), it might be a candidate for being a modifier gene in X-ALD, accounting for the heterogeneity of clinical phenotypes.

Figure I-2: Peroxisomal ABC half-transporters. A, Scheme of an ABC half-transporter. Transmembrane segments are shown as black boxes, the nucleotide binding fold as gray oval. B, Evolutionary relationship among human Adrenoleukodystrophy protein and its homologues. The picture was adapted from (Smith *et al.*, 1999). ALDP: Adrenoleukodystrophy protein; ALDRP: Adrenoleukodystrophy-related protein; PMP70: 70 kDa peroxisomal membrane protein; PMP69: 69 kDa peroxisomal membrane protein; PXA1/2: *Saccharomyces cerevisiae* peroxisomal ABC-transporter 1/2 Hs: Homo sapiens; Rn: *Rattus norvegicus*; Mm: *Mus musculus*; Ce: *Caenorhaditis elegans*; Sc: *Saccharomyces cerevisiae*.

2.2 Peroxisomal Biogenesis Disorders

The most dramatic loss of peroxisome function is observed in the peroxisomal biogenesis disorders (PBDs). Defective biogenesis of the peroxisome leads to complex developmental and metabolic phenotypes that can be organized into two clinical spectra: (i) The Cerebro-hepato-renal syndrome spectrum with Zellweger syndrome (ZS) as the most severe example and neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) as milder variants. (ii) The second spectrum is distinctive with classical rhizomelic chondrodysplasia punctata (RCDP) as its exemplar (Gould *et al*., 2001). The PBDs are inherited in an autosomal recessive manner and, in aggregate, occur in approximately 1/50000 live births (Gould *et al*., 2001).

Zellweger syndrome is characterized by an array of neural, hepatic and renal defects, hence its original designation as cerebro-hepto-renal syndrome. Individuals with ZS exhibit severe neurological dysfunction and rarely survive their first year (Gould & Valle, 2000). NALD patients display similar but less severe phenotypes then those of ZS patients and can survive up to a decade. IRD patients are even more mildly affected, with some surviving up to their third decade (Moser *et al*., 1995a). Virtually all Zellweger spectrum patients are defective in both the PTS1 and PTS2 matrix protein import (Chapter I-3.1). Therefore, the Zellweger spectrum is generally associated with severe, moderate, or mild defects in virtually all peroxisomal functions (Gould *et al*., 2001). RCDP, by contrast, is characterized by a more specific clinical and metabolic phenotype. The typical clinical features include proximal shortening of the limbs (rhizomelia), punctate epiphyseal calcifications, cataracts, and severe developmental delay. At the metabolic level, RCDP patients have deficiencies in just two metabolic pathways: Plasmalogen biosynthesis and branched fatty acid oxidation, due to an isolated PTS2-specific protein import defect (Chapter I-3.1) (Gould *et al*., 2001).

In somatic cell fusion experiments, fibroblasts from patients with peroxisomal biogenesis disorders have been shown to segregate into at least 12 complementation groups (CGs) (Moser, 1999; Shimozawa *et al*., 1998). These groups are listed in Table I-3, but investigators in the United States, Japan, and the Netherlands have utilized different numbering systems. The existence of 12 CGs suggests strongly that PBDs phenotypes can be caused by at least 12 distinct genetic defects (Moser, 1999). Mutations in *PEX*-genes, encoding peroxisomal assembly proteins ("peroxins"), are known to be the molecular cause of the phenotypes

represented by different CGs. At the beginning of this thesis, the molecular defects in 7 of the 12 CGs had been identified. Now, gene identification strategies for the PBDs have determined the molecular basis of disease in all known PBD-CGs other then CG-A (Gould & Valle, 2000). The molecular and biochemical evidence that CG-G is associated with mutations in human *PEX3* will be shown in appendix 6 of this thesis.

Table I-3: Peroxisomal Biogenesis Disorders Complementation Groups

Complementation group[a]			Gene[b]	Phenotypes[c]	%[d]	References
KKI	Jap	Ams				
1	E	2	*PEX1*	ZS, NALD, IRD	57%	(Portsteffen *et al*., 1997) (Reuber *et al*., 1997)
2		4	PEX5	ZS, NALD, IRD	1%	(Dodt *et al*., 1995)
3			PEX12	ZS, NALD, IRD	4%	(Chang *et al*., 1997)
4, 6	C	3	PEX6	ZS, NALD	9%	(Yahraus *et al*., 1996) (Fukuda *et al*., 1996)
7,5	B		PEX10	ZS, NALD	2%	(Warren *et al*., 1998) (Okumoto *et al*., 1998)
8	A	7	?	ZS, NALD, IRD	4%	
9	D		PEX16	ZS	<1%	(Honsho *et al*., 1998) (South & Gould, 1999)
10	F	5	PEX2	ZS, IRD	3%	(Shimozawa *et al*., 1992)
11	R	1	PEX7	RCDP	17%	(Braverman *et al*., 1997) (Motley *et al*., 1997) (Purdue *et al*., 1997)
12	**G**		*PEX3[c]*	**ZS**	**1%**	(South *et al*., 2000) (Muntau *et al*., 2000a)
13	H		PEX13	ZS, NALD	1%	(Shimozawa *et al*., 1999) (Liu *et al*., 1999b)
14	J		PEX19	ZS	<1%	(Matsuzono *et al*., 1999)

[a]Nomenclature: KKI: Kennedy Krieger Institute, USA; Jap: Gifu University, Japan; Ams: Amsterdam
[b]During preparation of this thesis, the molecular defects in CG-D (PEX16), CG-G (PEX3), CG-H (PEX13), and CG-J (PEX19) were discovered
[c]The molecular and biochemical evidence that **CG-G** is associated with mutations in human *PEX3* is shown in appendix 6 of this thesis
[d]Phenotypes in each CG are from (Gould *et al*., 2001)
[e]Proportion of the PBD patients are from (Gould *et al*., 2001)

Most of the Zellweger spectrum patients do synthesize peroxisomal membranes and import peroxisomal membrane proteins normally. By contrast, a few ZS patients lack detectable peroxisomal membranes. This might due to defects in the synthesis of peroxisomal membranes, or in the targeting of peroxisomal membrane proteins to the peroxisome, or in the integration of the membrane proteins into the bilayer of the organelle, or all with a secondary deficiency of peroxisomal matrix enzymes. The molecular cause of defective peroxisomal membrane biogenesis in two patients displaying a severe ZS-phenotype will be described in appendix 6.

3 The Peroxisomal Biogenesis

Figure I-3: Scheme of peroxisomal biogenesis. The assembly of peroxisomes includes the synthesis of peroxisomal proteins on free cytosolic polyribosomes, the generation of the peroxisomal membrane, the targeting and integration of peroxisomal membrane proteins into this membrane, and the translocation of peroxisomal matrix enzymes across the bilayer into the lumen of the peroxisome.

Peroxisomes do not contain DNA or an independent protein synthesis machinery. Accordingly, peroxisomal proteins are encoded by nuclear genes, synthesized on free cytosolic polyribosomes and imported post-translationally (Lazarow & Fujiki, 1985). The assembly and maintenance of peroxisomes is complex and involves several interrelated processes (Fig. I-3). These include the generation of the peroxisomal membrane, the recognition of proteins destined for this particular organelle, the targeting and insertion of peroxisomal membrane proteins into this membrane, and the transport of peroxisomal matrix proteins to and across this same bilayer. There is a remarkable degree of homology between different species in respect to the factors involved in peroxisome biogenesis, and analysis of various model organisms has revealed general rules governing peroxisomal assembly: First, all known membrane and matrix proteins are targeted to the peroxisome post-translationally. Second, the peroxisomal import machineries and targeting signals for membrane and matrix proteins are distinct. Third, the peroxisomal import of membrane and matrix proteins is mediated by their receptors, either cytosolic or membrane-associated, that interact with the peroxisomal targeting signals of their cargo proteins. Last, both folded, oligomeric and

unfolded, monomeric polypeptides are imported into the peroxisomal matrix (Titorenko & Rachubinski, 2001a). On the other hand, in addition to these general rules, there are some organism-specific differences in the peroxisomal protein import (Tab. I-4).

Table I-4: Common features and differences in peroxisomal protein import[a]

Feature	Yeasts				Nematode	Plants	Mammals	Humans
	S.c	P.p	H.p	Y.l				
Membrane proteins								
• Are targeted to peroxisomes post-translationally.	+	+	+	+	?	+	+	+
• Many are sorted to peroxisomes directly from the cytosol by the peroxisomal membrane targeting signal 1 (mPTS1).	+	+	+	+	?	+	+	+
• Some are sorted to peroxisomes indirectly, through the endoplasmic reticulum, by the peroxisomal membrane targeting signal 2 (mPTS2).	+	?	+	+	?	+	+	?
• Many are delivered to peroxisomes by a cytosolic receptor that interacts with the mPTS1.	+	–	?	–	?	?	?	+
• Many are assembled in the peroxisomal membrane by a chaperone that does not interact with the mPTS1.	?	+	?	?	?	?	?	?
Matrix proteins								
• Are targeted to peroxisomes post-translationally.	+	+	+	+	+	+	+	+
• Many are sorted to peroxisomes by the carboxy-terminal peroxisomal targeting signal 1 (PTS1).	+	+	+	+	+	+	+	+
• Some are sorted to peroxisomes by the amino-terminal peroxisomal targeting signal 2 (PTS2).	+	+	+	+	–	+	+	+
• PTS1- and PTS2-containing proteins are delivered to peroxisomes by cytosolic* receptors.	+	+	+	–	?	+	+	+
• PTS1 and PTS2 receptors are peroxisome-associated proteins* that interact with the PTSs.	+	+	–	+	?	–	–	–
• PTS2-containing proteins are delivered to peroxisomes by a cytosolic chaperone that does not interact with the PTS2.	–	–	–	+	–	?	–	–
• Some are imported as folded, oligomeric proteins.	+	?	?	+	?	+	+	+
• Some are imported as unfolded polypeptides.	?	+	+	?	?	+	?	+

*Contradictory reports exist on the subcellular localization of the PTS1 receptor in *Pichia pastoris* and of the PTS2 receptor in *Saccharomyces cerevisiae*. S.c., *Saccharomyces cerevisiae*; P.p., *Pichia pastoris*; H.p., *Hansenula polymorpha*; Y.l., *Yarrowia lipolytica*.

[a] from (Titorenko & Rachubinski, 2001a)

The proteins that are required for peroxisomal biogenesis are termed 'peroxins' and are encoded by *PEX* genes. Yeasts have emerged as convenient and powerful model organisms for the study of peroxisome biogenesis, therefore *PEX* genes have first been identified by genetic analysis of peroxisome-deficient mutants of yeast (Erdmann *et al*., 1989). While at least 23 peroxins (Tab. I-5) have been reported to be essential for peroxisomal biogenesis in yeast, the exact functions and interactions of only a limited number of these proteins have been determined so far. Human *PEX* genes have been identified by genetic phenotyp-complementation assays of Chinese hamster ovary cell mutants and by searching human expressed sequence tag databases using yeast *PEX* gene sequences (Tateishi *et al*., 1997). To date, 13 human orthologs of the 23 yeast *PEX* genes have been identified, and 11 human peroxins have been shown to complement the deficiencies of peroxisomal assembly in cells of PBD patients (Chapter I.2.2).

Table I-5: Features and functions of peroxins[a]

Peroxin	Subcell. location[b]	Human ortholog	Peroxin Interactions[c]	Features[d]	Proposed function[e]
PEX1	C/M/V	+	6	AAA ATPase	Matrix protein import, vesicle fusion
PEX2	M	+		Zn RING	Matrix protein import
PEX3	M	+	19		Membrane biogenesis; PMP import
PEX4	M		22	Ubc2p, binds Ub	PEX18 / PEX21 turnover PEX5 recycling, quality control
PEX5	C/P	+	7, 8, 12-14	TPR domains	PTS1 receptor
PEX6	C/M/V	+	1	AAA ATPase	Matrix import, vesicle fusion
PEX7	C/P	+	5, 13, 14, 18, 21	WD repeats	PTS2 receptor
PEX8	M		5, 20		Matrix protein import
PEX9	M				Matrix protein import
PEX10	M	+	12	Zn RING	Translocation machinery
PEX11	M	+		Two human isoforms	Proliferation, MCFA oxidation
PEX12	M	+	5, 10	Zn RING	Translocation machinery
PEX13	M	+	5, 7, 14	SH3 domain	Docking of receptors
PEX14	M	+	5, 7, 13, 14, 17	Phosphorylated	Docking of receptors
PEX15	M			Phosphorylated	Matrix protein import
PEX16	M	+			Membrane biogenesis, PMP import,
PEX17	M		14		Docking complex, PMP import
PEX18	C/P		7		PEX7 targeting / cycling
PEX19	C/P	+	Many PMPs	Can be farnesylated	PMP receptor or chaperone
PEX20	C/P		8		Thiolase dimerization / import
PEX21	C/P		7		PEX7 targeting / cycling
PEX22	M		4		PEX4 membrane anchoring matrix protein import
PEX23	M				Matrix protein import

[a]Table was adapted from (Purdue & Lazarow, 2001) and (Titorenko & Rachubinski, 2001a).
[b]C: cytosol; M: peroxisomal membrane; P: peroxisome; V: vesicle. Multiple localization indicates either a bimodal distribution (PEX5, PEX7, PEX18, PEX19, PEX20, PEX21) or species differences (PEX1 and PEX6). Peripheral PMPs: PEX8 is on the inner face of the membrane, whereas PEX1, PEX6 (when found in peroxisomes), and PEX4 are found on the cystolic face. Most of the other membrane proteins are integral PMPs with domains exposed on the cystolic face.
[c]Peroxin interaction may be stable (e.g. the docking complex) or transient (e.g. receptors). PMPs: peroxisomal membrane proteins
[d]SH3: src homology domain 3; TPR: tetratricopeptide repeat; Ub: ubiquitin.
[e]MCFA: medium chain fatty acids; PMPs: peroxisomal membrane proteins; PTS: peroxisomal targeting sequence.

3.1 Targeting and Import of Matrix Enzymes

Most of the identified peroxins are involved in the import of the soluble peroxisomal matrix enzymes from the cytosol into the peroxisomal lumen. The number of proteins involved in this process is far exceeding the number of proteins required by other translocation systems with the exception of nucleocytoplasmic transport (Smith & Schnell, 2001). Peroxisomal matrix proteins are synthesized with one of two types of intrinsic peroxisomal targeting signals (PTSs), that direct import into the organelle. Following synthesis in the cytoplasm, the PTS-containing proteins (ligands) are recognized and bound by specific soluble receptors. The receptor-ligand complex is then transported to the peroxisomal surface, where it docks via membrane associated docking factors. After translocation of the ligand into the peroxisomal matrix and dissociation of the receptor-ligand complex, the PTS receptor must be recycled back to the cytoplasm, where it can initiate another round of matrix protein import. All these steps are summarized in Fig. I-4.

Figure I-4: Model for peroxisomal matrix protein import. PEX5 and PEX7 act as receptors for newly synthesized PTS1- and PTS2-containing peroxisomal matrix proteins (ligands), respectively. The receptor-ligand complex is then transported to the peroxisome surface, where it interacts with docking factors. PEX2, PEX10, and PEX12 act in matrix protein import downstream of docking, possibly in translocation. In the "extended shuttle model", the receptors enter the peroxisomes as part of their cycles. PEX1 and PEX6 interact with one another upstream of PEX4 and PEX22 in the terminal steps (receptor recycling) of matrix protein import.

Peroxisomal matrix protein targeting signals and their receptors

There are two well-characterized classes of PTSs, known as PTS1 and PTS2. The majority of matrix enzymes are targeted via the PTS1 pathway. Previous studies on this targeting sequence characterized it as a C-terminal tripeptide with the consensus (S/A/C)-(K/R/H)-L (Gould *et al*., 1989). PTS1 signals interact directly with their receptor PEX5, which is absolutely required for their targeting to peroxisomes. PEX5 is one to the more intensively investigated and better understood of the peroxins. Originally identified as the PTS1 receptor in the yeast *Pichia pastoris*, (McCollum *et al*., 1993), it has been cloned from numerous species including mammals, yeast, invertebrates, plants, and protozoan parasites (Purdue & Lazarow, 2001). All these PEX5 orthologs share a region comprised of six to seven tetratricopeptide repeats (TPRs) within the C-terminal part of the protein, which is essential for PTS1 import and which interacts with the PTS1 signal (Brocard *et al*., 1994; Dodt *et al*., 1995; Fransen *et al*., 1995; Gatto *et al*., 2000; Terlecky *et al*., 1995). PTS2 consists of a nine residue signal with a broad consensus sequence of (R/K)-(L/V/I)-x5-(H/Q)-(L/A/F), located internally or near the N-terminus. It directs the import of a small number of proteins via the soluble PEX7 receptor (Marzioch *et al*., 1994). In addition to the well characterized PTS1 and PTS2 pathways, there might exist a third, as yet uncharacterized and possibly heterogeneous class of PTS. For example the peroxisomal *Saccharomyces cerevisiae* acyl-coenzyme A-oxidase, which lacks both PTS1 and PTS2, might be imported by a distinct machinery that is independent of both the PTS1 and PTS2 receptors (Zhang *et al*., 1993).

In mammalians, two isoforms of the PTS1 receptor, the short isoform (PEX5S) and the long isoform (PEX5L) have been reported (Braverman *et al*., 1998; Otera *et al*., 1998). PEX5S interacts in the cytosol with PTS1 and is required for peroxisomal import of PTS1-targeted proteins only. The second isoform, PEX5L, forms a cytosolic complex with the PTS2-receptor PEX7 and is essential for peroxisomal import of both PTS1 and PTS2 proteins (Braverman *et al*., 1998; Matsumura *et al*., 2000; Otera *et al*., 2000; Otera *et al*., 1998). In contrast in yeast, only one form of the PTS1 receptor PEX5 exists. Unlike PEX7-mediated import of PTS2-containing peroxisomal matrix proteins in mammalian cells, this process in yeast does not require PEX5 (Hettema *et al*., 1999; McCollum *et al*., 1993).

Peroxisomal docking

After ligand-binding, the ligand-receptor complexes dock to the cytosolic surface of the peroxisomal membrane to initiate the cascade of peroxins-mediated events that leads to the entrance of the ligand into the peroxisomal matrix and recycling of the receptors to the cytosol. Despite the overall similarity of this process in different organism, there are some mechanistic differences between higher and lower eukaryotes.

In mammalians, the initial docking site for both the PTS1 and the PTS2 complexes on the cytosolic surface of the peroxisomal membrane is PEX14 (Fransen *et al*., 1998; Otera *et al*., 2000). After their interaction with PEX14, the PTS1 and PTS2 receptors, together with their ligands, are transferred to other components of the import machinery, including PEX10, PEX12, and PEX13, which directly interact with PEX5L and PEX5S (Chang *et al*., 1999a; Otera *et al*., 2000). The peroxins PEX2, PEX10 and PEX12, all known to be members of the RING finger superfamily, might be involved in the translocation of the ligands, either alone or together with their receptors, across the membrane into the peroxisomal matrix (Chang *et al*., 1999a; Otera *et al*., 2000).

In yeast, a putative docking complex for both PTS1 and PTS2 pathways consists of three membrane-associated peroxins: PEX13, PEX14 and PEX17 (Girzalsky *et al*., 1999), (Elgersma *et al*., 1996; Huhse *et al*., 1998; Urquhart *et al*., 2000). These peroxins might also be part of, or functionally cooperate with, a translocation machinery for PTS1-containing proteins. Further steps in the import of peroxisomal matrix proteins involve the transfer of PEX5 and PEX7, either alone or together with their ligands, from the docking complex to PEX2, PEX10 and PEX12 (Collins *et al*., 2000).

Translocation across the peroxisomal membrane

It is well established that only unfolded, monomeric proteins can cross the ER and mitochondrial membranes, and folding and oligomerization of these proteins occur only within these organelles. By contrast, completely folded and oligomeric proteins can be imported into the matrix of the peroxisome (Glover *et al*., 1994; Walton *et al*., 1995; Walton *et al*., 1992). Furthermore, a key discussion in the recent literature concerns whether the PTS-receptors enter the peroxisomal lumen as part of their cycles. This "extended shuttle model", as proposed for the PTS1-receptor PEX5, predicts that after docking at the peroxisomal membrane, PEX5 remains bound to its substrate and is translocated into the matrix along with its ligand (Dammai & Subramani, 2001; Smith & Schnell, 2001). A challenge for the future

will be to define the mechanism by which this folded and oligomeric proteins translocate across the peroxisomal membrane. The role of the putative translocases PEX2, PEX10 and PEX12 and of chaperones like Hsp40 and Hsp70 in this process needs to be clarified. Different models for the transport of oligomeric proteins across the peroxisomal membrane have been proposed. One possibility is that the translocon assembles at the site of translocation in response to the docking of the receptor-ligand-complex. This would allow the formation of protein-conducting channels of a variety of sizes in response to the size of the transport substrate. Disassembly of the translocon immediately following membrane translocation would minimize the free diffusion of molecules across the channel, thereby maintaining the critical permeability of the organelle (Smith & Schnell, 2001). Other models involve vesicle transport via a system resembling modified endocytosis of the peroxisomal membrane (McNew & Goodman, 1994). A third model proposes that, similar to the cytoplasm-to-vacuole targeting of aminopeptidase (Teter & Klionsky, 1999), oligomeric complexes of matrix proteins, which are preassembled in the cytosol, can be sequestered in vesicles that subsequently fuse with the peroxisomes (Titorenko & Rachubinski, 2001a).

Receptor recycling

The recycling of the PTS receptors back to the cytosol might require several peroxins: PEX8, PEX4, PEX1, and PEX6. PEX8 interacts with the PTS1 receptor (Rehling *et al.*, 2000). The peripheral membrane protein PEX4 is a member of the E2 family of ubiquitin-conjugating enzymes (Wiebel & Kunau, 1992) and is anchored at the cytosolic face of the peroxisomal membrane through its interaction with the integral membrane protein PEX22 (Koller *et al.*, 1999). It has been proposed that PEX4 may be involved in PEX5 recycling from the matrix to the cytosol (van der Klei *et al.*, 1998) or in "quality control" at the peroxisomal membrane (Subramani *et al.*, 2000). PEX1 and PEX6 are ATPases belonging to the family of "ATPases associated with various cellular activities" (AAA). They are the only known peroxins with ATPase activity, however, reports of their subcellular localization and proposed function show striking differences among species (Purdue & Lazarow, 2001).

3.2 Peroxisomal Membrane Biogenesis

Organelle membranes are composed of proteins, phospholipids and a variety of other lipids, such as sterols and fatty acids, but it is unlikely that organelle membranes could form in the absence of integral membrane proteins. Therefore, the import of peroxisomal membrane proteins may be an essential aspect of peroxisome membrane biogenesis. The first hypothesis for peroxisomal membrane biogenesis suggested that peroxisomes bud from the ER (Novikoff & Shin, 1964). The "growth and division model" proposed by Lazarow and colleagues replaced this theory, reporting that peroxisomes are formed by growth and division via the posttranslational import of newly synthesized proteins into preexisting peroxisomes (Lazarow & Fujiki, 1985).

Like peroxisomal matrix enzymes, the integral peroxisomal membrane proteins are synthesized on free polyribosomes in the cytosol and posttranslational targeted to, and inserted into, the peroxisomal membrane (Lazarow & Fujiki, 1985). This process involves the protection of the hydrophobic transmembrane segments of the membrane proteins from aggregation and maintenance of their import-competent conformations during and after synthesis in the cytosol (Just & Diestelkotter, 1996; Pause *et al*., 1997), the targeting of proteins to the peroxisomal membrane via membrane targeting signals, docking to the membrane, and ATP hydrolysis-independent insertion of the proteins into the peroxisomal membrane (Diestelkotter & Just, 1993; Imanaka *et al*., 1996; Just & Diestelkotter, 1996).

Targeting of membrane proteins to the peroxisome

Integral peroxisomal membrane proteins lack functional PTS1 and PTS2 signals, and their import is independent of the PTS1- and PTS2-receptors PEX5 and PEX7 (Chang *et al*., 1999b; Hettema *et al*., 2000). Therefore, integral peroxisomal membrane proteins are thought to be imported into peroxisomes by a distinct targeting mechanism from that used by peroxisomal matrix enzymes. Multiple studies have attempted to characterize the targeting information in integral peroxisomal membrane proteins, but the knowledge of well-defined peroxisomal membrane protein targeting signals (mPTSs) is limited. Dyer and colleagues first described an internal targeting signal for the 47-kDa peroxisomal membrane protein (PMP47) of *Candida boidinii* (Dyer *et al*., 1996). This signal is characterized by a basic amino acid cluster directed to the peroxisomal membrane in addition to a cytosolic domain located in front of a transmembrane segment. We demonstrated that the N-terminal 40 amino acids of

human PEX3 are sufficient to target a reporter protein (GFP) to the peroxisome (Kammerer *et al*., 1998). These 40 amino acids include a highly conserved positive charged cluster (RNKKK, amino acids 11-15) as well as the first transmembrane segment (amino acids 16-33) (Kammerer *et al*., 1998; Soukupova *et al*., 1999). Furthermore, we were able to define a targeting region of peroxisomal ABC half-transporters containing a highly conserved 14 amino acid motif positioned immediately prior to the first transmembrane helix (Landgraf *et al*., 2003). In general, transmembrane domains within or close to peroxisomal targeting signals are crucial for targeting function: In PEX3, PEX11β, PEX14, and PEX22 one single transmembrane domain is directly integrated in the targeting signal (Koller *et al*., 1999; Sacksteder *et al*., 2000; Soukupova *et al*., 1999). Two transmembrane domains are required for the targeting of PMP22 (Brosius *et al*., 2001), and three for PMP34 (Wang *et al*., 2001). Besides the transmembrane domains, basic amino acid clusters also influence the peroxisomal membrane protein targeting. These clusters are stretches of at least five amino acids consisting of at least two basic amino acids and mainly aliphatic residues (Biermanns & Gartner, 2001; Brosius *et al*., 2001). Interestingly, some peroxisomal integral membrane proteins (yeast PMP47, human PMP34, human PEX13, human and rat PMP22) seem to be targeted via two distinct non-overlapping internal targeting signals, one at the N-terminus and one at the C-terminus of these proteins (Brosius *et al*., 2001; Jones *et al*., 2001; Wang *et al*., 2001).

Two models for targeting of peroxisomal membrane proteins have been proposed (Brosius *et al*., 2001): First, after synthesis in the cytosol, the peroxisomal membrane proteins are recognized and bound at their positively charged basic cluster to a reporter protein located in the peroxisomal membrane. The protein is then integrated into the peroxisomal membrane. Another model involves cytosolic docking proteins. The docking protein picks up the peroxisomal membrane protein in the cytosol and the regions containing the positively charged clusters might mediate this binding. The membrane proteins complexed to their cytosolic acceptors are then transported to the peroxisome. There the complex associates with the peroxisomal membrane either directly or by binding to a component of the peroxisomal membrane insertion machinery. Thereafter, the peroxisomal membrane protein is then integrated into the bilayer of the organelle. Then the docking protein shuttles back to the cytosol where it can receive new substrates.

The control of peroxisome proliferation

In both yeast and mammalian cells, the abundance of peroxisomes can vary significantly depending upon the environmental conditions. A well-characterized example of peroxisomal proliferation is the response of rodent liver cells to peroxisome proliferating agents, like fenofibrate. These agents act by stimulating the nuclear hormone receptor PPARα and to a lesser extent PPARγ, which, in turn, alter the transcription of numerous target genes (Wahli *et al*., 1999). Members of the PEX11 family function as positive regulators of peroxisome division, but are not required for peroxisomal protein import (Erdmann & Blobel, 1995; Marshall *et al*., 1995; Schrader *et al*., 1998). In human, two isoforms, PEX11α and PEX11β, have been reported (Passreiter *et al*., 1998; Schrader *et al*., 1998). PEX11β is expressed at robust levels in virtually all tissues, whereas PEX11α is expressed in a restricted set of tissues, primarily those that response to peroxisome proliferating agents (Passreiter *et al*., 1998; Schrader *et al*., 1998). Therefore, it has been proposed that PEX11β may mediate constitutive peroxisome proliferation, whereas PEX11α may mediate hormone- and diet-induced changes in peroxisome abundance (Schrader *et al*., 1998).

3.3 PEX3 and PEX19, Peroxins Expected to be Involved in the Early Steps of Peroxisomal Biogenesis

Most of the peroxins known today are involved in the peroxisomal matrix protein import. Therefore, defects in these genes lead to a disruption of peroxisomal matrix protein import, whereas various peroxisomal membrane components are synthesized and accumulate in peroxisomal membrane remnants, described as "peroxisomal ghosts". Nevertheless, yeast cells defective in the farnesylated protein PEX19 (Götte *et al.*, 1998) and in the integral membrane protein PEX3 (Baerends *et al.*, 1996; Höhfeld *et al.*, 1991; Wiemer *et al.*, 1996) seem to have not even such recognizable peroxisomal ghosts. This has led to the suggestion that these two peroxins might be implicated in the early steps of peroxisomal biogenesis. We have previously cloned and characterized the human ortholog of yeast *PEX3*, former termed *PAS3* in *Saccharomyces cerevisiae* (Höhfeld *et al.*, 1991), *PER9* in *Hansenula polymorpha* (Baerends *et al.*, 1996), and *PAS2* in *Pichia pastoris* (Wiemer *et al.*, 1996). Human *PEX3* encodes for an integral membrane protein of 373 amino acids with a molecular weight of 42 kDa and is localized at the peroxisome. As can be expect for a peroxisomal assembly protein, PEX3 is expressed in all human cells and tissues analyzed (Kammerer *et al.*, 1998). In yeast, PEX3 has been shown to interact with PEX19 *in vivo* (Götte *et al.*, 1998). PEX19 was originally isolated from a Chinese hamster cell line. It was localized to the outer surface of the peroxisome, exhibited a C-terminal farnesyl group and was therefore designated PxF (peroxisomal farnesylated protein) (James *et al.*, 1994). The human ortholog of the hamster protein was firstly described as HK33 (housekeeping gene encoding a 33 kDa protein) due to its ubiquitous transcription pattern (Braun *et al.*, 1994). For human PEX19, the intrinsic property for C-terminal farnesylation was demonstrated *in vitro* (Kammerer *et al.*, 1997). The covalent attachment of prenyl lipids, for example farnesyl groups or geranylgeranyl groups, by specific transferases is indispensable for the cellular sorting of some proteins (Clarke, 1992). These proteins exhibit the C-terminal sequence CaaX ("CaaX-box"), wherein 'C' is cysteine, 'a' is an aliphatic amino acid, and 'X' may represent one of several amino acids, predicting whether farnesyl groups or geranylgeranyl groups are attached (Marshall, 1993; Moomaw & Casey, 1992; Moores *et al.*, 1991; Reiss *et al.*, 1991) (Fig. I-5). Posttranslational prenylation seems to play a mayor role in cellular processes, such as targeting, membrane association, and vesicle fusion events (Gorvel *et al.*, 1991; Hancock *et al.*, 1989; Kato *et al.*, 1992b). PEX19 is the only peroxin known to own a C-terminal CaaX-box. In *Saccharomyces cerevisiae*, PEX19 is partly farnesylated *in vivo* and it was shown that the interaction of

PEX19 and PEX3 strongly depends on the presence of the farnesyl group (Götte *et al.*, 1998). The question whether farnesylation of human PEX19 is essential for its function in peroxisomal biogenesis will be further examined in this thesis.


Figure I-5: Scheme for protein prenylation. The C-terminal CaaX-box predicts whether farnesyl or geranylgeranyl groups are attached.

CHAPTER II

Aims of the Thesis

Aims of the Thesis

The genes coding for human PEX3 and PEX19, two peroxisomal assembly proteins ("peroxins"), were recently cloned and characterized by our research group. (Kammerer *et al.*, 1998; Kammerer *et al.*, 1997). Studies in yeast supported the hypothesis that PEX19 and its interacting protein PEX3 are involved in the early steps of peroxisomal assembly (Baerends *et al.*, 1996; Götte *et al.*, 1998; Höhfeld *et al.*, 1991). The main objective of this thesis was to gain insights into the functional role of human PEX3 and PEX19 in human biology and disease.

One task was to gain further knowledge on the protein-protein interaction network, regarding both interactions between peroxins and interactions between peroxins and other proteins. For this purpose, we aimed to extend the list of proteins harboring the ability to bind to PEX19.

In addition, we planed to perform experiments to investigate functional key properties of the human PEX19 protein, in particular the role of C-terminal farnesylation. The definition of functional regions of human PEX19 by the characterization of the encoded proteins of truncated *PEX19* splice variants (Kammerer *et al.*, 1997) was expected to contribute to the knowledge on specific protein domains of PEX19.

PEX19 as well as *PEX3* were candidate genes for human peroxisomal biogenesis disorders. Identification of yet unknown mutations in these two *PEX*-genes in candidate patients was expected to provide a natural human model for the elucidation of the very early steps of human peroxisome formation. Alternatively, the generation of animal (mouse) models, defective in *PEX3* and *PEX19* respectively, could address these issues.

CHAPTER III

Results and Discussion

1 PEX19 Interacts With a Variety of Peroxisomal Membrane Proteins

PEX19 has previously been shown to interact with PEX3 in yeast (Götte *et al.*, 1998). The characterization of this and other protein-protein interactions in human might contribute to a more detailed model of early human peroxisomal biogenesis. In order to investigate protein-protein interactions expected to occur between PEX19 and other proteins, we performed cDNA library screens using the LexA yeast two-hybrid system. Different LexA-PEX19 constructs (amino acids 1-299, 7-295, 7-166 and 139-299 of PEX19), if used as a bait, had been shown to be self-activating in the yeast two hybrid system (C. J. Glöckner, personal communication). Therefore, we tested directly the interaction between PEX19 and the Adrenoleukodystrophy Related Protein (ALDRP), a PMP we previously cloned and characterized in our laboratory (Holzinger *et al.*, 1997b). ALDRP belongs to the peroxisomal subgroup of ABC half-transporters (Chapter I.2.1 and Appendix 1). A contribution of ABC transporters to peroxisomal biogenesis cannot be excluded since it has been suggested that PMP70, another peroxisomal ABC half-transporter, might play an important role in peroxisomal assembly (Gärtner & Valle, 1993; Gärtner *et al.*, 1992). Furthermore, ALDRP is of special interest because it is the closest homologue of the Adrenoleukodystrophy Protein (ALDP), known to be the causative gene in X-Linked Adrenoleukodystrophy (X-ALD). Therefore, ALDRP is expected to act as a modifier gene in X-ALD, being responsible for the heterogeneity of clinical phenotypes. Ectopic ALDR expression or overexpression could possibly have a beneficial effect on the disease. First, the genomic organization, the putative promoter region and the chromosomal localization of the *ALDR* gene were characterized (Appendix 1). The human *ALDR* gene extents over 33 kb on chromosome 12q12 and consists of 10 exons. The genomic organization of *ALD* and *ALDR* is highly similar, confirming the expected close homology between both genes and a recent divergence from a common ancestor (Appendix 1). Furthermore, the *ALDR* full-length cDNA was completed and the ALDR protein was shown to be exclusively localized at the peroxisome (Appendix 1).

Using a yeast two-hybrid screen with parts of ALDR as a bait, we initially identified an interaction between ALDRP and PEX19 (Appendix 2). Further yeast two-hybrid and *in vitro* interaction assays confirmed this protein-protein interaction and, moreover, identified two other peroxisomal ABC half-transporters (ALDP and PMP70) being able to bind to PEX19 (Appendix 2). With regard to ALDP, the PEX19-interaction occurs in an internal region of ALDP that was shown to be important for the targeting of the protein to the peroxisome. This

provides evidence for one proposed biological function of PEX19 as PMP-receptor (further discussed in Chapter III-3). *In vitro* binding assays revealed that the farnesylated wild type PEX19 and a farnesylation-deficient PEX19 variant did not differ in their abilities to bind to ALDP (Appendix 2). Therefore, we further characterized the influence of PEX19-farnesylation as to PMP-interaction and induction of peroxisomal biogenesis using the encoded proteins of *PEX19* splice variants (Chapter III-2 and Appendix 3).

At the beginning of this thesis, PEX3 was the only PMP known to interact with PEX19 (Götte *et al*., 1998). We extended the list of proteins known to interact with PEX19 including not only peroxins, like PEX3, but also other PMPs, like the peroxisomal ABC half-transporters ALDP, ALDRP, and PMP70. Today, PEX19 protein has been shown to bind a variety of peroxisomal membrane proteins (Fig. III-1) including peroxins, ABC transporters, and other PMPs (Fransen *et al*., 2001; Gloeckner *et al*., 2000; Sacksteder *et al*., 2000; Snyder *et al*., 2000; Snyder *et al*., 1999a; Snyder *et al*., 1999b). Therefore, PEX19 is known to act as a broad specific PMP-binding protein.

Figure III-1: PEX19 binds multiple peroxisomal membrane proteins. PEX19 has been shown to interact with a set of peroxisomal membrane proteins (PMPs), including peroxins (PEX2, PEX3, PEX10, PEX11, PEX12, PEX13, PEX14, PEX16, PEX17, and PEX22), peroxisomal ABC half-transporters (ALDP, ALDRP, and PMP70), and other PMPs (PMP22, PMP24, and PMP34). PEX19 is farnesylated at the C-terminal farnesylation consensus sequence (CaaX-box). Protein-protein interactions that are characterized in this thesis are highlighted in dark.

2 Characterization of *PEX19* Splice Variants: Functional Diversity and New Insights in the Role of Posttranslational Farnesylation

PEX19 does not equally bind to all of its known PMP-interactors. Full-length PEX19 is required for efficient interaction with PEX10, PEX11αβ, PEX12, and PEX13. On the other hand, PEX19 has distinct binding sites for PEX3 and PEX16 (Fransen *et al.*, 2001), suggesting that PEX19 may bind to these PMPs simultaneously. Nevertheless, distinct PMP-binding sites of PEX19 had not been linked to a specific domain organization of the protein. We therefore characterized the domain organization of PEX19 by database analysis (Appendix 3). The protein is composed of three domains in direct succession (Fig. III-2), which are exclusively shared by ortholog PEX19 proteins of other species. However, these domains have not yet been linked to specific biological functions. Interestingly, the encoded proteins of two *PEX19* splice variants, each truncated in exactly one domain, resemble this modular domain organization (Fig. III-2): The variant PEX19ΔE2 lacks the N-terminal domain D1, whereas PEX19ΔpE8 lacks the C-terminal domain D3 including the farnesylation consensus sequence. We took advantage of these splice variants in order to assess their functional ability as to PMP binding, induction of peroxisomal membrane synthesis and the dependence of posttranslational farnesylation of PEX19.

Figure III-2: Functional diversity of different *PEX19* splice variants. Scheme of the domain structure of PEX19 (gray) and of the encoding proteins of the *PEX19* splice variants (white). The dashed box at the C-terminus of PEX19pΔE8 is indicating amino acids that differ from the wild type PEX19 sequence because of frame shifts. [a]Protein-protein interactions were analyzed between PEX19 variant proteins and the peroxisomal ABC transporters (ALDP, ALDRP, and PMP70) and two PEX3 variants (full-length PEX3 and Δ66aaPEX3): (+) the variant binds to all PMPs examined; (+/-) the variant binds to all PMPs examined except Δ66aaPEX3. [b]Functional complementation assays were performed in *PEX19*-deficient fibroblast: (+) restoration of functional peroxisomes; (-) no restoration of functional peroxisomes. The corresponding experiments are described in appendix 3. D1: domain 1 (ProDom-ID PD339396); D2: domain 2 (ProDom-ID PD024170); D3: domain 3 (ProDom-ID PD329985); E1-E8: exons 1-8; PMP: peroxisomal membrane protein; jagged line: farnesyl group

Functional diversity of *PEX19* splice variants

With regard to PMP-interaction, the encoded proteins of both *PEX19* splice variants (PEX19ΔE2 and PEX19ΔpE8) interact with peroxisomal ABC transporters (ALDP, ALDRP and PMP70) and with full-length PEX3. In contrast, PEX19ΔpE8 interacts with a truncated PEX3 protein lacking its N-terminal peroxisomal targeting sequence, whereas PEX19ΔE2 does not (Appendix 3). Functional complementation studies in *PEX19*-deficient human fibroblasts revealed that transfection of *PEX19ΔpE8*-cDNA leads to restoration of both, peroxisomal membranes and functional peroxisomes, whereas transfection of *PEX19ΔE2*-cDNA does not restore peroxisomal biogenesis. Taken together, these data provide the first experimental evidence for the functional diversity of *PEX19* splice variants as to PMP-interaction and induction of peroxisomal assembly (Fig. III-2). Functional diversities of splice variants as to protein-protein-interactions has been reported for many proteins. For example, PYK2 (proline-rich tyrosine kinase 2), but not its isoform PRNK (PYK2-related non-kinase), interacts with p130^{cas} (Crk-associated substrates) and Graf (GTPase regulator associated with focal adhesion kinase), indicating a PRNK-mediated regulation mechanism in certain cells (Xiong *et al*., 1998). Among the mammalian peroxins, the appearance of different splice variants has been reported for the PTS1-receptor PEX5 (Braverman *et al*., 1998; Otera *et al*., 1998). Two variants (PEX5S and PEX5L) are involved in the import of peroxisomal matrix enzymes in a different manner (Chapter I.3.1). In addition, humans, like other mammals, contain two forms of PEX11, namely PEX11α and PEX11β. Based on the differences in their tissue-specific patterns of expression and their differential regulation by peroxisome proliferation agents, it has been proposed that PEX11β may mediate constitutive peroxisome proliferation, whereas PEX11α may mediate hormone- and diet-induced changes in peroxisome abundance (Schrader *et al*., 1998). In addition to distinct functions, tissue- or cell specific expression of different splice variants has been reported for many genes (Atamas, 1997; Strehler & Zacharias, 2001). In the case of *PEX19*, the full-length variant has been described to be the predominant transcript in mRNA of several cells and tissues in human. However, the variant *PEX19ΔE2* has also been reported to account for a significant level of total human *PEX19* mRNA (Kammerer *et al*., 1997). Interestingly, the ratio between both variants was completely reversed in uterine tissue (Kammerer *et al*., 1997). The question whether this reversed expressions level in uterine tissue is linked to the functional diversity of *PEX19* splice variants has to be subjected to further examinations.

The role of farnesylation of PEX19

Among the peroxins known today, only PEX19 owns a C-terminal consensus sequence (CaaX-box; Chapter I.3.3) with the intrinsic property of being modified by posttranslational farnesylation. Farnesylation of *Saccharomyces cerevisiae* PEX19 was shown to be essential for the proper function of the protein in peroxisome biogenesis (Götte *et al.*, 1998). In contrast, this modification seems to be absent and dispensable for the function PEX19 in *Pichia pastoris* (Snyder *et al.*, 1999a). The human PEX19 protein has been reported to be farnesylated *in vitro* (Kammerer *et al.*, 1997) and *in vivo* (Matsuzono *et al.*, 1999). There was a controversial discussion at the beginning of this thesis whether farnesylation is essential for the function of PEX19 in human peroxisomal biogenesis (Matsuzono *et al.*, 1999) or has only an ancillary effect (Sacksteder *et al.*, 2000). By performing functional complementation studies, we clearly demonstrated that expression of *PEX19ΔpE8*-cDNA, encoding for a C-terminally truncated PEX19 protein that cannot be modified by a farnesyl group (Kammerer *et al.*, 1997), could restore functional peroxisomes in *PEX19*-deficient human fibroblasts (Appendix 3). We therefore concluded that posttranslational farnesylation is not essential for PEX19 to induce peroxisomal membrane synthesis in human. *In vivo*, however, we cannot rule out the possibility that farnesylation may enhance PEX19 function, perhaps in a regulating manner. Moreover, farnesylation might influence or regulate other functions of the PEX19 protein. It has been reported that farnesylation motif of PEX19 affects the binding properties for PEX10, PEX11αβ, PEX12, and PEX13, but not those for PEX3 and PEX16 (Fransen *et al.*, 2001). For PEX3, we were able to confirm these data. Furthermore, we demonstrated that farnesylation of PEX19 is not necessary for its interaction with peroxisomal ABC half-transporters (Appendix 3). Altogether, farnesylation might be able to regulate the interaction of PEX19 with different PMPs, perhaps in an intracellular location-specific manner, ensuring proper sorting and trafficking of the distinct PMPs.

3 Proposed Biological Functions of PEX19

In yeast, PEX19 and PEX3 are required for the proper localization of PMPs, and cells deficient in these peroxins mislocalize their PMPs to the cytosol (Hettema *et al*., 1999). Human PEX19 is a predominantly cytoplasmic, partly peroxisomal protein, and loss of PEX19 results in the absence of detectable peroxisomal structures, the destabilization of many integral PMPs, and the mislocalization of other PMPs to the mitochondrion (Sacksteder *et al*., 2000). Due to these observations, several models of PEX19 function are possible: First, PEX19 might act as a soluble receptor that binds newly synthesized PMPs in the cytosol and subsequently directs the PMPs to the peroxisomal membrane. Second, PEX19 might be a PMP-specific chaperone that keeps PMPs in an import-competent conformation. Third, PEX19 might facilitate the insertion of PMPs into the peroxisomal membrane. Last, PEX19 might play a role in peroxisomal membrane stabilization or maturation.

Interestingly, our *in vitro* targeting studies suggested that the PEX19-interaction domain of the peroxisomal ABC-transporter ALDP coincides with the region of ALDP that is required for its targeting to the peroxisome (Appendix 2). Similar results have been reported for other PMPs (PMP70, PEX11β, and PEX14), indicating that the targeting elements of some PMPs retain the ability to bind to PEX19 (Sacksteder *et al*., 2000). Furthermore, mislocalization of PEX19 has been shown to result in mislocalization of newly synthesized PMPs. These data, combined with the observation that a small but significant amount of PEX19 is associated with the outer surfaces of peroxisomes, made PEX19 to be a prime candidate for a cycling PMP-receptor protein (Gould & Valle, 2000). However, an increasing number of PMPs have been reported that bind to PEX19 at regions distinct from their targeting regions (Fransen *et al*., 2001; Snyder *et al*., 2000). Random mutagenesis studies of PEX13 demonstrated that the PEX19-binding domain and the peroxisomal targeting signal could be functionally separated (Fransen *et al*., 2001). Furthermore, interactions between PEX19 and PMPs were not reduced upon inhibition of new protein synthesis, suggesting that they occur with preexisting, and not newly synthesized, pools of PMPs (Snyder *et al*., 2000). In *Pichia pastoris*, the organelle-associated pool of PEX19 interacts with the PMPs at the peroxisome, and this interaction may occur at the cytosolic site of the membrane (Snyder *et al*., 2000). Taken these data together, the role of PEX19 as cycling PMP-receptor has been challenged. It has been suggested that PEX19 may have a chaperone-like role at the peroxisomal membrane. Nevertheless, since PEX19 is predominantly present in the cytosol, this peroxin most likely has also other

biological functions (Fransen *et al*., 2001). Recently, *PEX19* mutants in *Yarrowia lipolytica* have been shown capable of forming structures that are morphologically similar to wild-type peroxisomes and that are surrounded by a membrane whose protein composition is similar to wild-type peroxisomes (Lambkin & Rachubinski, 2001). A significant reduction in the levels of the integral membrane protein PEX2 in *PEX19*-mutants of *Yarrowia lipolytica* lends support to the proposal that PEX19 is important to the stability of PMPs, or of the peroxisomal membrane (Lambkin & Rachubinski, 2001). Although the overall mechanism of peroxisomal assembly has been conserved during evolution, the role played by individual peroxins, like PEX19, may not necessarily be exactly the same in different organism. In general, compared with the well-defined peroxisomal matrix protein receptors PEX5 and PEX7, it is not likely that PEX19 exhibits an analogous receptor function for all known PMPs. PEX19 may act in a more PMP-stabilizing manner, at or distinct-from the peroxisomal membrane. The question whether the cytosolic and peroxisomal intracellular localizations of PEX19 are linked to distinct biological functions of the PEX19 protein has to be subjected to further examinations.

4 *PEX3*, a Key Factor in Early Human Peroxisome Synthesis

PEX3 or *PEX19* mutants in yeast have been shown to lack functional peroxisomes (Baerends *et al*., 1996; Götte *et al*., 1998; Höhfeld *et al*., 1991). Therefore their human orthologs had been expected to be candidate genes for peroxisomal biogenesis disorders (PBDs; Chapter I.2.2). However, human phenotypes defective in theses genes had not been reported at the beginning of this thesis. Shortly thereafter, an inactivating mutation in human *PEX19*, causing Zellweger syndrome in CG-J of the PBDs, was reported (Matsuzono *et al*., 1999). Like their yeast counterparts, human cells defective in *PEX19* were shown to lack even peroxisomal membrane remnants. It was suggested that PEX19 might be involved at the very initial stages of peroxisomal membrane assembly, even before the import of matrix proteins (Matsuzono *et al*., 1999). Based on the observation that the cellular phenotypes of yeast cells defective in *PEX3* and *PEX19* are resembling each other, it was tempting to speculate that besides *PEX19*-mutants, mammalian cells with an inactivating *PEX3* mutation might also entirely lack peroxisomal membrane remnants.

The generation of a mouse model by targeted disruption of the *PEX3* gene is one strategy to clarify the exact contribution of *PEX3* to the formation of peroxisomes. Mouse models defective in *PEX* genes have already been described for *PEX2*, which encodes for a zinc-binding PMP, and for *PEX5*, the import receptor for the most peroxisomal matrix proteins (Baes *et al*., 1997; Faust & Hatten, 1997). Besides their ability to study the molecular details of peroxisomal assembly, these models could provide suitable *in vivo* systems to study disease mechanisms, and experimental treatment strategies for the peroxisomal biogenesis disorders. As a first step to generate a *PEX3*-deficient mouse model, the mouse *PEX3* gene was characterized (Appendix 4): The gene spans a region of about 30 kb, contains 12 exons, and is located on band A of chromosome 10. The 2 kb cDNA encodes for a mouse PEX3 protein of 372 amino acids (42 kDa). Compared to human PEX3 (373 amino acids), both proteins reveal an overall amino acid identity of 93.8%. The putative mouse *PEX3* promoter region exhibits characteristic housekeeping features, and *PEX3* expression was identified in all tissues analyzed, but could not be induced by fenofibrate. Taken together, these data are experimental prerequisites for the future generation of a mouse model defective in *PEX3*.

To prove the hypothesis that *PEX3* might be a candidate gene for peroxisomal biogenesis disorders, we searched for a *PEX3*-deficient human phenotype. As a prerequisite, we analyzed

the genomic structure, the putative promoter region, the chromosomal localization and fine-mapping of the human *PEX3* gene (Appendix 5). The gene spans a region of about 40 kb on chromosome 6q23-24. The human *PEX3* gene is composed of 12 exons and 11 introns, and these data were useful to design a strategy for *PEX3* mutation analysis based on PCR amplification and sequencing of amplicons from genomic DNA. This method was applied to screen the PBD complementation groups CG-E, CG-C, CG-B, CG-A, and CG-D for a *PEX3*-mutation, but no differences to the wild-type *PEX3* sequence were detected (Appendix 5). In the meantime, CG-E, CG-C, CG-B, and CG-D had been clarified to be caused by defects of *PEX1*, *PEX6*, *PEX10*, and *PEX16*, respectively (Table I-3). Only the causative gene in CG-A of the PBDs has not been identified so far.

Later on, fibroblast from two Zellweger patients (PBDG-01 and PBDG-02), assigned to an additional complementation group CG-G (Poulos *et al*., 1995), were available for further studies. Fibroblasts of this complementation group had been shown to lack peroxisomal membrane remnants (Shimozawa *et al*., 1998), and this was confirmed by performing own immunofluorescence microscopy analyses with fibroblasts of both patients (Appendix 6, Fig A6-2): In both mutant cell lines, PMPs are either degraded, as proposed for ALDP and PMP70, or mislocalized to the mitochondira, as shown for PEX14. Because of the lack of morphologically recognizable PMP-containing peroxisomal membranes, the cell lines of the two patients were excellent candidates for a *PEX3* mutation. By performing *PEX3* mutation analysis, we identified homozygous *PEX3* mutation in both patients, each leading to a C-terminal truncation of PEX3 (Appendix 6, Fig. A6-3): One of the mutations involved a single-nucleotide insertion in exon 7, whereas the other was a single-nucleotide substitution eight nucleotides form the normal splice site in the 3' acceptor site of intorn 10, which interferes with correct splicing. Expression of the wild-type *PEX3* cDNA in the mutant cell lines restored peroxisomal biogenesis, whereas transfection of the mutated cDNA did not (Appendix 6, Fig. A6-4). This confirmed that the causative gene had been identified, being responsible for Zellweger syndrome in CG-G. Biochemically, we were able to demonstrate that truncated PEX3 proteins of patient PBDG-01, lacking approximately the C-terminal halve, could not bind to full length PEX19 *in vitro* (Appendix 6, Fig. A6-5). Although this does not necessarily reflect the situation *in vivo*, this lack of interaction between both peroxins could functionally be responsible for the impaired peroxisomal membrane assembly. In yeast, this protein-protein interplay between PEX3 and PEX19 appears to be a prerequisite for

generation of preperoxisomal structures that can acquire and stabilize newly synthesized PMPs (Hettema *et al*., 2000).

The molecular and biochemical evidence shown in appendix 6 leaves little doubt that *PEX3* mutations are responsible for Zellweger syndrome in CG-G of the peroxisomal biogenesis disorders. So far, only mutations in human *PEX16* and *PEX19* have been reported to cause the unusual cellular phenotype characterized by the lack of functional peroxisomes and of detectable peroxisomal membranes (Matsuzono *et al*., 1999; South & Gould, 1999). Here, we complete the list of "early peroxins" including human *PEX3*. Expression of wild-type PEX3, PEX16, or PEX19 restored functional peroxisomes in the respective mutant cell line, providing evidence for the essential role of these early peroxins in a human peroxisome-formation pathway that does not require morphologically detectable preexisting peroxisomal structures. This challenges the theory that peroxisomes arise exclusively by growth and division of preexisting peroxisomes and establishes *PEX3* as a key factor in early human peroxisome synthesis.

5 Two-Path Model for Peroxisome Membrane Synthesis in Mammalian Cells

Prior the discovery of peroxin-deficient cells that lack peroxisomal ghosts, it had been suggested that peroxisomes arise exclusively by growth and division from preexisting peroxisomes (Lazarow & Fujiki, 1985). In appendix 6, we describe that expression of wild-type *PEX3* restored the peroxisomal biogenesis in *PEX3*-deficient human fibroblasts that have been shown to lack even morphologically detectable peroxisomal membranes. Corresponding results have been obtained for *PEX16*- and *PEX19*-deficient cells, respectively (Honsho *et al*., 1998; Matsuzono *et al*., 1999; South & Gould, 1999). Taken together, these observations of peroxisomal formation in the absence of morphologically recognizable peroxisomal membranes challenge the theory that peroxisomes arise exclusively from preexisting peroxisomes and suggest a model that incorporates two distinct paths for peroxisomal membrane synthesis (Fig. III-3) (Gould & Valle, 2000).

Figure III-3: Speculative two-path model for peroxisomal membrane biogenesis. (1) Growth and division model of peroxisome biogenesis. Growth results from the PEX5- and PEX7- mediated uptake of matrix proteins and involves the matrix-protein import machinery composed of several peroxins (Chapter I.3.1). Division is mediated by PEX11. PEX3, PEX16, and PEX19 would function primarily in PMP-import (2) In the second path, PEX3 and/or PEX16 and/or PEX19 mediate the formation of a nascent peroxisome from a pre-peroxisomal vesicle. Nascent peroxisomes import further PMPs, leading to the assembly of the peroxisomal matrix protein import machinery. Thereafter, matrix proteins can be imported, leading to mature peroxisomes.

The primary path would involve the growth and division of preexisting peroxisomes. Growth of the organelle would result from the uptake of newly synthesized matrix proteins, a process that involves all peroxins of the matrix protein import machinery including the receptors PEX5 and PEX7 (Chapter I.3.1). The peroxins PEX3, PEX16, and PEX19 would function primarily in PMP-import. Peroxisome division would be mediated by PEX11.

The two-path model also proposes a second route for peroxisomal formation in which PEX3 and/or PEX16 and/or PEX19 mediate the formation of a nascent peroxisome from a pre-peroxisomal vesicle, probably some other endomembranes of the cell. Such vesicle would be competent for the import of further PMPs, leading to the assembly of the peroxisomal matrix protein import machinery. Thereafter, matrix proteins could be imported, leading to mature, metabolic active peroxisomes, which could be further divided by 'growth and division'.

Such a two-path model is attractive because it could explain: (a) the absence of morphologically recognizable peroxisomal membranes in *PEX3-*, *PEX16-*, and *PEX19-*deficient mammalian cells and the ability to synthesize peroxisomes in these cells when the correct gene is expressed (Honsho *et al*., 1998; Matsuzono *et al*., 1999; Muntau *et al*., 2000a; South & Gould, 1999; South *et al*., 2000); (b) the extremely slow, stepwise nature of peroxisome formation after expression of the correct gene in *PEX3- PEX16-*, or *PEX19-*deficent cells lacking peroxisomal membranes (Matsuzono *et al*., 1999; Muntau *et al*., 2000a; South & Gould, 1999); (c) the PEX11-mediated hyperproliferation of peroxisomes and the presence of only a few large peroxisomes in *PEX11*-mutants (Erdmann & Blobel, 1995; Marshall *et al*., 1995; Schrader *et al*., 1998); (d) the ability of the N-terminal 50 amino acids of PEX3 to induce the formation of vesicles in the vicinity of the nuclear membrane in *PEX3-*deficient *Hensenula polymorpha* cells and the fact that these vesicles are the specific target for peroxisome development after subsequent synthesis of full-length PEX3 (Faber *et al*., 2002). Nevertheless, the major weakness of this model is that it does not explain the vesicle-fusion-events observed in the yeast *Yarrowia lipolytica* (Titorenko *et al*., 2000). But apart from the degree of homology between different species in respect to general rules governing peroxisomal assembly, several well-established differences in the peroxisomal protein import have been reported to occur between different organisms (Tab. I-4). Therefore, it is tempting to speculate that there might be some organism-specific differences in the general model of peroxisomal membrane synthesis.

6 Further Perspectives: Identification of the Origin of the Endomembrane Template

The peroxisomal membrane is a typical endomembrane, approximately 6.5–7 nm thick, with a phospholipid/protein ratio of 140-200 nmol/mg (Lazarow, 1984). The phospholipids are principally phosphatidyl choline and phosphatidyl ethanolamine, with a tendency toward somewhat longer-chain fatty acids than other membranes (Schneiter *et al.*, 1999). The ER is site of biosynthesis of these phospholipids, just as it is the site of synthesis of most mitochondrial phospholipids (Lazarow & Fujiki, 1985). To day, it is still unclear how these phospholipids are transported from the ER to the peroxisome. Furthermore, apart from the biosynthesis of these lipids, it has been proposed that some integral peroxisomal membrane proteins shuttle through the ER on their route to the peroxisome (Baerends *et al.*, 1996; Kammerer *et al.*, 1998; Kunau & Erdmann, 1998). Taken together, these data made the ER as prime candidate for being the origin of the pre-peroxisomal vesicles, formed in the PEX3/PEX16/PEX19-mediated second route of peroxisomal membrane synthesis. However, PEX3-mediated peroxisome membrane synthesis has been reported to occur independently of COPI- and COPII-dependent membrane trafficking through the ER (South *et al.*, 2000). Furthermore, the targeting of PEX2, PEX3, and PEX16 was not affected by inhibitors of COPI and COPII that block vesicle transport in the early secretory pathway of the ER (Voorn-Brouwer *et al.*, 2001). Together, these data suggest that the ER is not involved in PMP targeting and peroxisome formation. On the other hand, these data do not definitively rule-out a possible role for the ER in peroxisomal biogenesis because not all vesicle-budding and –fusion processes depend on COPI and COPII (Latterich *et al.*, 1995). For example in plants, it has been reported that vesicles can be formed at the ER that are morphologically distinct from COP-coated vesicles (Toyooka *et al.*, 2000). Recently, it has been demonstrated that the synthesis of the N-terminal 50 amino acids of PEX3 in *PEX3*-deficient *Hensenula polymorpha* cells is associated with the formation of vesicular membrane structures, and that the nuclear membrane is the donor membrane compartment of these vesicles (Faber *et al.*, 2002). Therefore, a challenge for the future will be to clarify the origin for the endomembranes that will be further converted to peroxisomal structures.

References

Abastado, J. P., Miller, P. F., Jackson, B. M. & Hinnebusch, A. G. (1991). Suppression of ribosomal reinitiation at upstream open reading frames in amino acid-starved cells forms the basis for GCN4 translational control. *Mol Cell Biol* **11**, 486-496.

Abe, I., Okumoto, K., Tamura, S. & Fujiki, Y. (1998). Clofibrate-inducible, 28-kDa peroxisomal integral membrane protein is encoded by PEX11. *FEBS Lett* **431**, 468-472.

Albet, S., Causeret, C., Bentejac, M., Mandel, J. L., Aubourg, P. & Maurice, B. (1997). Fenofibrate differently alters expression of genes encoding ATP-binding transporter proteins of the peroxisomal membrane. *FEBS Lett* **405**, 394-397.

Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* **25**, 3389-3402.

Arias, J. A., Moser, A. B. & Goldfischer, S. L. (1985). Ultrastructural and cytochemical demonstration of peroxisomes in cultured fibroblasts from patients with peroxisomal deficiency disorders. *J Cell Biol* **100**, 1789-1792.

Atamas, S. P. (1997). Alternative splice variants of cytokines: making a list. *Life Sci* **61**, 1105-1112.

Baerends, R. J., Salomons, F. A., Kiel, J. A., van der Klei, I. J. & Veenhuis, M. (1997). Deviant Pex3p levels affect normal peroxisome formation in Hansenula polymorpha: a sharp increase of the protein level induces the proliferation of numerous, small protein-import competent peroxisomes. *Yeast* **13**, 1449-1463.

Baerends, R. J., Rasmussen, S. W., Hilbrands, R. E., van der Heide, M., Faber, K. N., Reuvekamp, P. T., Kiel, J. A., Cregg, J. M., van der Klei, I. J. & Veenhuis, M. (1996). The Hansenula polymorpha PER9 gene encodes a peroxisomal membrane protein essential for peroxisome assembly and integrity. *J Biol Chem* **271**, 8887-8894.

Baes, M., Gressens, P., Baumgart, E., Carmeliet, P., Casteels, M., Fransen, M., Evrard, P., Fahimi, D., Declercq, P. E., Collen, D., van Veldhoven, P. P. & Mannaerts, G. P. (1997). A mouse model for Zellweger syndrome. *Nat Genet* **17**, 49-57.

Beldjord, C., Lapoumeroulie, C., Pagnier, J., Benabadji, M., Krishnamoorthy, R., Labie, D. & Bank, A. (1988). A novel beta thalassemia gene with a single base mutation in the conserved polypyrimidine sequence at the 3' end of IVS 2. *Nucleic Acids Res* **16**, 4927-4935.

Benson, D. A., Boguski, M. S., Lipman, D. J., Ostell, J., Ouellette, B. F., Rapp, B. A. & Wheeler, D. L. (1999). GenBank. *Nucleic Acids Res* **27**, 12-17.

Berger, J., Molzer, B., Fae, I. & Bernheimer, H. (1994). X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. *Biochem Biophys Res Commun* **205**, 1638-1643.

Berger, J., Albet, S., Bentejac, M., Netik, A., Holzinger, A., Roscher, A. A., Bugaut, M. & Forss-Petter, S. (1999). The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. *Eur J Biochem* **265**, 719-727.

Bezman, L. & Moser, H. W. (1998). Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. *Am J Med Genet* **76**, 415-419.

Biermanns, M. & Gartner, J. (2001). Targeting elements in the amino-terminal part direct the human 70-kDa peroxisomal integral membrane protein (PMP70) to peroxisomes. *Biochem Biophys Res Commun* **285**, 649-655.

Björkman, J., Stetten, G., Moore, C. S., Gould, S. J. & Crane, D. I. (1998). Genomic structure of PEX13, a candidate peroxisome biogenesis disorder gene. *Genomics* **54**, 521-528.

Boguski, M. S., Lowe, T. M. & Tolstoshev, C. M. (1993). dbEST--database for "expressed sequence tags" [letter]. *Nat Genet* **4**, 332-333.

Braiterman, L. T., Zheng, S., Watkins, P. A., Geraghty, M. T., Johnson, G., McGuinness, M. C., Moser, A. B. & Smith, K. D. (1998). Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. *Hum Mol Genet* **7**, 239-247.

Braun, A., Kammerer, S., Weissenhorn, W., Weiss, E. H. & Cleve, H. (1994). Sequence of a putative human housekeeping gene (HK33) localized on chromosome 1. *Gene* **146**, 291-295.

Braverman, N., Dodt, G., Gould, S. J. & Valle, D. (1998). An isoform of pex5p, the human PTS1 receptor, is required for the import of PTS2 proteins into peroxisomes. *Hum Mol Genet* **7**, 1195-1205.

Braverman, N., Steel, G., Obie, C., Moser, A., Moser, H., Gould, S. J. & Valle, D. (1997). Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. *Nat Genet* **15**, 369-376.

Breidenbach, R. W. & Beevers, H. (1967). Association of the glyoxylate cycle enzymes in a novel subcellular particle from castor bean endosperm. *Biochem Biophys Res Commun* **27**, 462-469.

Brocard, C., Kragler, F., Simon, M. M., Schuster, T. & Hartig, A. (1994). The tetratricopeptide repeat-domain of the PAS10 protein of Saccharomyces cerevisiae is essential for binding the peroxisomal targeting signal-SKL. *Biochem Biophys Res Commun* **204**, 1016-1022.

Brosius, U., Dehmel, T. & Gartner, J. (2001). Two different targeting signals direct human PMP22 to peroxisomes. *J Biol Chem*.

Candido, E. P., Reeves, R. & Davie, J. R. (1978). Sodium butyrate inhibits histone deacetylation in cultured cells. *Cell* **14**, 105-113.

Chang, C. C., Warren, D. S., Sacksteder, K. A. & Gould, S. J. (1999a). PEX12 interacts with PEX5 and PEX10 and acts downstream of receptor docking in peroxisomal matrix protein import. *J Cell Biol* **147**, 761-774.

Chang, C. C., Lee, W. H., Moser, H., Valle, D. & Gould, S. J. (1997). Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders. *Nat Genet* **15**, 385-388.

Chang, C. C., South, S., Warren, D., Jones, J., Moser, A. B., Moser, H. W. & Gould, S. J. (1999b). Metabolic control of peroxisome abundance. *J Cell Sci* **112**, 1579-1590.

Chumakov, I. M., Rigault, P., Le Gall, I., Bellanne-Chantelot, C., Billault, A., Guillou, S., Soularue, P., Guasconi, G., Poullier, E., Gros, I. & et al. (1995). A YAC contig map of the human genome. *Nature* **377**, 175-297.

Clarke, S. (1992). Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. *Annu Rev Biochem* **61**, 355-386.

Collins, C. S., Kalish, J. E., Morrell, J. C., McCaffery, J. M. & Gould, S. J. (2000). The peroxisome biogenesis factors pex4p, pex22p,

pex1p, and pex6p act in the terminal steps of peroxisomal matrix protein import. *Mol Cell Biol* **20**, 7516-7526.

Contreras, M., Mosser, J., Mandel, J. L., Aubourg, P. & Singh, I. (1994). The protein coded by the X-adrenoleukodystrophy gene is a peroxisomal integral membrane protein. *FEBS Lett* **344**, 211-215.

Dammai, V. & Subramani, S. (2001). The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol. *Cell* **105**, 187-196.

De Duve, C. & Baudhuin, P. (1966). Peroxisomes (microbodies and related particles). *Physiol Rev* **46**, 323-357.

Diestelkotter, P. & Just, W. W. (1993). In vitro insertion of the 22-kD peroxisomal membrane protein into isolated rat liver peroxisomes. *J Cell Biol* **123**, 1717-1725.

Distel, B., Erdmann, R., Gould, S. J., Blobel, G., Crane, D. I., Cregg, J. M., Dodt, G., Fujiki, Y., Goodman, J. M., Just, W. W., Kiel, J. A., Kunau, W. H., Lazarow, P. B., Mannaerts, G. P., Moser, H. W., Osumi, T., Rachubinski, R. A., Roscher, A., Subramani, S., Tabak, H. F., Tsukamoto, T., Valle, D., van der Klei, I., van Veldhoven, P. P. & Veenhuis, M. (1996). A unified nomenclature for peroxisome biogenesis factors. *J Cell Biol* **135**, 1-3.

Dodt, G., Braverman, N., Wong, C., Moser, A., Moser, H. W., Watkins, P., Valle, D. & Gould, S. J. (1995). Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. *Nat Genet* **9**, 115-125.

Dover, G. J., Brusilow, S. & Charache, S. (1994). Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. *Blood* **84**, 339-343.

Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G. & Wahli, W. (1992). Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell* **68**, 879-887.

Dyer, J. M., McNew, J. A. & Goodman, J. M. (1996). The sorting sequence of the peroxisomal integral membrane protein PMP47 is contained within a short hydrophilic loop. *J Cell Biol* **133**, 269-280.

Eitzen, G. A., Aitchison, J. D., Szilard, R. K., Veenhuis, M., Nuttley, W. M. & Rachubinski, R.

A. (1995). The Yarrowia lipolytica gene PAY2 encodes a 42-kDa peroxisomal integral membrane protein essential for matrix protein import and peroxisome enlargement but not for peroxisome membrane proliferation. *J Biol Chem* **270**, 1429-1436.

Elgersma, Y., Kwast, L., van den Berg, M., Snyder, W. B., Distel, B., Subramani, S. & Tabak, H. F. (1997). Overexpression of Pex15p, a phosphorylated peroxisomal integral membrane protein required for peroxisome assembly in S.cerevisiae, causes proliferation of the endoplasmic reticulum membrane. *Embo J* **16**, 7326-7341.

Elgersma, Y., Kwast, L., Klein, A., Voorn-Brouwer, T., van den Berg, M., Metzig, B., America, T., Tabak, H. F. & Distel, B. (1996). The SH3 domain of the Saccharomyces cerevisiae peroxisomal membrane protein Pex13p functions as a docking site for Pex5p, a mobile receptor for the import PTS1-containing proteins. *J Cell Biol* **135**, 97-109.

Erdmann, R. & Blobel, G. (1995). Giant peroxisomes in oleic acid-induced Saccharomyces cerevisiae lacking the peroxisomal membrane protein Pmp27p. *J Cell Biol* **128**, 509-523.

Erdmann, R., Veenhuis, M., Mertens, D. & Kunau, W. H. (1989). Isolation of peroxisome-deficient mutants of Saccharomyces cerevisiae. *Proc Natl Acad Sci U S A* **86**, 5419-5423.

Erdmann, R., Wiebel, F. F., Flessau, A., Rytka, J., Beyer, A., Frohlich, K. U. & Kunau, W. H. (1991). PAS1, a yeast gene required for peroxisome biogenesis, encodes a member of a novel family of putative ATPases. *Cell* **64**, 499-510.

Faber, K. N., Haan, G. J., Baerends, R. J., Kram, A. M. & Veenhuis, M. (2002). Normal Peroxisome Development from Vesicles Induced by Truncated Hansenula polymorpha Pex3p. *J Biol Chem* **277**, 11026-11033.

Faisst, S. & Meyer, S. (1992). Compilation of vertebrate-encoded transcription factors. *Nucleic Acids Res* **20**, 3-26.

Faust, P. L. & Hatten, M. E. (1997). Targeted deletion of the PEX2 peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder. *J Cell Biol* **139**, 1293-1305.

Fibach, E., Prasanna, P., Rodgers, G. P. & Samid, D. (1993). Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. *Blood* **82**, 2203-2209.

Fransen, M., Terlecky, S. R. & Subramani, S. (1998). Identification of a human PTS1 receptor docking protein directly required for peroxisomal protein import. *Proc Natl Acad Sci U S A* **95**, 8087-8092.

Fransen, M., Wylin, T., Brees, C., Mannaerts, G. P. & Van Veldhoven, P. P. (2001). Human pex19p binds peroxisomal integral membrane proteins at regions distinct from their sorting sequences. *Mol Cell Biol* **21**, 4413-4424.

Fransen, M., Brees, C., Baumgart, E., Vanhooren, J. C., Baes, M., Mannaerts, G. P. & Van Veldhoven, P. P. (1995). Identification and characterization of the putative human peroxisomal C-terminal targeting signal import receptor. *J Biol Chem* **270**, 7731-7736.

Fukuda, S., Shimozawa, N., Suzuki, Y., Zhang, Z., Tomatsu, S., Tsukamoto, T., Hashiguchi, N., Osumi, T., Masuno, M., Imaizumi, K., Kuroki, Y., Fujiki, Y., Orii, T. & Kondo, N. (1996). Human peroxisome assembly factor-2 (PAF-2): a gene responsible for group C peroxisome biogenesis disorder in humans. *Am J Hum Genet* **59**, 1210-1220.

Gärtner, J. & Valle, D. (1993). The 70 kDa peroxisomal membrane protein: an ATP-binding cassette transporter protein involved in peroxisome biogenesis. *Semin Cell Biol* **4**, 45-52.

Gärtner, J., Moser, H. & Valle, D. (1992). Mutations in the 70K peroxisomal membrane protein gene in Zellweger syndrome. *Nat Genet* **1**, 16-23.

Gärtner, J., Jimenez-Sanchez, G., Roerig, P. & Valle, D. (1998a). Genomic organization of the 70-kDa peroxisomal membrane protein gene (PXMP1). *Genomics* **48**, 203-208.

Gärtner, J., Brosius, U., Obie, C., Watkins, P. A. & Valle, D. (1998b). Restoration of PEX2 peroxisome assembly defects by overexpression of PMP70. *Eur J Cell Biol* **76**, 237-245.

Gärtner, J., Braun, A., Holzinger, A., Roerig, P., Lenard, H. G. & Roscher, A. A. (1998c). Clinical and genetic aspects of X-linked adrenoleukodystrophy. *Neuropediatrics* **29**, 3-13.

Gatto, G. J., Jr., Geisbrecht, B. V., Gould, S. J. & Berg, J. M. (2000). Peroxisomal targeting signal-1 recognition by the TPR domains of human PEX5. *Nat Struct Biol* **7**, 1091-1095.

Gebel, T., Arand, M. & Oesch, F. (1992). Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. *FEBS Lett* **309**, 37-40.

Geraghty, M. T., Bassett, D., Morrell, J. C., Gatto, G. J., Jr., Bai, J., Geisbrecht, B. V., Hieter, P. & Gould, S. J. (1999). Detecting patterns of protein distribution and gene expression in silico. *Proc Natl Acad Sci U S A* **96**, 2937-2942.

Ghosh, D. (1991). New developments of a transcription factors database. *Trends Biochem Sci* **16**, 445-447.

Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R. M. & Otulakowski, G. (1994). Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. *Genes Dev* **8**, 538-553.

Girzalsky, W., Rehling, P., Stein, K., Kipper, J., Blank, L., Kunau, W. H. & Erdmann, R. (1999). Involvement of Pex13p in Pex14p localization and peroxisomal targeting signal 2-dependent protein import into peroxisomes. *J Cell Biol* **144**, 1151-1162.

Gloeckner, C. J., Mayerhofer, P. U., Landgraf, P., Muntau, A. C., Holzinger, A., Gerber, J. K., Kammerer, S., Adamski, J. & Roscher, A. A. (2000). Human adrenoleukodystrophy protein and related peroxisomal ABC transporters interact with the peroxisomal assembly protein PEX19p. *Biochem Biophys Res Commun* **271**, 144-150.

Glover, J. R., Andrews, D. W. & Rachubinski, R. A. (1994). Saccharomyces cerevisiae peroxisomal thiolase is imported as a dimer. *Proc Natl Acad Sci U S A* **91**, 10541-10545.

Gorvel, J. P., Chavrier, P., Zerial, M. & Gruenberg, J. (1991). rab5 controls early endosome fusion in vitro. *Cell* **64**, 915-925.

Götte, K., Girzalsky, W., Linkert, M., Baumgart, E., Kammerer, S., Kunau, W. H. & Erdmann, R. (1998). Pex19p, a farnesylated protein essential for peroxisome biogenesis. *Mol Cell Biol* **18**, 616-628.

Gould, S. J. & Valle, D. (2000). Peroxisome biogenesis disorders Genetics and cell biology. *Trends Genet* **16**, 340-345.

Gould, S. J., Raymond, G. V. & Valle, D. (2001). The Peroxisome Biogenesis Disorders. In *The Metabolic and Molecular Bases of Inherited Disease*, pp. 3181-3215. Edited by C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Valle. New York: McGraw-Hill.

Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J. & Subramani, S. (1989). A conserved tripeptide sorts proteins to peroxisomes. *J Cell Biol* **108**, 1657-1664.

Green, S. (1993). *Nature* **361**, 590-591.

Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. (1989). All ras proteins are polyisoprenylated but only some are palmitoylated. *Cell* **57**, 1167-1177.

Heim, P., Claussen, M., Hoffmann, B., Conzelmann, E., Gartner, J., Harzer, K., Hunneman, D. H., Kohler, W., Kurlemann, G. & Kohlschutter, A. (1997). Leukodystrophy incidence in Germany. *Am J Med Genet* **71**, 475-478.

Hettema, E. H., Distel, B. & Tabak, H. F. (1999). Import of proteins into peroxisomes. *Biochim Biophys Acta* **1451**, 17-34.

Hettema, E. H., Girzalsky, W., van Den Berg, M., Erdmann, R. & Distel, B. (2000). Saccharomyces cerevisiae pex3p and pex19p are required for proper localization and stability of peroxisomal membrane proteins. *Embo J* **19**, 223-233.

Höhfeld, J., Veenhuis, M. & Kunau, W. H. (1991). PAS3, a Saccharomyces cerevisiae gene encoding a peroxisomal integral membrane protein essential for peroxisome biogenesis. *J Cell Biol* **114**, 1167-1178.

Holzinger, A., Kammerer, S. & Roscher, A. A. (1997a). Primary structure of human PMP69, a putative peroxisomal ABC-transporter. *Biochem Biophys Res Commun* **237**, 152-157.

Holzinger, A., Kammerer, S., Berger, J. & Roscher, A. A. (1997b). cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. *Biochem Biophys Res Commun* **239**, 261-264.

Holzinger, A., Muntau, A., Mayerhofer, P., Kammerer, S., Albet, S., Bugaut, M. & Roscher, A. A. (1998). The mouse gene encoding the peroxisomal membrane protein 1-like protein (PXMP1-L): cDNA cloning, genomic organization and comparative expression studies. *FEBS Lett* **433**, 179-183.

Honsho, M., Tamura, S., Shimozawa, N., Suzuki, Y., Kondo, N. & Fujiki, Y. (1998). Mutation in PEX16 is causal in the peroxisome-deficient Zellweger syndrome of complementation group D. *Am J Hum Genet* **63**, 1622-1630.

Huhse, B., Rehling, P., Albertini, M., Blank, L., Meller, K. & Kunau, W. H. (1998). Pex17p of Saccharomyces cerevisiae is a novel peroxin and component of the peroxisomal protein translocation machinery. *J Cell Biol* **140**, 49-60.

Imanaka, T., Shiina, Y., Takano, T., Hashimoto, T. & Osumi, T. (1996). Insertion of the 70-kDa peroxisomal membrane protein into peroxisomal membranes in vivo and in vitro. *J Biol Chem* **271**, 3706-3713.

Ioannou, P. A., Amemiya, C. T., Garnes, J., Kroisel, P. M., Shizuya, H., Chen, C., Batzer, M. A. & de Jong, P. J. (1994). A new bacteriophage P1-derived vector for the propagation of large human DNA fragments. *Nat Genet* **6**, 84-89.

James, G. L., Goldstein, J. L., Pathak, R. K., Anderson, R. G. & Brown, M. S. (1994). PxF, a prenylated protein of peroxisomes. *J Biol Chem* **269**, 14182-14190.

Jones, J. M., Morrell, J. C. & Gould, S. J. (2001). Multiple distinct targeting signals in integral peroxisomal membrane proteins. *J Cell Biol* **153**, 1141-1150.

Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A. & Desvergne, B. (1997). DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. *J Biol Chem* **272**, 25252-25259.

Just, W. W. & Diestelkotter, P. (1996). Protein insertion into the peroxisomal membrane. *Ann N Y Acad Sci* **804**, 60-75.

Kalish, J. E., Keller, G. A., Morrell, J. C., Mihalik, S. J., Smith, B., Cregg, J. M. & Gould, S. J. (1996). Characterization of a novel component of the peroxisomal protein import apparatus using fluorescent peroxisomal proteins. *Embo J* **15**, 3275-3285.

Kamijo, K., Taketani, S., Yokota, S., Osumi, T. & Hashimoto, T. (1990). The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. *J Biol Chem* **265**, 4534-4540.

Kammerer, S., Holzinger, A., Welsch, U. & Roscher, A. A. (1998). Cloning and characterization of the gene encoding the human peroxisomal assembly protein Pex3p. *FEBS Lett* **429**, 53-60.

Kammerer, S., Arnold, N., Gutensohn, W., Mewes, H. W., Kunau, W. H., Hofler, G., Roscher, A. A. & Braun, A. (1997). Genomic organization and molecular characterization of a gene encoding HsPXF, a human peroxisomal farnesylated protein. *Genomics* **45**, 200-210.

Karpichev, I. V., Luo, Y., Marians, R. C. & Small, G. M. (1997). A complex containing two transcription factors regulates peroxisome proliferation and the coordinate induction of beta-oxidation enzymes in Saccharomyces cerevisiae. *Mol Cell Biol* **17**, 69-80.

Kato, K., Der, C. J. & Buss, J. E. (1992a). Prenoids and palmitate: lipids that control the biological activity of Ras proteins. *Semin Cancer Biol* **3**, 179-188.

Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E. & Der, C. J. (1992b). Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. *Proc Natl Acad Sci U S A* **89**, 6403-6407.

Kemp, S., Wei, H. M., Lu, J. F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A. & Smith, K. D. (1998). Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy [see comments]. *Nat Med* **4**, 1261-1268.

Klein, I., Sarkadi, B. & Varadi, A. (1999). An inventory of the human ABC proteins. *Biochim Biophys Acta* **1461**, 237-262.

Kobayashi, T., Yamada, T., Yasutake, T., Shinnoh, N., Goto, I. & Iwaki, T. (1994). Adrenoleukodystrophy gene encodes an 80 kDa membrane protein. *Biochem Biophys Res Commun* **201**, 1029-1034.

Koller, A., Snyder, W. B., Faber, K. N., Wenzel, T. J., Rangell, L., Keller, G. A. & Subramani, S. (1999). Pex22p of Pichia pastoris, essential for peroxisomal matrix protein import, anchors the ubiquitin-conjugating enzyme, Pex4p, on the peroxisomal membrane. *J Cell Biol* **146**, 99-112.

Komori, M., Rasmussen, S. W., Kiel, J. A., Baerends, R. J., Cregg, J. M., van der Klei, I. J. & Veenhuis, M. (1997). The Hansenula polymorpha PEX14 gene encodes a novel peroxisomal membrane protein essential for peroxisome biogenesis. *Embo J* **16**, 44-53.

Kozak, M. (1991). Structural features in eukaryotic mRNAs that modulate the initiation of translation. *J Biol Chem* **266**, 19867-19870.

Krawczak, M., Reiss, J. & Cooper, D. N. (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. *Hum Genet* **90**, 41-54.

Kunau, W. H. & Erdmann, R. (1998). Peroxisome biogenesis: back to the endoplasmic reticulum? *Curr Biol* **8**, R299-302.

Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.

Lambkin, G. R. & Rachubinski, R. A. (2001). Yarrowia lipolytica cells mutant for the peroxisomal peroxin Pex19p contain structures resembling wild-type peroxisomes. *Mol Biol Cell* **12**, 3353-3364.

Landgraf, P., Mayerhofer, P. U., Polanetz, R., Roscher, A. A., & Holzinger, A. (2003). Targeting of the human adrenoleukodystrophy protein to the peroxisomal membrane by an internal region containing a highly conserved motif. *Eur J Cell Biol,* **accepted**.

Latterich, M., Frohlich, K. U. & Schekman, R. (1995). Membrane fusion and the cell cycle: Cdc48p participates in the fusion of ER membranes. *Cell* **82**, 885-893.

Lazarow, P. B. (1984). The peroxisomal membrane. In *Membrane Structure and Function*, pp. 1-31. Edited by E. E. Bittar. New York: Wiley.

Lazarow, P. B. & Fujiki, Y. (1985). Biogenesis of peroxisomes. *Annu Rev Cell Biol* **1**, 489-530.

Lazarow, P. B. & Moser, H. W. (1995). Disorders of peroxisome biogenesis. In *The Metabolic and Molecular Bases of Inherited Disease*, pp. 2287-2324. Edited by C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Valle. New York: McGraw-Hill.

Lazo, O., Contreras, M., Bhushan, A., Stanley, W. & Singh, I. (1989). Adrenoleukodystrophy: impaired oxidation of fatty acids due to peroxisomal lignoceroyl-CoA ligase deficiency. *Arch Biochem Biophys* **270**, 722-728.

Leenders, F., Tesdorpf, J. G., Markus, M., Engel, T., Seedorf, U. & Adamski, J. (1996). Porcine 80-kDa protein reveals intrinsic 17 beta-hydroxysteroid dehydrogenase, fatty acyl-CoA-hydratase/dehydrogenase, and sterol transfer activities. *J Biol Chem* **271**, 5438-5442.

Lehrach, H. (1990). In *Genome Analysis*, pp. 39-81. Edited by K. E. Davies & S. M. Tilghman. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.

Lichter, P., Cremer, T., Borden, J., Manuelidis, L. & Ward, D. C. (1988). Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. *Hum Genet* **80**, 224-234.

Lichter, P., Tang, C. J., Call, K., Hermanson, G., Evans, G. A., Housman, D. & Ward, D. C. (1990). High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. *Science* **247**, 64-69.

Litwin, J. A. & Bilinska, B. (1995). Morphological heterogeneity of peroxisomes in cultured mouse Leydig cells. *Folia Histochem Cytobiol* **33**, 255-258.

Liu, L. X., Janvier, K., Berteaux-Lecellier, V., Cartier, N., Benarous, R. & Aubourg, P. (1999a). Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. *J Biol Chem* **274**, 32738-32743.

Liu, Y., Bjorkman, J., Urquhart, A., Wanders, R. J., Crane, D. I. & Gould, S. J. (1999b). PEX13 is mutated in complementation group 13 of the peroxisome-biogenesis disorders. *Am J Hum Genet* **65**, 621-634.

Lombard-Platet, G., Savary, S., Sarde, C. O., Mandel, J. L. & Chimini, G. (1996). A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. *Proc Natl Acad Sci U S A* **93**, 1265-1269.

Marshall, C. J. (1993). Protein prenylation: a mediator of protein-protein interactions. *Science* **259**, 1865-1866.

Marshall, P. A., Krimkevich, Y. I., Lark, R. H., Dyer, J. M., Veenhuis, M. & Goodman, J. M. (1995). Pmp27 promotes peroxisomal proliferation. *J Cell Biol* **129**, 345-355.

Marzioch, M., Erdmann, R., Veenhuis, M. & Kunau, W. H. (1994). PAS7 encodes a novel yeast member of the WD-40 protein family essential for import of 3-oxoacyl-CoA thiolase, a PTS2-containing protein, into peroxisomes. *Embo J* **13**, 4908-4918.

Matsumura, T., Otera, H. & Fujiki, Y. (2000). Disruption of the interaction of the longer isoform of Pex5p, Pex5pL, with Pex7p abolishes peroxisome targeting signal type 2 protein import in mammals. Study with a novel Pex5-impaired

Chinese hamster ovary cell mutant. *J Biol Chem* **275**, 21715-21721.

Matsuzono, Y., Kinoshita, N., Tamura, S., Shimozawa, N., Hamasaki, M., Ghaedi, K., Wanders, R. J., Suzuki, Y., Kondo, N. & Fujiki, Y. (1999). Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly. *Proc Natl Acad Sci U S A* **96**, 2116-2121.

McCollum, D., Monosov, E. & Subramani, S. (1993). The pas8 mutant of Pichia pastoris exhibits the peroxisomal protein import deficiencies of Zellweger syndrome cells--the PAS8 protein binds to the COOH-terminal tripeptide peroxisomal targeting signal, and is a member of the TPR protein family [published erratum appears in J Cell Biol 1993 Sep;122(5):following 1143]. *J Cell Biol* **121**, 761-774.

McNew, J. A. & Goodman, J. M. (1994). An oligomeric protein is imported into peroxisomes in vivo. *J Cell Biol* **127**, 1245-1257.

Moomaw, J. F. & Casey, P. J. (1992). Mammalian protein geranylgeranyltransferase. Subunit composition and metal requirements. *J Biol Chem* **267**, 17438-17443.

Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L. & Gibbs, J. B. (1991). Sequence dependence of protein isoprenylation. *J Biol Chem* **266**, 14603-14610.

Moser, A. B., Rasmussen, M., Naidu, S., Watkins, P. A., McGuinness, M., Hajra, A. K., Chen, G., Raymond, G., Liu, A., Gordon, D. & et al. (1995a). Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. *J Pediatr* **127**, 13-22.

Moser, H. W. (1999). Genotype-Phenotype Correlations in Disorders of Peroxisome Biogenesis. *Mol Genet Metab* **68**, 316-327.

Moser, H. W., D., S. K. & Moser, A. B. (1995b). X-linked adrenoleukodystrophy. In *The Metabolic and Molecular Bases of Inherited Disease*, pp. 2325-2350. Edited by C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Valle. New York: McGraw-Hill.

Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., Poustka, A. M., Mandel, J. L. & Aubourg, P. (1993). Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. *Nature* **361**, 726-730.

Mosser, J., Lutz, Y., Stoeckel, M. E., Sarde, C. O., Kretz, C., Douar, A. M., Lopez, J., Aubourg, P. & Mandel, J. L. (1994). The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. *Hum Mol Genet* **3**, 265-271.

Motley, A. M., Hettema, E. H., Hogenhout, E. M., Brites, P., ten Asbroek, A. L., Wijburg, F. A., Baas, F., Heijmans, H. S., Tabak, H. F., Wanders, R. J. & Distel, B. (1997). Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. *Nat Genet* **15**, 377-380.

Muntau, A. C., Mayerhofer, P. U., Paton, B. C., Kammerer, S. & Roscher, A. A. (2000a). Defective peroxisome membrane synthesis due To mutations in human PEX3 causes zellweger syndrome, complementation group G. *Am J Hum Genet* **67**, 967-975.

Muntau, A. C., Holzinger, A., Mayerhofer, P. U., Gartner, J., Roscher, A. A. & Kammerer, S. (2000b). The human PEX3 gene encoding a peroxisomal assembly protein: genomic organization, positional mapping, and mutation analysis in candidate phenotypes. *Biochem Biophys Res Commun* **268**, 704-710.

Novikoff, A. & Shin, W. Y. (1964). The endoplasmic reticulum in the golgi zone and its relation to microbodies, golgi apparatus and autophagic vacuoles in rat liver cells. *J Microsc* **3**, 187-206.

Okumoto, K. & Fujiki, Y. (1997). PEX12 encodes an integral membrane protein of peroxisomes. *Nat Genet* **17**, 265-266.

Okumoto, K., Itoh, R., Shimozawa, N., Suzuki, Y., Tamura, S., Kondo, N. & Fujiki, Y. (1998). Mutations in PEX10 is the cause of Zellweger peroxisome deficiency syndrome of complementation group B. *Hum Mol Genet* **7**, 1399-1405.

Olivieri, N. F., Rees, D. C., Ginder, G. D., Thein, S. L., Waye, J. S., Chang, L., Brittenham, G. M. & Weatherall, D. J. (1998). Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia. *Ann N Y Acad Sci* **850**, 100-109.

Otera, H., Harano, T., Honsho, M., Ghaedi, K., Mukai, S., Tanaka, A., Kawai, A., Shimizu, N. & Fujiki, Y. (2000). The mammalian peroxin Pex5pL, the longer isoform of the mobile peroxisome targeting signal (PTS) type 1 transporter, translocates the Pex7p.PTS2 protein complex into peroxisomes via its initial docking site, Pex14p. *J Biol Chem* **275**, 21703-21714.

Otera, H., Okumoto, K., Tateishi, K., Ikoma, Y., Matsuda, E., Nishimura, M., Tsukamoto, T., Osumi, T., Ohashi, K., Higuchi, O. & Fujiki, Y. (1998). Peroxisome targeting signal type 1 (PTS1) receptor is involved in import of both PTS1 and PTS2: studies with PEX5-defective CHO cell mutants. *Mol Cell Biol* **18**, 388-399.

Packard, C. J. (1998). Overview of fenofibrate. *Eur Heart J* **19**, A62-65.

Padgett, R. A., Grabowski, P. J., Konarska, M. M., Seiler, S. & Sharp, P. A. (1986). Splicing of messenger RNA precursors. *Annu Rev Biochem* **55**, 1119-1150.

Pahan, K., Khan, M. & Singh, I. (1998). Therapy for X-adrenoleukodystrophy: normalization of very long chain fatty acids and inhibition of induction of cytokines by cAMP [In Process Citation]. *J Lipid Res* **39**, 1091-1100.

Passreiter, M., Anton, M., Lay, D., Frank, R., Harter, C., Wieland, F. T., Gorgas, K. & Just, W. W. (1998). Peroxisome biogenesis: involvement of ARF and coatomer. *J Cell Biol* **141**, 373-383.

Pause, B., Diestelkotter, P., Heid, H. & Just, W. W. (1997). Cytosolic factors mediate protein insertion into the peroxisomal membrane. *FEBS Lett* **414**, 95-98.

Portsteffen, H., Beyer, A., Becker, E., Epplen, C., Pawlak, A., Kunau, W. H. & Dodt, G. (1997). Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. *Nat Genet* **17**, 449-452.

Poulos, A., Christodoulou, J., Chow, C. W., Goldblatt, J., Paton, B. C., Orii, T., Suzuki, Y. & Shimozawa, N. (1995). Peroxisomal assembly defects: clinical, pathologic, and biochemical findings in two patients in a newly identified complementation group. *J Pediatr* **127**, 596-599.

Prestridge, D. S. (1991). Signal Scan: A computer program that scans DNA sequences for eukaryotic transcription elements. *Comput. Appl. Biosci.* **7** , 203-206.

Purdue, P. E. & Lazarow, P. B. (2001). Peroxisome biogenesis. *Annu Rev Cell Dev Biol* **17**, 701-752.

Purdue, P. E., Yang, X. & Lazarow, P. B. (1998). Pex18p and Pex21p, a novel pair of related peroxins essential for peroxisomal targeting by the PTS2 pathway. *J Cell Biol* **143**, 1859-1869.

Purdue, P. E., Zhang, J. W., Skoneczny, M. & Lazarow, P. B. (1997). Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. *Nat Genet* **15**, 381-384.

Quandt, K., Frech, K., Karas, H., Wingender, E. & Werner, T. (1995). MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. *Nucleic Acids Res* **23**, 4878-4884.

Rehling, P., Skaletz-Rorowski, A., Girzalsky, W., Voorn-Brouwer, T., Franse, M. M., Distel, B., Veenhuis, M., Kunau, W. H. & Erdmann, R. (2000). Pex8p, an intraperoxisomal peroxin of Saccharomyces cerevisiae required for protein transport into peroxisomes binds the PTS1 receptor pex5p. *J Biol Chem* **275**, 3593-3602.

Reiss, Y., Stradley, S. J., Gierasch, L. M., Brown, M. S. & Goldstein, J. L. (1991). Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. *Proc Natl Acad Sci U S A* **88**, 732-736.

Reuber, B. E., Germain-Lee, E., Collins, C. S., Morrell, J. C., Ameritunga, R., Moser, H. W., Valle, D. & Gould, S. J. (1997). Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. *Nat Genet* **17**, 445-448.

Rhodin, J. (1954). Correlation of ultrastructural organization and function in normal and experimentally changed proximal convoluted tubule cells of the mouse kidney. In *Karolinska Institut*. Stockholm.

Roscher, A., Molzer, B., Bernheimer, H., Stockler, S., Mutz, I. & Paltauf, F. (1985). The cerebrohepatorenal (Zellweger) syndrome: an improved method for the biochemical diagnosis and its potential value for prenatal detection. *Pediatr Res* **19**, 930-933.

Roscher, A. A., Hoefler, S., Hoefler, G., Paschke, E., Paltauf, F., Moser, A. & Moser, H. (1989). Genetic and phenotypic heterogeneity in disorders of peroxisome biogenesis--a complementation study involving cell lines from 19 patients. *Pediatr Res* **26**, 67-72.

Russell, L., Finley, J. R. & Brent, R. (1996). In *DNA Cloning-Expression Systems: A Practical Approach*, pp. 169-203. Edited by D. Glover & B. D. Hames. Oxford: Oxford Univ. Press.

Sacksteder, K. A., Jones, J. M., South, S. T., Li, X., Liu, Y. & Gould, S. J. (2000). PEX19 Binds Multiple Peroxisomal Membrane Proteins, Is Predominantly Cytoplasmic, and Is Required for

Peroxisome Membrane Synthesis. *J Cell Biol* **148**, 931-944.

Savary, S., Troffer-Charlier, N., Gyapay, G., Mattei, M. G. & Chimini, G. (1997). Chromosomal localization of the adrenoleukodystrophy-related gene in man and mice. *Eur J Hum Genet* **5**, 99-101.

Schatz, G. & Dobberstein, B. (1996). Common principles of protein translocation across membranes. *Science* **271**, 1519-1526.

Schneiter, R., Brugger, B., Sandhoff, R., Zellnig, G., Leber, A., Lampl, M., Athenstaedt, K., Hrastnik, C., Eder, S., Daum, G., Paltauf, F., Wieland, F. T. & Kohlwein, S. D. (1999). Electrospray ionization tandem mass spectrometry (ESI-MS/MS) analysis of the lipid molecular species composition of yeast subcellular membranes reveals acyl chain-based sorting/remodeling of distinct molecular species en route to the plasma membrane. *J Cell Biol* **146**, 741-754.

Schrader, M., Reuber, B. E., Morrell, J. C., Jimenez-Sanchez, G., Obie, C., Stroh, T. A., Valle, D., Schroer, T. A. & Gould, S. J. (1998). Expression of PEX11beta mediates peroxisome proliferation in the absence of extracellular stimuli. *J Biol Chem* **273**, 29607-29614.

Scotto, J. M., Hadchouel, M., Odievre, M., Laudat, M. H., Saudubray, J. M., Dulac, O., Beucler, I. & Beaune, P. (1982). Infantile phytanic acid storage disease, a possible variant of Refsum's disease: three cases, including ultrastructural studies of the liver. *J Inherit Metab Dis* **5**, 83-90.

Shani, N. & Valle, D. (1996). A Saccharomyces cerevisiae homolog of the human adrenoleukodystrophy transporter is a heterodimer of two half ATP-binding cassette transporters. *Proc Natl Acad Sci U S A* **93**, 11901-11906.

Shani, N., Sapag, A., Watkins, P. A. & Valle, D. (1996). An S. cerevisiae peroxisomal transporter, orthologous to the human adrenoleukodystrophy protein, appears to be a heterodimer of two half ABC transporters: Pxa1p and Pxa2p. *Ann N Y Acad Sci* **804**, 770-772.

Shani, N., Jimenez-Sanchez, G., Steel, G., Dean, M. & Valle, D. (1997). Identification of a fourth half ABC transporter in the human peroxisomal membrane. *Hum Mol Genet* **6**, 1925-1931.

Shapiro, M. B. & Senapathy, P. (1987). RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res* **15**, 7155-7174.

Shimizu, N., Itoh, R., Hirono, Y., Otera, H., Ghaedi, K., Tateishi, K., Tamura, S., Okumoto, K., Harano, T., Mukai, S. & Fujiki, Y. (1999). The peroxin Pex14p. cDNA cloning by functional complementation on a Chinese hamster ovary cell mutant, characterization, and functional analysis. *J Biol Chem* **274**, 12593-12604.

Shimozawa, N., Tsukamoto, T., Suzuki, Y., Orii, T., Shirayoshi, Y., Mori, T. & Fujiki, Y. (1992). A human gene responsible for Zellweger syndrome that affects peroxisome assembly. *Science* **255**, 1132-1134.

Shimozawa, N., Suzuki, Y., Zhang, Z., Imamura, A., Toyama, R., Mukai, S., Fujiki, Y., Tsukamoto, T., Osumi, T., Orii, T., Wanders, R. J. & Kondo, N. (1999). Nonsense and temperature-sensitive mutations in PEX13 are the cause of complementation group H of peroxisome biogenesis disorders. *Hum Mol Genet* **8** , 1077-1083.

Shimozawa, N., Suzuki, Y., Zhang, Z., Imamura, A., Kondo, N., Kinoshita, N., Fujiki, Y., Tsukamoto, T., Osumi, T., Imanaka, T., Orii, T., Beemer, F., Mooijer, P., Dekker, C. & Wanders, R. J. (1998). Genetic basis of peroxisome-assembly mutants of humans, Chinese hamster ovary cells, and yeast: identification of a new complementation group of peroxisome-biogenesis disorders apparently lacking peroxisomal- membrane ghosts [letter]. *Am J Hum Genet* **63**, 1898-1903.

Singh, I., Pahan, K. & Khan, M. (1998). Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. *FEBS Lett* **426**, 342-346.

Smith, B. T., Sengupta, T. K. & Singh, I. (2000). Intraperoxisomal localization of very-long-chain fatty acyl-CoA synthetase: implication in X-adrenoleukodystrophy. *Exp Cell Res* **254**, 309-320.

Smith, K. D., Kemp, S., Braiterman, L. T., Lu, J. F., Wei, H. M., Geraghty, M., Stetten, G., Bergin, J. S., Pevsner, J. & Watkins, P. A. (1999). X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. *Neurochem Res* **24**, 521-535.

Smith, M. D. & Schnell, D. J. (2001). Peroxisomal protein import. the paradigm shifts. *Cell* **105**, 293-296.

Snyder, W. B., Koller, A., Choy, A. J. & Subramani, S. (2000). The Peroxin Pex19p Interacts with Multiple, Integral Membrane Proteins

at the Peroxisomal Membrane. *J Cell Biol* **149**, 1171-1178.

Snyder, W. B., Faber, K. N., Wenzel, T. J., Koller, A., Luers, G. H., Rangell, L., Keller, G. A. & Subramani, S. (1999a). Pex19p interacts with Pex3p and Pex10p and is essential for peroxisome biogenesis in Pichia pastoris. *Mol Biol Cell* **10**, 1745-1761.

Snyder, W. B., Koller, A., Choy, A. J., Johnson, M. A., Cregg, J. M., Rangell, L., Keller, G. A. & Subramani, S. (1999b). Pex17p is required for import of both peroxisome membrane and lumenal proteins and interacts with pex19p and the peroxisome targeting signal- receptor docking complex in pichia pastoris [In Process Citation]. *Mol Biol Cell* **10**, 4005-4019.

Soukupova, M., Sprenger, C., Gorgas, K., Kunau, W. H. & Dodt, G. (1999). Identification and characterization of the human peroxin PEX3. *Eur J Cell Biol* **78**, 357-374.

South, S. T. & Gould, S. J. (1999). Peroxisome synthesis in the absence of preexisting peroxisomes. *J Cell Biol* **144**, 255-266.

South, S. T., Sacksteder, K. A., Li, X., Liu, Y. & Gould, S. J. (2000). Inhibitors of COPI and COPII do not block PEX3-mediated peroxisome synthesis. *J Cell Biol* **149**, 1345-1360.

Spong, A. P. & Subramani, S. (1993). Cloning and characterization of PAS5: a gene required for peroxisome biogenesis in the methylotrophic yeast Pichia pastoris. *J Cell Biol* **123**, 535-548.

Spranger, J. W., Opitz, J. M. & Bidder, U. (1971). Heterogeneity of Chondrodysplasia punctata. *Humangenetik* **11**, 190-212.

Steinberg, S. J., Kemp, S., Braiterman, L. T. & Watkins, P. A. (1999a). Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. *Ann Neurol* **46**, 409-412.

Steinberg, S. J., Wang, S. J., Kim, D. G., Mihalik, S. J. & Watkins, P. A. (1999b). Human very-long-chain acyl-CoA synthetase: cloning, topography, and relevance to branched-chain fatty acid metabolism. *Biochem Biophys Res Commun* **257**, 615-621.

Strehler, E. E. & Zacharias, D. A. (2001). Role of alternative splicing in generating isoform diversity among plasma membrane calcium pumps. *Physiol Rev* **81**, 21-50.

Subauste, J. S. & Koenig, R. J. (1995). Comparison of the DNA binding specificity and function of v-ErbA and thyroid hormone receptor alpha 1. *J Biol Chem* **270**, 7957-7962.

Subramani, S. (1993). Protein import into peroxisomes and biogenesis of the organelle. *Annu Rev Cell Biol* **9**, 445-478.

Subramani, S. (1997). PEX genes on the rise [news]. *Nat Genet* **15**, 331-333.

Subramani, S. (1998). Components involved in peroxisome import, biogenesis, proliferation, turnover, and movement. *Physiol Rev* **78**, 171-188.

Subramani, S., Koller, A. & Snyder, W. B. (2000). Import of peroxisomal matrix and membrane proteins. *Annu Rev Biochem* **69**, 399-418.

Tamanoi, F. (1993). Inhibitors of Ras farnesyltransferases. *Trends Biochem Sci* **18**, 349-353.

Tamura, S., Okumoto, K., Toyama, R., Shimozawa, N., Tsukamoto, T., Suzuki, Y., Osumi, T., Kondo, N. & Fujiki, Y. (1998). Human PEX1 cloned by functional complementation on a CHO cell mutant is responsible for peroxisome-deficient Zellweger syndrome of complementation group I. *Proc Natl Acad Sci U S A* **95**, 4350-4355.

Tan, X., Waterham, H. R., Veenhuis, M. & Cregg, J. M. (1995). The Hansenula polymorpha PER8 gene encodes a novel peroxisomal integral membrane protein involved in proliferation. *J Cell Biol* **128**, 307-319.

Tateishi, K., Okumoto, K., Shimozawa, N., Tsukamoto, T., Osumi, T., Suzuki, Y., Kondo, N., Okano, I. & Fujiki, Y. (1997). Newly identified Chinese hamster ovary cell mutants defective in peroxisome biogenesis represent two novel complementation groups in mammals. *Eur J Cell Biol* **73**, 352-359.

Terlecky, S. R., Nuttley, W. M., McCollum, D., Sock, E. & Subramani, S. (1995). The Pichia pastoris peroxisomal protein PAS8p is the receptor for the C-terminal tripeptide peroxisomal targeting signal. *Embo J* **14**, 3627-3634.

Teter, S. A. & Klionsky, D. J. (1999). How to get a folded protein across a membrane. *Trends Cell Biol* **9**, 428-431.

Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* **22**, 4673-4680.

Titorenko, V. I. & Rachubinski, R. A. (1998). The endoplasmic reticulum plays an essential role in peroxisome biogenesis. *Trends Biochem Sci* **23**, 231-233.

Titorenko, V. I. & Rachubinski, R. A. (2001a). The life cycle of the peroxisome. *Nat Rev Mol Cell Biol* **2**, 357-368.

Titorenko, V. I. & Rachubinski, R. A. (2001b). Dynamics of peroxisome assembly and function. *Trends Cell Biol* **11**, 22-29.

Titorenko, V. I., Chan, H. & Rachubinski, R. A. (2000). Fusion of small peroxisomal vesicles in vitro reconstructs an early step in the in vivo multistep peroxisome assembly pathway of Yarrowia lipolytica. *J Cell Biol* **148**, 29-44.

Titorenko, V. I., Smith, J. J., Szilard, R. K. & Rachubinski, R. A. (1998). Pex20p of the yeast Yarrowia lipolytica is required for the oligomerization of thiolase in the cytosol and for its targeting to the peroxisome. *J Cell Biol* **142**, 403-420.

Tolbert, N. E. (1981). Metabolic pathways in peroxisomes and glyoxysomes. *Annu Rev Biochem* **50**, 133-157.

Toyama, R., Mukai, S., Itagaki, A., Tamura, S., Shimozawa, N., Suzuki, Y., Kondo, N., Wanders, R. J. & Fujiki, Y. (1999). Isolation, characterization and mutation analysis of PEX13-defective Chinese hamster ovary cell mutants. *Hum Mol Genet* **8**, 1673-1681.

Toyooka, K., Okamoto, T. & Minamikawa, T. (2000). Mass transport of proform of a KDEL-tailed cysteine proteinase (SH-EP) to protein storage vacuoles by endoplasmic reticulum-derived vesicle is involved in protein mobilization in germinating seeds. *J Cell Biol* **148**, 453-464.

Troffer-Charlier, N., Doerflinger, N., Metzger, E., Fouquet, F., Mandel, J. L. & Aubourg, P. (1998). Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines. *Eur J Cell Biol* **75**, 254-264.

Tsukamoto, T., Miura, S. & Fujiki, Y. (1991). Restoration by a 35K membrane protein of peroxisome assembly in a peroxisome-deficient mammalian cell mutant. *Nature* **350**, 77-81.

Ulrich, J., Herschkowitz, N., Heitz, P., Sigrist, T. & Baerlocher, P. (1978). Adrenoleukodystrophy. Preliminary report of a connatal case. Light- and electron microscopical, immunohistochemical and biochemical findings. *Acta Neuropathol (Berl)* **43**, 77-83.

Urquhart, A. J., Kennedy, D., Gould, S. J. & Crane, D. I. (2000). Interaction of Pex5p, the type 1 peroxisome targeting signal receptor, with the peroxisomal membrane proteins Pex14p and Pex13p. *J Biol Chem* **275**, 4127-4136.

van den Bosch, H., Schutgens, R. B., Wanders, R. J. & Tager, J. M. (1992). Biochemistry of peroxisomes. *Annu Rev Biochem* **61**, 157-197.

van der Klei, I. J., Hilbrands, R. E., Kiel, J. A., Rasmussen, S. W., Cregg, J. M. & Veenhuis, M. (1998). The ubiquitin-conjugating enzyme Pex4p of Hansenula polymorpha is required for efficient functioning of the PTS1 import machinery. *Embo J* **17**, 3608-3618.

Verleur, N., Hettema, E. H., van Roermund, C. W., Tabak, H. F. & Wanders, R. J. (1997). Transport of activated fatty acids by the peroxisomal ATP-binding-cassette transporter Pxa2 in a semi-intact yeast cell system. *Eur J Biochem* **249**, 657-661.

Voorn-Brouwer, T., Kragt, A., Tabak, H. F. & Distel, B. (2001). Peroxisomal membrane proteins are properly targeted to peroxisomes in the absence of COPI- and COPII-mediated vesicular transport. *J Cell Sci* **114**, 2199-2204.

Wahli, W., Devchand, P. R., A, I. J. & Desvergne, B. (1999). Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. *Adv Exp Med Biol* **447**, 199-209.

Walton, P. A., Hill, P. E. & Subramani, S. (1995). Import of stably folded proteins into peroxisomes. *Mol Biol Cell* **6**, 675-683.

Walton, P. A., Gould, S. J., Rachubinski, R. A., Subramani, S. & Feramisco, J. R. (1992). Transport of microinjected alcohol oxidase from Pichia pastoris into vesicles in mammalian cells: involvement of the peroxisomal targeting signal. *J Cell Biol* **118**, 499-508.

Wanders, R. J. (1999). Peroxisomal disorders: clinical, biochemical, and molecular aspects. *Neurochem Res* **24**, 565-580.

Wanders, R. J. & Tager, J. M. (1998). Lipid metabolism in peroxisomes in relation to human disease. *Mol Aspects Med* **19**, 69-154.

Wanders, R. J. A., Barth, P. G. & Heymans, H. S. A. (2001). Single Peroxisomal Enzyme

Deficiencies. In *The Metabolic and Molecular Bases of Inherited Disease*, pp. 3219-3256. Edited by C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Valle. New York: McGraw-Hill.

Wang, X., Unruh, M. J. & Goodman, J. M. (2001). Discrete targeting signals direct Pmp47 to oleate-induced peroxisomes in Saccharomyces cerevisiae. *J Biol Chem* **276**, 10897-10905.

Warren, D. S., Morrell, J. C., Moser, H. W., Valle, D. & Gould, S. J. (1998). Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders. *Am J Hum Genet* **63**, 347-359.

Waterham, H. R., Titorenko, V. I., Haima, P., Cregg, J. M., Harder, W. & Veenhuis, M. (1994). The Hansenula polymorpha PER1 gene is essential for peroxisome biogenesis and encodes a peroxisomal matrix protein with both carboxy- and amino-terminal targeting signals. *J Cell Biol* **127**, 737-749.

Watkins, P. A., Lu, J. F., Steinberg, S. J., Gould, S. J., Smith, K. D. & Braiterman, L. T. (1998). Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations. *J Biol Chem* **273**, 18210-18219.

Watkins, P. A., Gould, S. J., Smith, M. A., Braiterman, L. T., Wei, H. M., Kok, F., Moser, A. B., Moser, H. W. & Smith, K. D. (1995). Altered expression of ALDP in X-linked adrenoleukodystrophy. *Am J Hum Genet* **57**, 292-301.

Wiebel, F. F. & Kunau, W. H. (1992). The Pas2 protein essential for peroxisome biogenesis is related to ubiquitin-conjugating enzymes. *Nature* **359**, 73-76.

Wiemer, E. A. C., Luers, G. H., Faber, K. N., Wenzel, T., Veenhuis, M. & Subramani, S. (1996). Isolation and characterization of Pas2p, a peroxisomal membrane protein essential for peroxisome biogenesis in the methylotrophic yeast Pichia pastoris. *J Biol Chem* **271**, 18973-18980.

Xiong, W. C., Macklem, M. & Parsons, J. T. (1998). Expression and characterization of splice variants of PYK2, a focal adhesion kinase-related protein. *J Cell Sci* **111 (Pt 14)**, 1981-1991.

Yahraus, T., Braverman, N., Dodt, G., Kalish, J. E., Morrell, J. C., Moser, H. W., Valle, D. & Gould, S. J. (1996). The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. *Embo J* **15**, 2914-2923.

Yamasaki, M., Hashiguchi, N., Fujiwara, C., Imanaka, T., Tsukamoto, T. & Osumi, T. (1999). Formation of peroxisomes from peroxisomal ghosts in a peroxisome-deficient mammalian cell mutant upon complementation by protein microinjection. *J Biol Chem* **274**, 35293-35296.

Zellweger, H. (1987). The cerebro-hepato-renal (Zellweger) syndrome and other peroxisomal disorders. *Dev Med Child Neurol* **29**, 821-829.

Zhang, B., Marcus, S. L., Sajjadi, F. G., Alvares, K., Reddy, J. K., Subramani, S., Rachubinski, R. A. & Capone, J. P. (1992). Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl- CoA dehydrogenase. *Proc Natl Acad Sci U S A* **89**, 7541-7545.

Zhang, J. W., Luckey, C. & Lazarow, P. B. (1993). Three peroxisome protein packaging pathways suggested by selective permeabilization of yeast mutants defective in peroxisome biogenesis. *Mol Biol Cell* **4**, 1351-1359.

Appendix 1

Full Length cDNA Cloning, Promoter Sequence and Genomic Organization of the Human Adrenoleukodystrophy Related (*ALDR*) Gene Functionally Redundant to the Gene Responsible for X-Linked Adrenoleukodystrophy

Andreas Holzinger[1], Peter U. Mayerhofer[1], Johannes Berger[2], Peter Lichtner[1]
Stefan Kammerer[1], and Adelbert A. Roscher*

[1]Dr. v. Hauner Children's Hospital, Ludwig-Maximilian-University, Department of Pediatrics, Division of Clinical Chemistry and Metabolism, Lindwurmstrasse 4, 80337 Munich, Germany.
[2]Institute of Neurology, University of Vienna, Austria

*Contributions to the manuscript: Outline of the project by A.A.R and J.B.; concept by A.H. and **P.U.M.**; cDNA cloning, and genomic library screening by A.H.; FISH analysis by P.L.; southern blot analysis by **P.U.M.**; determination of the transcriptional start, determination of the genomic structure, cloning of the putative promoter region, and subcellular localization by A.H. and **P.U.M.**; writing by A.H. and **P.U.M.**; editorial help by A.A.R., J.B., and S.K.*

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a functional defect of the ALD Protein (ALDP), an ABC half-transporter localized in the peroxisomal membrane. It is characterized by defective very long chain fatty acid (VLCFA) ß-oxidation resulting in progressive cerebral demyelination. Since individual mutations in the *ALD*-gene may result in a variety of clinical phenotypes the existence of modifying genetic factors has been proposed. The adrenoleukodystrophy related protein (ALDRP) a close homolog of ALDP has been shown to complement the defect of VLCFA oxidation if transfected into X-ALD cells or chemically induced in ALDP-deficient mice. Chemical ALDRP induction holds a potential for a novel therapeutic stragegy. We report here the exclusively peroxisomal localization of human ALDRP, the full length cDNA, the transcriptional start and 2.4 kb of the putative promoter region DNA sequence. The human *ALDR* gene extends over 33 kb on chromosome 12q12 and consists of 10 exons. The gene structure is highly similar to the *ALD*-gene indicating a recent divergence from a common ancestor. The putative human promoter sequence contains a novel motif conserved in peroxisomal ABC-transporters in the mouse. Our data will enable sequence analysis in X-ALD patients to determine a possible role of ALDRP as a modifier and provide tools for the study of therapeutic ALDRP induction.

Introduction

X-linked adrenoleukodystrophy (X-ALD; McKusick 300100) (Gärtner *et al.*, 1998c; Moser *et al.*, 1995b) is the most frequent peroxisomal with an incidence of 0.8 to 1.6 per 100.000 live births (Bezman & Moser, 1998; Heim *et al.*, 1997). It is characterized by progressive demyelination of the nervous system and adrenocortical insufficiency with marked heterogeneity of clinical manifestations ranging from the childhood cerebral form leading to premature death within several years to asymptomatic forms. Other forms include the cerebral adult form, adrenomyeloneuropathy (AMN) mainly affecting the spinal cord of adults and isolated adrenal insufficiency. The identification of the *ALD*-gene by positional cloning (Mosser *et al.*, 1993) demonstrated the corresponding gene product to be a member of the ABC-transporter protein family. These integral membrane proteins are involved in the transport of various substrates across biological membranes. Mutational analysis in X-ALD patients showed no predictable genotype-phenotype correlation (Gärtner *et al.*, 1998c). Individuals from a family carrying the same and no other mutation in the *ALD*-gene may be affected by any of the clinical phenotypes (Berger *et al.*, 1994). ALDP is likely to be involved in the peroxisomal transport or catabolism of very long chain fatty acids (VLCFA; >C22) since a defect of peroxisomal VLCFA ß-oxidation resulting in elevated VLCFA in plasma and tissues is the biochemical correlate of all forms of X-ALD. It has been proposed that ALDP might be a transporter translocating Coenzyme A-activated VLCFA into the peroxisome, the exclusive site of β-oxidation of VLCFA (Verleur *et al.*, 1997).

The cDNA of the mouse adrenoleukodystrophy related protein (ALDRP) was cloned by a PCR-based search for novel ABC-transporters in the mouse genome (Lombard-Platet *et al.*, 1996). In the mouse ALDRP is mainly expressed in brain, adrenal glands and liver. ALDRP is the closest of three ALDP homologs belonging to the peroxisomal subgroup of ABC half-transporters also including PMP70 (synonym: PXMP1) and PMP69 (synonyms: P70R, PXMP1-L). PMP70 has been proposed to be involved in peroxisome biogenesis, the function of PMP69 is unknown. ABC-half-transporters are expected to form dimers in order to constitute a functional transporter complex. Homodimerization or interaction with another ABC-half-transporter has been proposed. The only two yeast peroxisomal ABC-half-transporters Pat1 and Pat2 have been shown to associate with each other and to be involved in β-oxidation of fatty acids (Shani *et al.*, 1996). We have recently cloned the complete coding region of the human *ALDR*-cDNA (although lacking the full 5´ and 3´ ends) and demonstrated an expression pattern similar to mouse ALDRP mRNA different from other

peroxisomal ABC-transporters (Holzinger *et al*., 1997b). Analysis of human cell lines and mouse tissues showed mirror expression of *ALD* and *ALDR* genes suggesting a similar function in different tissues (Troffer-Charlier *et al*., 1998).

ALDR or *PMP70* cDNA - if transfected into X-ALD-fibroblasts - have been shown to correct the defect of ß-oxidation indicating a functional redundancy of peroxisomal ABC-transporters (Braiterman *et al*., 1998; Kemp *et al*., 1998). *ALDR* mRNA has previously been demonstrated to be inducible by the peroxisome proliferator fenofibrate in the rat (Albet *et al*., 1997). Kemp and colleagues showed inducibility by 4-phenylbutyrate of PMP70 and ALDRP in mouse and human normal and ALDP-deficient cultured fibroblasts. Moreover, 4-phenylbutyrate treatment of cultured human X-ALD fibroblasts as well as 4-phenylbutyrate feedings of ALDP-deficient mice was able to correct the biochemical defect of peroxisomal ß-oxidation. Singh and colleagues (Pahan *et al*., 1998; Singh *et al*., 1998) have reported that Lovastatin (an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase) and sodium phenylacetate as well as 8-Br-cAMP, Forskolin und Rolipram stimulated the beta-oxidation of lignoceric acid (C24:0) and normalized the elevated levels of VLCFA in X-ALD skin fibroblasts. This effect is independent of ALDP. Whether the effect was attributable to the induction of other peroxisomal ABC-transporters has not been determined yet. These findings have raised hopes for a new therapeutic strategy for X-ALD and have enhanced the medical interest in the *ALDR* gene and its regulation of expression. Ectopic *ALDR* expression or overexpression could possibly have a beneficial effect on the disease. The example of the induction of fetal hemoglobin in hemoglobinopathies such as sickle-cell disease and beta-thalassemia have demonstrated the feasibility of an approach employing the induction of a „surrogate gene"(Fibach *et al*., 1993).

We report here the sequence of the 5´ and 3´ untranslated regions of the human *ALDR* cDNA, the exclusively peroxisomal localization of human ALDRP, the transcriptional start, the putative promoter sequence including the description of a motif conserved in fenofibrate-inducible peroxisomal ABC-transporters and the detailed genomic structure of the gene including exon-flanking intronic sequence. These data will be useful tools to investigate a possible role of ALDRP in the determination of the clinical course of X-ALD and will enable further analyis of the mechanism of therapeutic induction of ALDRP. Knowledge of this mechanism might lead to the development of new therapeutic agents for the treatment of X-ALD.

Material and Methods

cDNA cloning and determination of the transcriptional start

A human 1365-bp *ALDRP* cDNA probe ranging from bp 1336 to 2700 in the updated NCBI Genbank entry No. AJ000327 was generated by polymerase chain reaction from randomly primed human liver cDNA. This probe was [α-32P]dATP labeled by hexanucleotide random priming and used for screening the human fetal brain library No. 507 from the Resource Center of the German Human Genome Project, Heidelberg/Berlin (Lehrach, 1990). A clone (ICRF P507D21235Q11) containing a 3547 bp insert including the full coding region was isolated. It contained 135 bp of DNA sequence at the 5´ untranslated region and 1190 bp at the 3´ untranslated region including the polyA-signal. Cloning of the full 5´ untranslated region to determine the transcriptional start was performed by RACE-PCR (Rapid Amplification of cDNA Ends) using the human brain adaptor-ligated cDNA kit (Marathon, Clontech). RACE products were subcloned into the pGemTeasy vector (Promega) and sequenced. The presence on mRNA level of the 5´ untranslated region identified was confirmed by RT-PCR from human brain mRNA. 3´- RACE-PCR was performed accordingly to determine a possible alternative mRNA 3´ end.

Genomic library screening and determination of the genomic structure

A human genomic DNA library generated with the pCYPAC2 vector and genomic DNA derived from cultured skin fibroblasts with an average insert size of approximately 100 kb (Ioannou *et al*., 1994) was screened with the 3547 bp human *ALDR* cDNA probe mentioned above. The probe was [α-32P]dATP labeled by random priming and three positive clones were isolated (Screening Service of the Resource Center of the German Human Genome Project, Heidelberg/Berlin, (Lehrach, 1990)). Genomic fragments containing complete introns were PCR-amplified from pCYPAC2 DNA templates using cDNA-derived oligonucleotide primers. pCYPAC2 DNA preparation was performed by ion-exchange columns (Qiagen midiprep) according to the manufacturer´s protocol for P1-derived constructs. PCR amplification of intron-containing fragments was performed using the Expand Long Template system (Boehringer Mannheim). To estimate intron sizes the PCR products were separated on 0.7% agarose gels and compard to appropriate molecular size markers. The PCR-products were directly sequenced from either end after purification from oligonucleotides (Qiaquick, Quiagen) without further subcloning

using the amplification oligonucleotide primers. Sequencing was also performed directly from pCYPAC DNA templates. All sequencing was performed by the rhodamine fluorescent didesoxy dye terminator method on an ABI 377 sequencer.

Southern blot analysis of pCYPAC clones

The three isolated pCYPAC *ALDR* clones were characterized by nonradioactive Southern blotting of *Eco*RI, *Hind*III and *Xba*I restriction digests using the 3547-bp *ALDR* cDNA as a probe. The probe was digoxigenin-labeled using the PCR DIG Probe Synthesis Kit (Boehringer Mannheim). Transfer of DNA fragments onto nylon membranes was performed by an alkaline capillary method (Turboblotter, Schleicher and Schuell) according to the manufacturer. Hybridization and chemoluminescent detection by an alkaline phosphatase-labeled anti-digoxigenin antibody and the substrate CDP-Star (Boehringer Mannheim) followed the manufacturer´s protocol.

Cloning of the putative promoter region

Genomic DNA from the region upstream from the transcriptional start was cloned by identification by nonradioactive Southern blotting of the appropriate fragment size using an exon 1specific probe in a *Hind*III digest of the pCYPAC clone 3 (LLNLP704H12113Q16) and ligation of a band of appropriate size into the pCDNA3 vector (Invitrogen). A 1700 bp *Hind*III fragment was amplified from this ligation reaction with an exon1-specific reverse oligonucleotide primer and a T7 vector-specific primer and sequenced. Additionally, a restriction-digested adaptor-ligated genomic DNA library (Genome Walker Kit, Clontech) was used to obtain sequence information from the putative promoter region.

Subcellular localization of human ALDR

In order to determine the subcellular localization of human ALDRP, epitope-tagged plasmid expression constructs containing a myc/hexahistidine tag (pcDNA3.1 Myc/His, Invitrogen) or a hemagglutinin tag at the COOH-terminus were generated by PCR and sequenced. Cos7 cells were transfected with these constructs using Lipofectamine (Life Technologies) according to the manufacturer and indirect immunofluorescence double staining with was performed after 72 hours using mouse monoclonal antibodies against the HA or Myc epitopes and rabbit anti-catalase antibodies to identify peroxisomes. Species-specific tetrarhodamine-isothiocyanate-(TRITC)-labeled goat anti-mouse IgG antibodies and fluoresceine-isothiocyanate (FITC)-labeled goat anti-rabbit

IgG antibodies (Dianova, Hamburg) were used as secondary antibodies.

Cytogenetic mapping using fluorescence in situ hybridization (FISH) analysis

Human metaphase cells were prepared from phytohemagglutinin-stimulated peripheral blood lymphocytes according to standard procedures. FISH was performed using pCYPAC2-DNA from clone 3 (LLNLP704H12113Q16) which contained the complete *ALDR* gene. pCYPAC2-DNA was labeled with biotin-14-dUTP (Life Technologies) by nick-translation and preannealed with Cot-1 DNA (Life Technologies). Detection and visualization was achieved using the avidin-fluorescein isothiocyanat/antiavidin antibody system described elsewhere (Lichter *et al*., 1988; Lichter *et al*., 1990) and chromosomes were identified by staining with 4,6-diamino-2-phenylindole dihydrochloride (DAPI).

Figure A1-1: Immunofluorescence analysis of the subcellular localization of human ALDRP. Human hemagglutinin epitope-tagged ALDRP (A) colocalizes with catalase (B) a peroxisomal marker.

Results

Full length cDNA cloning and determination of the transcriptional start

Human fetal brain cDNA library screening in combination with 5´ RACE PCR yielded a 3968 bp human *ALDR* cDNA. The longest 5´ RACE products defined the transcriptional start. Several clones containing identical RACE products were identified as the longest. PCR amplification of *ALDR* cDNA across exon-intron boundaries excluded an artifact of the 5´ RACE procedure resulting from genomic DNA amplification. A 1500-bp *ALDR*-specific product could be amplified from human randomly primed brain cDNA with an exon 2 specific reverse oligonucleotide primer and a forward primer from the start of the transcript. 3´ RACE procedures to determine a possible alternative 3´ mRNA end yielded the same poly-A signal as the clone identified in cDNA library screening. The total length of 3968 bp of the cloned cDNA is in good agreement with the size estimation of the human *ALDR* tanscript in Northern blot analysis of 4.2 kb (Albet *et al*., 1997) if a variable length of the poly-A tail is considered. Our previous NCBI GenBank entry No. AJ000327 containing the human *ALDR* cDNA sequence was updated accordingly.

Human ALDRP is an exclusively peroxisomal protein

Indirect immunoflourescence double staining using human *ALDR* cDNA HA or Myc/hexahistidine epitope-tagged at the COOH-terminus showed that human ALDRP colocalized with catalase, a well-established peroxisomal marker enzyme (Fig. A1-1A and A1-1B). The exclusively peroxisomal localization of human ALDRP was expected in analogy to the mouse data available (Lombard-Platet *et al*., 1996) but had not been directly shown prevously.

Characterization of a human pCYPAC-2 clone containing the complete *ALDR* gene

Three clones from a human genomic DNA pCYPAC-2 library were identified with an *ALDR*-specific cDNA probe (clone 1: LLNLP704H03232Q13; clone 2: LLNLP704K24206Q13; clone 3: LLNLP704H12113Q16). Rescreening of these clones was performed by Southern blot analysis on *Eco*RI/*Hind*III/*Xba*I digests using the 3547 bp cDNA derived from the above-mentioned *ALDR* cDNA clone (ICRF P507D21235Q11) as probe (Fig. A1-2A). Clone No. 3 was found to contain additional *ALDR*-specific bands compared to the two others and was further characterized. Fluorescence in situ hybridization

analysis using this clone as probe showed a single signal on chromosome 12q12 (Fig. A1-2B). This locus has been previously reported for the human *ALDR* gene using a cDNA probe (Savary *et al.*, 1997). Exon-exon PCR-analysis using oligonucleotide primers derived from the 5´ and 3´ cDNA ends revealed that pCYPAC-2 clone 3 (LLNLP704H12113Q16) contained the entire ALDR gene including the 5´ flanking region containing the putative promoter.


Figure A1-2: Characterization of three human *ALDR* pCYPAC clones. A. Southern blot analysis of *Eco*RI, *Hind*III and *Xba*I digests using a human *ALDR* cDNA probe Clone No.3 containded more specific bands and was found to contain the entire *ALDR* gene. **B.** Fluorescence in situ hybridization analysis using clone No. 3 as probe. A single signal was obtained at chromosome 12q12.

Striking similatrity of the genomic organization of the human *ALDR* gene with the *ALD* gene

The complete exon-intron-structure could be determined by exon-exon PCR. All introns could be amplified using the pCYPAC-2 clone as template. All intron sizes were determined by agarose gel electrophoresis exon-exon PCR fragments in relation to standard size markers. The human *ALDR* gene contains 10 exons and covers approximately 33 kb of genomic DNA. Exon 1 contains the largest fragment of the protein coding sequence. The exon-intron structure of the human *ALDR* gene is presented in Fig. A1-3A. A comparison of the human *ALD* and *ALDR* genes is shown in Fig. A1-3B.

Figure A1-3: Analysis of *ALDR* gene structure. A. Exon-Intron structure of the human *ALDR* Gene. **B.** Striking similarity of the genomic organization of *ALD* and *ADLR* genes. Intron sizes are variable and not displayed proportionally.

Computational analysis of the putative *ALDR* promoter region

A genomic DNA sequence of 2.4 kb of the putative promoter region upstream from the transcriptional start was analyzed. A TATA-Box (TATATTCT) was found 64 bp upstream of the transcriptional start defined by the longest RACE PCR product obtained. A repetitive element of the ALU-family is present from nt 1155-1401. Computer-aided search for potential binding sites to known regulatory factors using MatInspector (Quandt *et al.*, 1995) revealed several Sp1 and AP1 sites. We searched for peroxisome proliferator responsive elements (PPRE), the cis-acting sequences thought to mediate a response to peroxisomal proliferators. The consensus PPRE sequence consists of two direct AGG(A/T)CA repeats separated by a single nucleotide (Dreyer *et al.*, 1992; Green, 1993; Juge-Aubry *et al.*, 1997). A survey of 2353 bp 5´ flanking DNA of the *ALDR* gene displayed no perfect matches for the consensus sequence or for the exact sequence of 16 known PPREs (Juge-Aubry *et al.*, 1997). Several PPRE-like sequences, spaced by one nucleotide (DR+1), were observed. One PPRE-like sequence repeat with a four-nucleotide spacer (DR+4) was detected by the MatInspector program as an antisense-oriented thyroid hormone response element (TRE)-like binding site (Subauste & Koenig, 1995) combined with an orphan receptor binding site (Giguere *et al.*, 1994) separated by four nucleotides (2529 - AGGTCG AATCAGGCCA - 2514). A similar sequence (AGGTCGAATGAGGTCA ; bp 1118 - 1133 in Genbank entry

No. AJ009991) is present 177 nucleotides upstream from the transcriptional start site of the mouse *ALDR* gene. This element was not found in the known sequences of the mouse or human *ALD*, mouse *PMP70* or *P70R* promoter regions. A detailed comparison of the mouse and human orthologs revealed a sequence (GTAGTAAACATGAACATT), which was also present in the upstream region of the mouse *ALDR* gene (AAGAAAAACATGAAGAAA) and in antisense orientation in the 5' flanking DNA of the *PMP70* gene (AAGAAAAACATGAAGAAA). This sequence shows no homology to any known PPRE or other described cis-acting elements but however is conserved between these three genes and is located at a comparable distance from the initiation codon: at 1162, 1122, and 1355 nucleotides in the human *ALDR*, the mouse *ALDR* and the mouse *PMP70* gene respectively (Fig. A1-4B).

Figure A1-4: Computational analysis of the putative promoter region. A. Linear map demonstrating the trancriptional start (angled arrow), potential Sp1 binding sites (full circles), potential AP1 sites (open circles), the ORF (bold bar) and the motifs discussed. B. Identification of a conseved motif in the putative promoters of mouse *ALDR* and *PMP70* genes. Conservation of the central fraction (8 bp) of this motif at a similar distance from the start codon in the putative human *ALDR* promoter.

Discussion

No cure is currently available for X-linked adrenoleukodystrophy. Dietary regimens have failed to revert the progressive nature of the disease (for review see (Gärtner *et al*., 1998c)). Successful bone marrow transplants have been reported although the general risk is high and measures have to be started early in the course of the disease (Gärtner *et al*., 1998c). Alternative therapeutic strategies are therefore under investigation. One such approach suggests the induction of *ALDR* gene since some functional redundancy to the *ALD* gene has been shown.

We have previously reported the sequence of a human *ALDR* cDNA fragment containing the complete coding region but lacking the full 5´and 3´ ends. Here we report the full length cDNA including 556 bp of the 5´ untranslated and 1189 bp of the 3´ untranslated ends. The length of this cDNA sequence corresponds to the data from Northern blot analysis. Transcript variants (such as observed in the mouse) have not been detected. Although only 191 bp of the sequence corresponding to the 557 bp human 5´ UTR are transcribed in mouse (Fig. A1-4A) the entire 557 bp are highly conserved between human and mouse (72.8% bp identity under the permission of 27 gaps). There are eight start codons within the human *ALDR* 5´ untranslated region, however all of them are closely followed by a termination codon. Most of these ATG codons are in a very week initiation context with the exception of one ATG at the position 2809-2811. This start codon has a G residue following the ATG codon and a purine, A, three nucleotides upstream (Kozak, 1991). In theory, this upstream translation initiation site that runs into a terminator codon after six amino acids, thereby creating a small upstream ORF, should reduce but not abolish translation of the major downstream ORF (Abastado *et al*., 1991). Interestingly, an expression construct containing 135 bp upstream from the ORF (including the ATG codon at postion 2809-2811) is effectively translated as determined by immunofluorescence and western blot analysis and is able to restore ß-oxidation in X-ALD fibroblasts (Berger et. al., unpublished data). A regulatory effect of this ATG codon on translation efficiency seems very likely.

The human ALDR protein is localized exclusively in the peroxisome as shown by immunocytological analysis. It belongs thus to the group of peroxisomal ABC-half-transporters as has been deduced from mouse data and sequence similarity.

The genomic organization of the human *ALDR* gene shows striking similarity to the structure of the *ALD* gene, its closest homolog (Fig. A1-3B). This is additional evidence for a recent divergence of these two genes from a common ancestor. No apparent gene structure similarity with the remaining peroxisomal ABC-transporters (PMP70, PMP69) has been observed. The mirror expression of ALDP and ALDRP (Troffer-Charlier *et al*., 1998) i.e. tissues with high ALDP expression are low in ALDRP (and vice versa) has been interpreted as ALDP and ALDRP serving the same or very similar functions in different tissues. Kemp et al. (Kemp *et al*., 1998) have recently demonstrated that the ß-oxidation defect in X-ALD can be corrected by transfection of *ALDR* cDNA or induction of *ALDR* transcription. The authors concluded that there must be redundancy of the function of peroxisomal ABC-transporters. Since X-ALD has a wide spectrum of clinical manifestations - even within a family with identical ALD phenotype - the existence of modifying genetic factors independent of the *ALD* gene has long be postulated. The data on suspected functional redundancy render this hypothesis attractive and the *ALDR* gene is a plausible candidate for such a modifier determining (together with an obligate defect in the *ALD* gene) the clinical course of X-ALD. Since ALDRP is predominantly expressed in the brain sequence analysis in X-ALD patients without the knowledge of the gene structure is difficult and has not been undertaken to date. The sequence data presented here will allow the search for polymorphisms in the *ALDR* gene using genomic DNA as starting material within the complete coding region as well as the 5´and 3´ untranslated regions of the mRNA and intronic sequence.

The fact that *ALDR* transcription can be upregulated by 4-phenylbutyrate leading to a correction of ß-oxidation in human X-ALD fibroblasts (Kemp *et al*., 1998) has immediate therapeutic implications. The induction of a „surrogate gene" of overlappping or identical function is a principle of therapy used in diseases such as hemoglobinopathies (Dover *et al*., 1994; Olivieri *et al*., 1998). The mechanism of action of 4-phenylbutyrate on the transcription of the *ALDR* gene is not well understood. In general, regulation of gene expression by butyrate is thought to function via inhibition of the enzyme histone deacetylase, leading to elevated levels of core histone acetylation which affect chromatin structure and transcription rates (Candido *et al*., 1978). The transcriptional start defined by 5´ RACE-procedures corresponds to the size of the mRNA in Northern analysis and was also confirmed by cDNA amplification across intron 1. As a consequence the thyroid hormone response element (TRE)-like binding site identified is part of the transcript. mRNA

arizing from a further downstream transcriptional start might occur, although a single signal corresponding to the upstream start is obtained in Northern analysis. The central 8 bp of a 18-bp motif conserved in mouse *ALDR* and *PMP70* genes (within otherwise non-homologous regions) are conserved in the human *ALDR* promoter (Fig. A1-4B) at a similar distance from the initiation codon. One might speculate this sequence to play a role in the regulation of peroxisomal ABC-transporters in general. Further investigations in particular electrophoretic mobility shift assays will show if this element is in fact a protein binding regulatory element. The putative promoter sequence reported here will allow specific studies on transcriptional regulation of the *ALDR* gene including testing of substances potentially suitable for induction. Furthermore a decrease in *ALDR* transcription due to a polymorphism in the promoter region could possibly explain the clinical heterogeneity of X-ALD. In this context the sequence data presented represent tools to investigate the role of the *ALDR* gene in X-ALD.

Acknowledgments

References

The references are listed on pages 38–49.

Appendix 2

Human Adrenoleukodystrophy Protein and Related Peroxisomal ABC Transporters Interact with the Peroxisomal Assembly Protein PEX19p

Christian J. Gloeckner[1], Peter U. Mayerhofer[2], Pablo Landgraf[2],

Ania C. Muntau[2], Andreas Holzinger[2], Josef-Karl Gerber[1], Stefan Kammerer[3],

Jerzy Adamski[1], and Adelbert A. Roscher[2]

[1]GSF-National Research Center for Environment and Health, Institute of Mammalian Genetics, Ingolstaedter Landstr.1, 85764 Neuherberg, Germany

[2]Dr. v. Hauner Children´s Hospital, Department of Clinical Chemistry and Metabolism, Ludwig-Maximilians-University, Lindwurmstr. 4, 80337 Munich, Germany

[3] Address: SEQUENOM Inc., 11555 Sorrento Valley Road, San Diego, CA 92121, United States of America

*Contributions to the manuscript: Outline of the project by J.A. and A.A.R; concept by C.J.G. and **P.U.M.**; Yeast two-hybrid assays by C.J.G.; in vitro targeting studies by P.L.; in vitro interaction assays by C.J.G. and **P.U.M.**; writing by C.J.G. and **P.U.M.**; editorial help by the co-authors.*

Abstract

Four ABC half transporters (ALDP, ALDRP, PMP70, and PMP69) have been identified in the mammalian peroxisomal membrane but no function has been unambiguously assigned to any of them. To date X-linked adrenoleukodystrophy (X-ALD) is the only human disease known to result from a defect of one of these ABC-transporters, ALDP. Using the yeast two-hybrid system and *in vitro* GST pull down assays we identified the peroxin PEX19p as a novel interactor of ALDP, ALDRP and PMP70. The cytosolic farnesylated protein PEX19p was previously shown to be involved in an early step of the peroxisomal biogenesis. The PEX19p interaction occurs in an internal N-terminal region of ALDP which we verified to be important for proper peroxisomal targeting of this protein. Farnesylated wildtype PEX19p and a farnesylation-deficient mutant PEX19p did not differ in their ability to bind to ALDP. Our data provide evidence that PEX19p is a cytosolic acceptor-protein for the peroxisomal ABC transporters ALDP, PMP70 and ALDRP and might be involved in the intracellular sorting and trafficking of these proteins to the peroxisomal membrane.

Introduction

In higher organisms proper function and assembly of peroxisomes is of vital importance as evidenced by a variety of severe human diseases caused by malfunction of these organelles (Lazarow & Moser, 1995). These include defects in many genes required for peroxisome biogenesis, termed *PEX* genes (Distel *et al*., 1996; Hettema *et al*., 1999). Peroxins, the proteins encoded by *PEX* genes, are responsible for the evolutionarily highly conserved process of post-translational trafficking of proteins to the peroxisomal membrane or into the peroxisomal matrix (Hettema *et al*., 1999; Subramani, 1998). The most common peroxisomal disorder is X-linked adrenoleukodystrophy (X-ALD, OMIM #300100), causing severe neurodegenerative disease with a broad spectrum of clinical manifestations (Moser *et al*., 1995b). Biochemical hallmarks of the disease are increased tissue and plasma concentrations of very-long-chain fatty acids (VLCFA; C > 22:0) (Lazo *et al*., 1989; Moser *et al*., 1995b). It had been generally accepted that accumulation of VLCFA in X-ALD is due to an impaired activity of very-long-chain acyl-CoA synthetase (VLCS) required for the activation of VLCFAs to their CoA thioesters (Steinberg *et al*., 1999a; Steinberg *et al*., 1999b; Watkins *et al*., 1998). Surprisingly, it turned out that not defects in VLCS, but mutations in the ALD gene, encoding an integral peroxisomal membrane protein (ALDP), are undoubtedly the primary genetic cause of this disease (Contreras *et al*., 1994; Mosser *et al*., 1994). ALDP belongs to the superfamily of ATP binding cassette (ABC) transporters capable of transporting a wide variety of ligands, ranging from ions to proteins, across biological membranes. In eukaryotic organisms ABC transporters typically consist of two hydrophobic transmembrane domains and two hydrophilic domains each containing a nucleotide binding fold (Klein *et al*., 1999). ALDP, however, is a half transporter composed of only one transmembrane domain and one nucleotide binding fold and has to form homo- or heterodimers to be functional. In humans, three other closely related peroxisomal ABC half transporters, ALDRP (ALD-related protein), PMP70 (PXMP1) and PMP69 (PXMP1-L) have been identified. (Gärtner *et al*., 1998a; Holzinger *et al*., 1997a; Kamijo *et al*., 1990; Shani *et al*., 1997). These may act as interaction or dimerization partners for ALDP (Shani & Valle, 1996; Smith *et al*., 1999). Using the yeast two-hybrid system it has recently been demonstrated that homo- as well as heterodimerization can occur between the carboxy-terminal halves of ALDP, ALDRP, and PMP70 (Liu *et al*., 1999a). It has also been suggested that a loss of ALDP dimerization plays a role in the pathogenesis of X-ALD. Nevertheless, it is unclear, how a malfunction of ALDP might be correlated to the accompanying deficient

activity of VLCS being responsible for VLCFA accumulation (Smith *et al*., 1999) (Kemp *et al*., 1998; Smith *et al*., 2000). Moreover, the factors that mediate trafficking and targeting of ALDP have not been investigated yet. Imanaka and co-workers had shown, that the related peroxisomal ABC half transporter PMP70 is translated in the cytosol and transported to the peroxisome by cytosolic factors using *in vitro* targeting experiments (Imanaka *et al*., 1996). Very recent evidence suggests that the peroxin PEX19p might act as a cytosolic binding protein for PMP70 (Sacksteder *et al*., 2000). The observation that approximately 70% of the X-ALD mutations result in loss of ALDP immunoreactivity (Smith *et al*., 1999; Watkins *et al*., 1995) is consistent with the hypothesis that ALDP, once translated in the cytosol, needs further protein interaction to be stabilized and properly targeted to the peroxisome.

In order to further elucidate the targeting and interaction network of peroxisomal ABC half transporters, we screened for interaction partners using the yeast two-hybrid system. For that purpose, defined portions of ALDRP were tested against a cDNA library derived from human brain tissue. We provide evidence that internal N-terminal domains of ALDP, ALDRP and PMP70 strongly interact with human PEX19p, a 33kD farnesylated protein known to be involved in early steps of the peroxisomal biogenesis (Götte *et al*., 1998). These interactions were confirmed in *in vitro* pull-down assays. As the interaction of PEX19p occurs in a region which is important for the targeting of ALDP, our results are consistent with the idea that PEX19p is an acceptor protein for ALDP and related peroxisomal ABC transporters and might be involved in their trafficking to the peroxisomal membrane.

Material and Methods

Yeast two-hybrid screen and interaction assay

PCR using standard protocols was performed to obtain specifically selected cDNA fragments. PCR primers contained appropriate restriction sites to achieve in-frame ligation to the LexA gene. Additionally, a spacer of 3 glycine codons was inserted between LexA and the fragment of interest. The reverse primer contained a termination codon. Produced PCR fragments were restriction digested and cloned into the pEG202 vector. The correctness of the constructs was confirmed by DNA sequencing. Several constructs (ALDRP1-218, ALDRP181-297, ALDRP273-489, and ALDRP365-741) were then screened against a human brain tissue cDNA library in pJG4-5 vector (Clontech #HL4500AK). Before being used in the library screen, baits were tested in repression assays for their ability to enter the nucleus (Russell *et al.*, 1996). The library screen was performed in the yeast strain EGY48 (*Matα, trp1, his3, ura3, (lexAop)6-Leu2*). Yeast transformants were selected for leucine auxotrophy (Leu2-reporter) on galactose/raffinose drop-out medium lacking leucine and for activation of β-galactosidase (*lacZ*-reporter). Yeast clones containing interacting proteins were identified by growth on galactose/raffinose-medium without leucine and blue color development on galactose/raffinose-X-Gal-medium. pJG4-5 plasmids of positive clones were rescued, amplified in *E.coli* (strain XL1-Blue MRF'), and sequenced. Determined sequences were analyzed by peforming a BLAST search (Benson *et al.*, 1999). The LexA yeast two-hybrid system (interaction trap) was kindly provided by R. Brent (Massachusetts General Hospital). Assay procedures and appropriate controls are described elsewhere (Russell *et al.*, 1996). Using a yeast two-hybrid interaction assay, human peroxisomal ABC transporters were then tested for interaction with PEX19p. For this purpose constructs of the N-terminal region of ALDP, ALDRP and PMP70 were cloned into the pEG202 vector and checked for interaction with PEX19p (clone pJG4-5-PEX19pΔ6) as described above.

Expression and purification of GST-fusion proteins

For *in vitro* binding assays the PEX19p and a CaaX-Box-mutated PEX19p (C296S-PEX19p) were cloned into the pGEXΔBamHI expression plasmid for the production of glutathione-S-transferase (GST) fusion-proteins (Leenders *et al.*, 1996). Full length human PEX19p cDNA (GenBank #NM_002857) was recently cloned in our lab and the mutations in the CaaX motif were introduced by PCR (Kammerer *et al.*, 1997). Expression in the *E.coli* strain (BL21-DE3) and affinity purification of GST-PEX19p and GST-

C296S-PEX19p fusion-proteins were performed as described previously (Braun *et al.*, 1994; Kammerer *et al.*, 1997).

In vitro farnesylation of PEX19p at the C-terminal CaaX-box

6 μg of purified GST-PEX19p or GST-C296S-PEX19p were incubated with 25 μl TNT rabbit reticulocyte lysate supplying the essential CaaX farnesyltransferase, 2 μl reaction buffer (TNT Coupled Reticulocyte Lysate System, Promega) and 2 μl farnesyl pyrophosphate (10mM, Sigma) in a total volume of 50 μl for 2h at 30°C (Kammerer *et al.*, 1997). Both the farnesylated wild type protein and the farnesyl-deficient C296S mutant protein were bound to GSH-Sepharose beads and used in a GST pull-down assay as described below.

In vitro translation and ^{35}S-methionine labeling of peroxisomal ABC transporter proteins

For *in vitro* translation and labeling, full length ALDP, ALDRP, PMP70, and several N-terminally truncated constructs of ALDP (Δ66, Δ186 and Δ281) were cloned into pcDNA3.1 plasmid (Invitrogen). The proteins were transcribed *in vitro* from the T7-promotor of pcDNA3.1, translated and labeled with ^{35}S-methionine (Amersham) using the TNT Coupled Reticulocyte Lysate System (Promega) following standard protocols.

In vitro interaction assay (GST pull-down)

The purified GST fusion proteins were bound to glutathione-Sepharose beads (Pharmacia) in PBS for 1h at 4 °C and washed three times in PBS. For the *in vitro* interaction assay the GST-fusion proteins (0.5-1.5 μg protein bound to 1 μl bead suspension) were incubated with 5 μl of *in vitro* translated protein in 200 μl binding buffer (100 mM NaCl, 50 mM potassium phosphate pH 7.4, 1 mM MgCl$_2$, 10 % glycerol, 0.1 % Tween 20, 1.5 % BSA) for 2h at 4 °C. Samples were pelleted and washed four times in 1 ml binding buffer without BSA. Pellets were resuspended in SDS-sample buffer and boiled for 5 min before being analyzed by SDS-PAGE according to standard protocols (Laemmli, 1970). To verify stability of the GST-fusion proteins and equal loading, gels were stained with Coomassie blue. The gels were dried and exposed to X-ray film for 24 h.

Transfection and analysis of ALDP- GFP fusion proteins

For *in vivo* targeting studies deletion constructs of ALDP were fused to the N-terminus of the green fluorescent protein (GFP). For this purpose ALDP1-281 and Δ281 ALDP were cloned into pEGFPN1 vector (Clontech). Plasmids were transfected into Cos7 cells using lipofectamine

(Life Technologies) following protocols provided by the manufacturer. After 48 h transfected cells were fixed with 3% formalin/PBS for 30 min and permeabilized with 1% Triton X-100 for 5 min. Catalase was used as marker for peroxisomes. Cells were incubated with a 1:100 dilution of a polyclonal rabbit antibody against catalase (Biodesign) for 1 hour. The cells were then washed thoroughly with PBS and incubated with a 1:50 dilution of the secondary tetrarhodamine isothiocyanate (TRITC)-labeled anti mouse IgG antibody (Jackson Immunoresearch Laboratory Inc.) for 1 hour. The cells were embedded in an anti-fading reagent (Vectashield, Vector Laboratories Inc.). Fluorescence microscopy was performed using an Axiovert 135 inverted fluorescence microscope (Zeiss).

Figure A2-1: Interaction of peroxisomal ABC transporters with PEX19p in the yeast two-hybrid assay. A scheme of peroxisomal ABC half-transporter structure with the six transmembrane helices (TM) and the nuclear binding fold (NBF) is represented on the top. The N-terminal regions marked by the bar in the scheme were fused to LexA and tested against PEX19p (clone PEX19pΔ6) for interaction in a yeast two-hybrid assay (bottom). Panel 1 presents the Leu2-reporter activity (growth on galactose/raffinose media without leucine), panel 2 the negative control on glucose media without leucine, where the Leu2-reporter is inhibited. Panel 3 presents the color development caused by LacZ-reporter activity for yeasts plated on galactose/raffinose-X-Gal-medium.

Results

Identification of PEX19p as an interactor of ALD-related protein

To identify proteins, which interact with peroxisomal ABC transporters, we performed a cDNA library screen using the LexA yeast two-hybrid system with parts of ALD-related protein (ALDRP), recently cloned in our lab, as a bait (Holzinger *et al.*, 1997b).

Prior to the library screen we verified if baits were able to enter the nucleus. Generally for large proteins and especially for complex membrane proteins a separation into several smaller baits (not bigger than 60 kDa) is necessary, probably because of impairment of nuclear import by molecular mass or by hydrophobic domains. ALDRP constructs corresponding to amino acids 1-218, 181-297, 273-489 and 365-741 (ALDRP1-218, ALDRP181-297, ALDRP273-489, and ALDRP365-741, respectively) were imported into the nucleus (data not shown).

A cDNA library from human brain tissue (Clontech) was screened with all constructs. With the N-terminal construct containing the first 218 amino acids of ALDRP (ALDRP1-218) we obtained a strong interaction with human PEX19p (data not shown). The cDNA of the isolated clone (PEX19pΔ6) encompassed nearly the complete coding sequence (missing only the fist 6 amino acids out of 299) of PEX19p. The interaction between ALDRP and PEX19p was confirmed *in vitro* using the GST pull-down assay as described later on.

PEX19p interacts with the human peroxisomal ABC transporters ALDP, ALDRP and PMP70 in a yeast two-hybrid assay

In order to test if the closely related ABC transporters ALDP and PMP70 also interact with PEX19p as initially established for the N-terminal domain of ALDRP, a yeast two-hybrid interaction assay was performed. Therefore, the regions of ALDP and PMP70, that are homologous to the N-terminal part of ALDRP (ALDRP1-218), were cloned into the pEG202 vector (ALDP1-203 and PMP70 1-199) and used as a bait against the clone PEX19pΔ6 in the pJG4-5 vector. The ALDP and PMP70 constructs comprise, similar to ALDRP, the N-terminal region including the first two transmembrane helices but not the third and further C-terminal domains (FIG A2-1. top). Like ALDRP, both, ALDP and PMP70 interacted strongly with PEX19p. These interactions activated the LEU2 gene allowing a growth on media lacking leucine (FIG. A2-1, panel 1). The activation of LEU2 is due to a PEX19p interaction with ALDP, ALDRP or PMP70, because supression of PEX19p expression by glucose hampers yeast growth (FIG. A2-1, panel 2). The strength of the interaction is illustrated by

blue color development within 24h due to the activation of LacZ gene when grown on X-Gal media (FIG. A2-1, panel 3).


Figure A2-2: Mapping of the PEX19p interaction domain on ALDP using a GST pull-down. A. Scheme of ALDP-constructs: A full-length (fl.) construct and the deletion constructs Δ66, Δ186 and Δ286 were generated. They were ^{35}S-methionine labeled by *in vitro* translation using a rabbit reticulocyte lysate and tested for interaction with GST-PEX19p in a pull-down assay. The GST-PEX19p co-purified proteins were separated on 12% SDS polyacrylamide gel electrophoresis. B. Autoradiography of the gel: On the left, 20% of the total amount of the ^{35}S-labeled proteins (input) used in the GST pull-down was loaded and illustrates the molecular masses of these proteins (left part). The labeled proteins that were co-purified with GST-PEX19p are depicted on the right. Lower molecular mass bands might correspond to alternative internal start codons or proteolytic cleavage of the *in vitro* translated proteins. No signal was obtained for a GST negative control (see Fig. A2-4).

Mapping of the PEX19p interaction domain of ALDP

To validate the observation that segments within the N-terminal domain of the peroxisomal ABC transporters ALDP, ALDRP and PMP70 are sufficient for interaction with PEX19p, we performed an *in vitro* interaction assay (GST pull-down) using ALDP as our model system. Full-length PEX19p was expressed as GST fusion protein and bound to glutathione-sepharose beads. Several deletion constructs of ALDP lacking the first 66, 186, and 281 amino acids (Δ66, Δ186, and Δ281) were ^{35}S labeled by *in vitro* translation (FIG. A2-2A) and subjected to a GST-PEX19p pull-down assay.

Full-length and Δ66 ALDP constructs showed interaction with PEX19p. Deletion constructs Δ186 and Δ281, however, did not interact with PEX19p since at the same level of input only faint signals were observed (FIG. A2-2B). These results show that the binding site of PEX19p lies in a region of about 120 amino acid residues (between amino acid 67 and 186) within the N-terminal domain.

In vivo targeting studies of ALDP

To test the hypothesis that the region of ALDP interacting with PEX19p might be involved in the intracellular trafficking of ALDP deletion constructs were tested for their targeting to peroxisomes. For that purpose an ALDP-deletion construct (Δ281 ALDP) comprising a region which did not interact with PEX19p in the pull-down assay (Fig. A2-2) was compared to a construct containing amino acids 1-281 of ALDP in its cellular localization. The proteins were labeled by N-terminal fusion to the green fluorescent protein and expressed in Cos7 cell culture. The peroxisomal localization of the constructs was determined by the co-localization of catalase, detected by immunofluorescence staining. ALDP1-281 shows a proper peroxisomal localization while Δ281 ALDP exhibits a non-peroxisomal pattern (Fig. A2-3).

Figure A2-3: Targeting of ALDP-GFP fusion protein constructs The cellular distribution of Δ281 ALDP-GFP, missing the N-terminal amino acids 1-281 (A), and ALDP1-281-GFP, coding for the N-terminal amino acids 1-281 only (C), is compared with the localization of catalase detected by immunofluorescence staining (B, D) in Cos7 cells. ALDP1-281-GFP is co-localizing with catalase. Δ281 ALDP-GFP shows a diffuse cytosolic pattern with some spots that do not co-localize with catalase.

Farnesylation is not necessary for the *in vitro* interaction of PEX19p with peroxisomal ABC transporters

Farnesylation of a C-terminal CaaX-motif of PEX19p (CLIM) was shown to be important for its biological function (Götte *et al*., 1998; Matsuzono *et al*., 1999). To test the influence of the farnesylation of PEX19p on its interaction with peroxisomal ABC transporters, a CaaX-box mutant of PEX19p (C296S-PEX19p) was compared with wildtype PEX19p in a GST pull-down after *in vitro* farnesylation. As shown previously, C296S-PEX19p can not be farnesylated *in vitro* (Kammerer *et al*., 1997). To conduct the assay, equal amounts of GST-PEX19p and GST-C296S-PEX19p were incubated in rabbit reticulocyte lysate under conditions that ensure attachment of the farnesyl group at the cysteine residue of the CLIM motif of PEX19p (FIG. A2-4A). Both, wild type farnesylated and mutated farnesyl-deficient protein were then tested for interaction with *in vitro* translated and ^{35}S-labeled full-length ALDP, ALDRP and PMP70. The mutant PEX19p (C296S-PEX19p) shows no significantly different binding capacity to the peroxisomal ABC-transporters *in vitro* compared to wild type PEX19p (FIG. A2-4b)

Figure A2-4: Effect of *in vitro* farnesylation of PEX19p on its interaction with the peroxisomal ABC-transporters. A. Scheme of C-terminal farnesylation motif (CaaX-box) of PEX19p. Single letter notation of the consensus sequence: C- cysteine, a aliphatic amino acid, X any amino acid. A PEX19p wildtype (wt) and a CaaX-box mutated (C296S) PEX19p were expressed as GST-fusion proteins and subjected to an *in vitro* farnesylation assay as described in Methods. Farnesylated wt PEX19p and farnesyl-deficient C296S mutated PEX19p were tested for interaction with *in vitro* translated and ^{35}S-labeled full-length ALDP, ALDRP and PMP70 in a GST pull-down. Co-purified proteins were separated on 12% SDS polyacrylamid gelelectrophoresis. B. Autoradiography: 20% of the total amount of the ^{35}S-labeled ABC transporter proteins (input) used in the GST pull-down is shown on the left. Retention of labeled protein with GST-PEX19p and GST-C296S-PEX19p, respectively, is depicted on the right. GST only was used as a negative control. Lower molecular mass bands might correspond to alternative internal start codons or proteolytic cleavage of the *in vitro* translated proteins.

Discussion

In humans, four ABC half transporters have been localized to the peroxisomal membrane but no precise function has been unequivocally assigned to any of them. X-ALD is the only human disease known so far that results from mutations in the *ALD* gene. It is, however, unclear how a defective transport function of ALDP might be related to the abnormality in fatty acid metabolism observed in X-ALD as a biochemical hallmark (Kemp *et al*., 1998; Smith *et al*., 2000). One approach to unravel protein functions is to elucidate the cellular network by identifying protein interaction partners. The yeast two-hybrid system has previously been used to show that peroxisomal ABC transporters can form either homodimers or heterodimers with one of the related ABC half transporters (Liu *et al*., 1999a; Verleur *et al*., 1997). In this study the aim was to identify ALDP interaction partners beyond those required for dimerization.

Using a yeast two-hybrid screen we initially identified a strong interaction of ALDRP with a small protein first cloned and described as the human peroxisomal farnesylated protein PxF (Kammerer *et al*., 1997). PxF is, typical for housekeeping genes, ubiquitously expressed (Braun *et al*., 1994). Since PxF has subsequently been shown to be crucial for peroxisomal biogenesis (Götte *et al*., 1998) it is now designated PEX19p. By performing yeast two-hybrid and *in vitro* interaction assays we confirmed that internal N-terminal parts of ALDP, ALDRP and PMP70 directly interact with PEX19p. These findings also suggest a functional relationship between the processes of peroxisome assembly driven by peroxins such as PEX19p and those of peroxisomal membrane transport accomplished by peroxisomal ABC transporters. The cellular site of interaction seems to be outside of the peroxisome since PEX19p appears to be mainly located in the cytosol (Sacksteder *et al*., 2000), although immunocytochemical evidence suggests that it can also associate with the peroxisomal membrane (James *et al*., 1994; Kammerer *et al*., 1997). Very recently Pex19p has been shown to interact with a broad range of integral peroxisomal membrane proteins, but not matrix proteins (Sacksteder *et al*., 2000; Snyder *et al*., 1999b). Such data have implicated that PEX19p may act as a broad specificity cellular chaperone for newly synthesized PMPs. Recently, an inactivating mutation in *PEX19* has been described that results in a complete lack of even residual peroxisomal membrane vesicles ("ghosts") in fibroblasts of a patient with Zellweger syndrome (Matsuzono *et al*., 1999). Since ghosts are usually identified by anti-PMP70 antibodies, these findings indirectly demonstrate that a lack of the PEX19p

acceptor site prevents PMP70 to reach its designated location within peroxisomal vesicular structures. Lack of interaction may thereby result in mislocalization and degradation of newly synthesized PMP70 and other PMPs (Sacksteder *et al.*, 2000).

We show here that PEX19p is interacting with ALDP and ALDRP which might contribute to the pathogenesis of X-ALD, the most common peroxisomal disorder. By using N-terminal constructs of ALDP we were able to delimit the interaction domain to an N-terminal stretch of ALDP comprising amino acid residues 67-186. The precise location of the specific interaction epitope was beyond the scope of this study since this would require experimental strategies delivering much higher resolution. Nonetheless, our *in vivo* targeting studies with ALDP deletion constructs suggest that the PEX19p interaction domain coincides with the region of ALDP required for targeting to the peroxisome. The data are consistent with the hypothesis that PEX19p may bind to a targeting element of ALDP thereby facilitating the intracellular trafficking of the transporter protein to the peroxisomal membrane.

In this context it is noteworthy that PEX19p is the only peroxin that can be farnesylated at a carboxyl-terminal CaaX motif (Kammerer *et al.*, 1997). The covalent attachment of prenyl lipids, i.e. farnesyl groups or geranylgeranyl groups, by specific transferases has been shown to be indispensable for the intracellular sorting and membrane association of some proteins (Clarke, 1992; Hancock *et al.*, 1989; Kato *et al.*, 1992a; Tamanoi, 1993). Thus, we investigated whether *in vitro* farnesylation of PEX19p might influence its interaction with peroxisomal ABC transporters. Our findings were that a CaaX-box mutated and therefore farnesyl-deficient PEX19p (C296S-PEX19p) can bind peroxisomal ABC transporters as well as wildtype PEX19p. Though PEX19p farnesylation may not be a prerequisite for its *in vitro* interaction with peroxisomal ABC transporters it has been suggested to be essential for its overall biological action *in vivo*, e.g. in rescuing impaired peroxisomal assembly of PEX19p deficient fibroblasts (Matsuzono *et al.*, 1999). Moreover, in yeast the interaction of Pex19p with the cytosolic domain of Pex3p appears to be influenced in a farnesyl-dependent manner (Götte *et al.*, 1998; Snyder *et al.*, 1999a). The post-translational modification of PEX19p by farnesylation might thereby provide an additional regulatory mechanism to ensure proper sorting and trafficking of PMPs (Hettema *et al.*, 2000).

Our results might have implications in several ways. They may add to the understanding of the pathogenesis and phenotypic heterogeneity of X-ALD by demonstrating a mechanism by which newly synthesized ALDP may either be stabilized and/or translocated to the peroxisomal membrane. So far it is not clear why a surprisingly high percentage of missense mutations in the *ALD* gene is resulting in a loss of ALDP immunoreactivity (Smith *et al.*,

1999; Watkins *et al*., 1995). Recent data suggest that ALDP instability may be a direct consequence of deficiency of dimerization that resides in the C-terminus of ALDP (Liu *et al*., 1999a). The fact that interaction with PEX19p occurs within an internal N-terminal domain of ALDP implies that a much wider range of *ALD* mutations could potentially result in ALDP degradation as a consequence of "interaction deficiencies". Additional interaction domains of ALDP need to be postulated in order to explain the influence of ALDP mutations on peroxisomal ß-oxidation at the level of the VLCS protein (Smith *et al*., 2000; Steinberg *et al*., 1999a). To date we and others also have not yet obtained conclusive data whether PMP69 is sharing interaction properties similar to the three other members of the peroxisomal ABC transporter family. These questions clearly need to be addressed for further understanding of the complex picture of X-ALD pathogenesis.

The demonstration of *in vitro* interaction of peroxisomal ABC transporters with PEX19p also supports the idea of direct functional interaction between peroxins and other peroxisomal membrane components during peroxisome maturation. Another indirect hint for this kind of interaction is provided by the observation that a PEX2p deficiency can be restored by overexpression of peroxisomal ABC transporters (Braiterman *et al*., 1998; Gärtner *et al*., 1998b). The identification of PEX19p as an acceptor molecule for ALDP suggests that PEX19p may modulate the function of some tissues afflicted by *ALD* mutations and could thereby influence clinical disease manifestation.

Acknowledgements

References

The references are listed on pages 38–49.

Appendix 3

Two Splice Variants of Human *PEX19* Exhibit Distinct Functions in Peroxisomal Assembly

Peter U. Mayerhofer, Tanja Kattenfeld, Adelbert A. Roscher, and
Ania C. Muntau

Dr. v. Hauner Children's Hospital,
Department of Clinical Chemistry and Biochemical Genetics,
Ludwig-Maximilians-University Munich, Lindwurmstr. 4, D-80337 Munich, Germany

Contributions to the manuscript: Outline of the project by A.A.R.; concept by A.C.M. and ***P.U.M.****; Computational analysis by A.A.R. and* ***P.U.M.****; experimental work by T.K. and* ***P.U.M.****; writing by* ***P.U.M.*** *editorial help by the co-authors*

Abstract

PEX19 has been shown to play a central role in the early steps of peroxisomal membrane synthesis. Computational database analysis of the PEX19 sequence revealed three different conserved domains: D1 (aa 1-87), D2 (aa 88-272), and D3 (aa 273-299). However, these domains have not yet been linked to specific biological functions. We elected to functionally characterize the proteins derived from two naturally occurring *PEX19* splice variants: PEX19ΔE2 lacking the N-terminal domain D1 and PEX19ΔE8 lacking the domain D3. Both interact with peroxisomal ABC transporters (ALDP, ALDRP, PMP70) and with full-length PEX3 as shown by *in vitro* protein interaction studies. PEX19ΔE8 also interacts with a PEX3 protein lacking the peroxisomal targeting region located at the N-terminus (Δ66aaPEX3), whereas PEX19ΔE2 does not. Functional complementation studies in *PEX19*-deficient human fibroblasts revealed that transfection of *PEX19ΔE8*-cDNA leads to restoration of both peroxisomal membranes and of functional peroxisomes, whereas transfection of *PEX19ΔE2*-cDNA does not restore peroxisomal biogenesis. Human PEX19 is partly farnesylated *in vitro* and *in vivo*. The farnesylation consensus motif CLIM is located in the PEX19 domain D3. The finding that the protein derived from the splice variant lacking D3 is able to interact with several peroxisomal membrane proteins and to restore peroxisomal biogenesis challenges the previous assumption that farnesylation of PEX19 is essential for its biological functionality. The data presented demonstrate a considerable functional diversity of the proteins encoded by two *PEX19* splice variants and thereby provide first experimental evidence for specific biological functions of the different predicted domains of the PEX19 protein.

Introduction

The biogenesis of peroxisomes (reviewed by (Purdue & Lazarow, 2001; Subramani, 1998; Titorenko & Rachubinski, 2001a) is a complex process including the biosynthesis of the peroxisomal membrane, the targeting and insertion of peroxisomal membrane proteins (PMPs) into this membrane, and the import of peroxisomal matrix enzymes across the bilayer into the peroxisomal lumen. The proteins involved are termed "peroxins" and are encoded by at least 23 different *PEX* genes. In most cases, human *PEX* mutants display defects in the import of peroxisomal matrix proteins whereas the synthesis of some peroxisomal membrane vesicles and the insertion of PMPs into these membrane remnants ("peroxisomal ghosts") remain unaffected. Only mutants in *PEX3*, *PEX16*, and *PEX19* appear to lack even such peroxisomal ghosts (Matsuzono *et al*., 1999; Muntau *et al*., 2000a; South & Gould, 1999), implicating a crucial role of these proteins in the very early stage of peroxisomal membrane synthesis.

Among these PEX19 is the only peroxin known to own a C-terminal CAAX-box, thereby harboring the intrinsic property of being modified by posttranslational farnesylation. In human, PEX19 is in part farnesylated *in vivo* and it has been suggested that farnesylation is required for the peroxisomal localization of PEX19 (Matsuzono *et al*., 1999). Whether farnesylation is essential for the function of PEX19 in peroxisomal biogenesis (Matsuzono *et al*., 1999) or has only an ancillary effect (Sacksteder *et al*., 2000) remains unclear to date. PEX19 appears to be bimodally distributed between the cytoplasm and the peroxisomes, with most of the protein in the cytoplasm (Sacksteder *et al*., 2000). PEX19 protein has been shown to bind a wide variety of peroxisomal membrane proteins including peroxins and peroxisomal ABC transporters (Fransen *et al*., 2001; Gloeckner *et al*., 2000; Götte *et al*., 1998; Sacksteder *et al*., 2000; Snyder *et al*., 2000; Snyder *et al*., 1999a; Snyder *et al*., 1999b). Among these, PEX19 has been shown to interact with PEX3, another key component in early peroxisomal membrane synthesis, in yeast (Götte *et al*., 1998) and human (Muntau *et al*., 2000a; Soukupova *et al*., 1999; South & Gould, 1999). In yeast, this particular protein-protein interplay appears to be a prerequisite for the generation of preperoxisomal structures that can acquire and stabilize newly synthesized PMPs (Hettema *et al*., 2000). PEX19 harbors distinct binding sites for PEX3 and PEX16 (Fransen *et al*., 2001). However, these sites have not yet been linked to a specific protein domain organization of PEX19.

We have previously cloned and characterized the human *PEX19* gene, which is composed of eight exons (Kammerer *et al*., 1997). On the transcriptional level, we identified different

PEX19 splice variants (Kammerer *et al.*, 1997). The unspliced variant *PEX19all* encodes for the full-length PEX19 protein, whereas the variants *PEX19ΔE2* and *PEX19pΔE8* are expected to lack N- or C-terminal parts of the protein.

Tissue- or cell-specific expression of splice variants has been reported for many genes, e.g. for genes encoding cytokines or tyrosine kinases. Functional diversities of these variants, like distinct protein-protein interactions, are known (Atamas, 1997; Strehler & Zacharias, 2001; Xiong *et al.*, 1998). For *PEX19*, the splice variant *PEX19all* has been described to be the predominant transcript in mRNA of several cells and tissues in human, although the variant *PEX19ΔE2* has also been reported to account for a significant level of total human *PEX19* mRNA. Interestingly, the ratio between *PEX19all* and *PEX19ΔE2* expression was completely reversed in uterine mRNA prepared from total human uterine tissue (Kammerer *et al.*, 1997), but a possible biological impact of these findings remained still unclear. Therefore, the characterization of *PEX19* splice-variants as to their ability to interact with other peroxisomal proteins and to initiate early peroxisomal membrane synthesis could provide insights into the potential biological relevance of these *PEX19* splice variants. Furthermore, the definition of functional regions of PEX19 by the characterization of truncated PEX19 splice variants could contribute to the knowledge on specific protein domains within PEX19.

Material and Methods

Computational analysis

Database searches for the prediction of the protein domain structure of human PEX19 were performed using the NCBI-BLASTP 2.2.1 program (Altschul *et al.*, 1997) and the ProDom 2001.2 database (http://prodes.toulouse.inra.fr/prodom/doc/prodom. html).

Eukaryotic expression plasmids

Plasmids expressing full-length ALDP, ALDRP, and PMP70 have been previously described (Gloeckner *et al.*, 2000). The plasmids pcDNA3/PEX19all, pcDNA3/PEX19ΔE2, and pcDNA3/PEX19pΔE8 encoding different PEX19 splice variants have been generated by Kammerer et al. (Kammerer *et al.*, 1997). The plasmid encoding the first 40 amino acids of PEX3 fused to the green fluorescent protein (GFP) has been described previously (Kammerer *et al.*, 1998). The N-terminal deletion construct missing the first 66 amino acids of PEX3 was generated by Muntau et al. (Muntau *et al.*, 2000a).

***In vitro* protein-protein interaction (GST-pull-down) assay**

For *in vitro* translation and labeling pcDNA3 (Invitrogen) derived expression plasmids were used. The proteins were transcribed *in vitro* from the T7-promotor of pcDNA3, translated and labeled with [^{35}S]-methionine (Amersham) using the TNT Coupled Reticulocyte Lysate System (Promega) following standard protocols. For the generation of glutathione-S-transferase (GST) fusion proteins, different cDNAs of human *PEX19*-splice variants were subcloned into the prokaryotic expression plasmid pGEX-3X (Pharmacia) as described elsewhere (Kammerer *et al.*, 1997). Expression and affinity purification using glutathione-sepharose 4B (Pharmacia) of the fusion proteins were performed as previously described (Braun *et al.*, 1994). The various purified GST-fusion proteins were bound to glutathione-sepharose beads (Pharmacia) in PBS for 1h at 4 °C and washed three times in PBS. For

the *in vitro* interaction assay the GST-fusion proteins (0.5-1.5 μg protein bound to 1 μl bead suspension) were incubated with 5 μl of *in vitro* translated, [^{35}S]-labeled protein in 200 μl binding buffer (100 mM NaCl, 50 mM potassium phosphate pH 7.4, 1 mM MgCl$_2$, 10 % glycerol, 0.1 % Tween 20, 1.5 % BSA) for 2h at 4 °C. The beads were then pelleted and washed four times in 1 ml binding buffer not containing BSA. Pellets were resuspended in SDS-sample buffer and boiled for 5 min before being analyzed by SDS-PAGE according to standard protocols. To verify stability of the GST-fusion proteins and equal loading, gels were stained with Coomassie blue. The gels were dried and exposed to X-ray film for 24 h.

Transfection, antibodies, and indirect immunofluorescence analysis

Plasmids were transfected into COS7 cells or into human *PEX19*-deficient fibroblasts using lipofectamine (Life Technologies) following protocols provided by the manufacturer. To create stable transfectants, the fibroblasts were incubated with 500 μg/ml neomycin (SIGMA). For indirect immunofluorescence analysis, stable transfectants were fixed with 3% formalin/PBS for 30 min and permeabilized with 1% Triton X-100 for 5 min. Thereafter, cells were incubated for 1 hour with a polyclonal rabbit antibody against catalase (Biodesign; 1:100 dilution) and/or a monoclonal mouse antibody against ALDP (ALD-1D6, Euromedex; 1:100 dilution). The cells were then washed 10 times with PBS and incubated for 1 hour with secondary antibodies: Rhodamine (TRITC)-conjugated goat anti-mouse IgG and/or fluorescein (FITC)-conjugated goat anti-rabbit IgG (all Jackson Immunoresearch Laboratory Inc.; 1:50 dilution). After 10 washing steps in PBS, the cells were embedded in an anti-fading reagent (Vectashield, Vector Laboratories Inc.). Fluorescence microscopy was performed using an Axiovert 135 inverted fluorescence microscope (Zeiss).

Results

Domain structure of the human PEX19 protein in relation to *PEX19* splice variants

Computational database analysis of the full-length PEX19 protein sequence using the NCBI-BLASTP program and the ProDom database revealed three different conserved domains in direct succession (Fig. A3-1B): Domain D1 (ProDom-ID: PD339396) ranging form the N-terminus to amino acid 87, domain D2 (ProDom-ID: PD024170) ranging from amino acids 88 to 272, and the C-terminal domain D3 (ProDom-ID: PD329985). These domains are shared by ortholog PEX19 proteins of other species. Interestingly, the C-terminal domain is composed of amino acids that are encoded exclusively by exon 8 of human *PEX19*, whereas the transition from domain D1 to D2 is not linked to a special exon-exon boundary (Fig. A3-1B).

Figure A3-1: Human *PEX19* splice variants and the predicted domain structure of PEX19 protein. A, Scheme of the *PEX19* splice variants. The transcript *PEX19all* contains all eight exons, the transcript *PEX19ΔE2* lacks exon 2, and the transcript *PEX19pΔE8* lacks a part of exon 8. Exons (E1-E8) are indicated as gray boxes for coding or white boxes for noncoding regions. The dashed lines span regions of the transcript that are excised by splicing. The second in-frame initiation codon utilized during translation of *PEX19ΔE2* is shown by a white arrow. Termination codons resulting from frame shifts are indicated by black asterisks. B, Domain structure of PEX19 and the corresponding proteins of the *PEX19* splice variants. The domains D1 (ProDom-ID PD339396), D2 (ProDom-ID PD024170), and D3 (ProDom-ID PD329985) were predicted using the NCBI-BLASTP program and the ProDom database. The encoded proteins of the *PEX19* splice variants including the C-terminal farnesyl group (jagged line) are shown as white boxes. The corresponding exons are numbered E1-E8. The dashed box at the C-terminus of PEX19pΔE8 is indicating amino acids that differ from the wild type PEX19 sequence because of frame shifts.

This predicted domain structure was compared with proteins expected to be encoded by different *PEX19*-splice variants (Kammerer *et al*., 1997): The unspliced transcript *PEX19all* contains all eight exons and encodes the full-length PEX19 protein. The *PEX19ΔE2* transcript-variant lacks the complete sequence of exon 2. The possible re-initiation of translation at the second in-frame ATG results in a N-terminally truncated protein (PEX19ΔE2) that lacks the first 90 amino acids. The *PEX19pΔE8* transcript-variant exhibits a deletion of the first 52 bp of exon 8. As a consequence, a C-terminally truncated PEX19 protein (PEX19pΔE8) is produced with terminal seven amino acids that are distinct from the wild type PEX19 protein sequence and lack the C-terminal farnesylation motif CLIM. The comparison of these variant PEX19 proteins to the predicted PEX19 domain structure (Fig. A3-1B) reveals that the splice variant PEX19ΔE2 lacks the N-terminal domain D1 whereas PEX19pΔE8 is composed of the domains D1 and D2 but entirely lacks the domain D3, which contains the C-terminal farnesylation consensus motif. Therefore, these two splice variants were subsequently utilized for further studies to delineate specific domain functions.

In vitro interaction of variant PEX19 proteins with peroxisomal membrane proteins

We performed *in vitro* interaction studies to investigate whether the N-terminally truncated protein PEX19ΔE2 lacking domain D1 and the C-terminally truncated protein PEX19pΔE8 lacking domain D3 bind to peroxisomal membrane proteins known to interact with the full-length PEX19 protein. Among those we used the [^{35}S]-labeled peroxisomal ABC half transporters ALDP, ALDRP, and PMP70 and the peroxisomal assembly protein PEX3 in an *in vitro* GST-pull-down assay. Both the full-length PEX19 protein GST-PEX19all (Fig. A3-2A) and the truncated proteins GST-PEX19ΔE2 (Fig. A3-2B) and GST-PEX19pΔE8 (Fig. A3-2C) retained [^{35}S]-radioactivity indicating binding to the peroxisomal membrane proteins ALDP, ALDRP, PMP70, and PEX3. GST alone did not bind to either protein (data not shown).

With regard to PEX3, retention of [^{35}S]-radioactivity resulted in two distinct bands (Fig. A3-2A and C). This can be explained by the observation that *in vitro* translation of full length *PEX3* yields two proteins of different molecular weight. The lower band is a result of the utilization of the internal start codon at position 199 of the coding region of *PEX3* (Muntau *et al*., 2000a). The corresponding protein (Δ66aaPEX3) lacks the first 66 amino acids but retains the ability to bind to full length PEX19 (Fig. A3-2A) and to PEX19pΔE8 (Fig. A3-2C). Based on data of previous studies (Fransen *et al*., 2001; Soukupova *et al*., 1999), Δ66aaPEX3 is predicted to be devoid of its peroxisomal targeting sequence. To demonstrate that this

information is contained within the N-terminal 40 amino acids of PEX3, the first 40 amino acids of PEX3 were N-terminally fused to GFP (1-40aa PEX3-GFP) and were expressed in COS7 cells. The intrinsic GFP fluorescence subsequently revealed a punctate pattern indicative for peroxisomal localization (data not shown).


Figure A3-2: *In vitro* **binding of the encoded proteins of *PEX19* splice variants to peroxisomal membrane proteins.** The peroxisomal membrane proteins ALDP, ALDRP, PEX3, and PMP70 were [^{35}S]-methionine labeled by *in vitro* translation and then tested for interaction in a GST-pull-down assay with immobilized GST-PEX19all (A and D), GST-PEX19ΔE2 (B and D), and GST-PEX19pΔE8 (C and D) fusion proteins. Eluted [^{35}S]-labeled proteins were separated on 12% SDS-polyacrylamide gel electrophoresis and exposed to autoradiography. Bands indicate protein-protein binding by the presence of the [^{35}S]-labeled PMPs being retained and eluted from the PEX19-constructs. Full length [^{35}S]-labeled ALDP, ALDRP, PEX3, and PMP70 were eluted from GST-PEX19all (A), GST-PEX19ΔE2 (B) and GST-PEX19pΔE8 (C) but not from GST alone (data not shown), indicating binding to the PEX19 variants. D, The nature of the double band representing PEX3 was evaluated in a separate *in vitro* binding assay. The lower band, corresponding to a 66 amino acid N-terminally truncated PEX3 protein (Δ66aaPEX3), results from the utilization of the second in frame start codon of *PEX3* cDNA. [^{35}S]-labeled Δ66aaPEX3 was eluted from GST-PEX19all and GST-PEX19pΔE8, but not from GST-PEX19ΔE2. This indicates that Δ66aaPEX3 binds to GST-PEX19all and GST-PEX19pΔE8, but not to GST-PEX19ΔE2. In contrast, full length [^{35}S]-labeled PEX3 was eluted from all three GST-PEX19 variants. GST alone did not bind to either of the PEX3 proteins. On the left, 20% of the total amount of the [^{35}S]-labeled proteins (input) used in the pull-down assay was loaded to illustrate the molecular masses of both PEX3 variants.

However, it is interesting to note that the N-terminally truncated PEX19 variant GST-PEX19ΔE2 showed only binding to a single PEX3 band (Fig. A3-2B). To demonstrate that this band corresponds to the full length PEX3 protein, we performed an *in vitro* binding assay comparing the binding of [^{35}S]-labeled PEX3 and Δ66aaPEX3 to the GST-immobilized PEX19 variants (Fig A3-2D). Both PEX3 translation products were detected when the retained [^{35}S]-labeled PEX3 proteins were eluted from the GST-PEX19all and GST-

PEX19pΔE8 beads. In contrast, only one PEX3 translation product was retained after elution from the GST-PEX19ΔE2 beads (Fig. A3-2D). This protein migrates at the molecular weight corresponding to the full length PEX3 protein. This indicates that the N-terminally truncated PEX19ΔE2 protein binds to the full length PEX3 protein, but not to the N-terminally truncated Δ66aaPEX3 protein.


Figure A3-3: Functional complementation of *PEX19*-deficient fibroblasts by *PEX19* splice variants. *PEX19*-deficient fibroblasts were transfected with pcDNA3 derived cDNA-vectors expressing the human *PEX19* splice variants *PEX19all*, *PEX19pΔE8*, and *PEX19ΔE2*. Stable transfectants were processed for indirect immunofluorescence using rhodamine-labeled antibodies to the peroxisomal membrane protein adrenoleukodystropy-protein (ALDP; A, C, E, and G) and fluorescein-labeled antibodies to catalase (B, D, F, and H), a peroxisomal matrix protein. After transfection with the plasmid pcDNA3/*PEX19all* (A and B), coding for the full-length PEX19 protein, the punctate pattern for ALDP (A) and catalase (B) indicated that these proteins were co-localized either at or within restored peroxisomes. Transfection with the plasmid pcDNA3/*PEX19pΔE8* (C and D), coding for a C-terminally truncated PEX19 protein lacking the farnesylation consensus sequence, restored both peroxisomal membranes and functional peroxisomes as demonstrated by a punctate immunofluorescent pattern. In contrast, transfection of the empty vector pcDNA3 (E and F) as a control did not lead to restoration of a peroxisomal punctate pattern. Transfection with the plasmid pcDNA3/*PEX19ΔE2* (G and H) coding for a 90 amino acids N-terminally truncated PEX19 variant did not restore peroxisomal biogenesis as indicated by the diffuse cytosolic signal after staining for ALDP (G) and catalase (H).

Functional complementation studies in *PEX19*-deficient fibroblasts

The ability of the *PEX19* splice variants to restore the formation of peroxisomal membranes was investigated by functional complementation studies in *PEX19*-deficient fibroblasts that entirely lack morphologically recognizable peroxisomal membranes (Matsuzono *et al*., 1999). Transfection of *PEX19all*-cDNA encoding the full-length PEX19 protein restored peroxisomal biogenesis (Fig. A3-3A and B). Indirect immunofluorescence analysis was performed by staining with antibodies to the peroxisomal membrane protein ALDP (Fig. A3-

3A) and to the matrix enzyme catalase (Fig. A3-3B) and yielded a co-localized peroxisomal punctate pattern. This indicates both the presence of peroxisomal membranes and of import-competent intact peroxisomes.

The splice variant *PEX19pΔE8* encodes a C-terminally truncated PEX19 protein that lacks the domain D3 and therefore does not contain the farnesylation motif (CLIM). Transfection of *PEX19pΔE8*-cDNA revealed a co-localized punctate staining for ALDP (Fig. A3-3C) and for catalase (Fig. A3-3D) indicating the restoration of peroxisomal membranes and of functional peroxisomes in the *PEX19*-deficient fibroblasts. As a control, transfection of the empty vector pcDNA3 (Fig. A3-3E and F) yielded only a diffuse pattern when stained with antibodies to ALDP (Fig. A3-3E) and to catalase (Fig. A3-3F) indicating the mislocalization of these two proteins to the cytosol.

In contrast, transfection of *PEX19ΔE2*-cDNA (Fig. A3-3G and H), encoding a 90 amino acids N-terminally truncated PEX19 protein lacking the domain D1, yielded only a diffuse pattern when stained with antibodies to ALDP (Fig. A3-3G) and to catalase (Fig. A3-3H). This indicates a mislocalization of these two proteins to the cytosol in the absence of peroxisomal membranes or functional peroxisomes. The ability of the *PEX19ΔE2*-cDNA-construct to produce a protein with the expected length had been shown earlier by *in vitro* translation (Kammerer *et al*., 1997). This observation is consistent with the hypothesis that the *PEX19ΔE2*-cDNA-construct is fully functional. Furthermore, integration of the *PEX19ΔE2*-cDNA into the genome was confirmed by positive neomycin-selection of the fibroblasts. Nevertheless, transfection of *PEX19ΔE2*-cDNA in *PEX19*-deficient fibroblasts did not lead to restoration of peroxisomal biogenesis.

Discussion

The current knowledge about the domain organization of PEX19 and the exact function of these domains is limited. Computational database analysis of the human PEX19 protein sequence reveals three domains in direct succession, which are exclusively shared by ortholog PEX19 proteins of other species. However, these domains have not yet been linked to specific biological functions. The encoded proteins of two natural occurring *PEX19* splice variants, each lacking exactly one of these domains, resemble this modular domain organization of PEX19. Therefore, we took advantage of these splice variants to assess their functional ability as to PMP-binding and restoration of peroxisomal membrane synthesis. The data presented provide first informations on the role of these domains in different aspects of the biological function of PEX19.

The data derived from the analysis of truncated PEX19 splice variants indicate that the C-terminal truncation of domain D3 does not disturb the ability of PEX19 to bind full length PEX3, ALDP, ALDRP, and PMP70. At least *in vitro*, this interaction apparently does not require the farnesylation motif at the C-terminus of PEX19. Recent other studies utilized the yeast two-hybrid system to define PEX19 protein sites that are essential for PMP binding. In these studies farnesylation of PEX19 was required for binding of PEX19 to PEX10, PEX11β, PEX12, and PEX13 but not for binding to PEX3 (Fransen *et al*., 2001). We show here that the interaction of PEX19 with the peroxisomal ABC half transporters ALDP, ALDRP, and PMP70 may occur independently from posttranslational farnesylation.

The interaction between PEX19 and PEX3 is considered to be crucial for the early peroxisomal membrane synthesis. Our data indicate that a truncation of 90 amino acids that correspond to the domain D1 at the N-terminus of the PEX19 protein (PEX19ΔE2) does not abolish the *in vitro* binding to full length PEX3. Therefore, our data support the hypothesis that a PEX19 variant composed of the domains D2 and D3 is able to interact with full length PEX3. In contrast, using the yeast two-hybrid system, the PEX3 interaction region of PEX19 has been narrowed down to approximately 50 amino acids at the N-terminus of PEX19 protein in human (Fransen *et al*., 2001) and *Pichia pastoris* (Snyder *et al*., 1999a). Furthermore, a truncation of 30 amino acids at the N-terminus of PEX19 abolished the interaction with PEX3 in the yeast two-hybrid system (Fransen *et al*., 2001). These conflicting *in vitro* findings could be explained by the fact that full length PEX19 is needed to perform a functional interaction with PEX3 *in vivo*, whereas *in vitro* shorter fragments of PEX19 are sufficient to bind PEX3. Alternatively, PEX19 might contain distinct binding-sights for

PEX3: One at the extreme N-terminus, as reported by Fransen et al. and Snyder et al. (Fransen *et al*., 2001; Snyder *et al*., 1999a), and one composed of the domains D2 and D3. Since domain D3 of PEX19 is dispensable for the interaction with the PMPs examined here, we conclude that a putative second PEX3-binding site within the PEX19 protein is most probably situated in domain D2.

With regard to PEX3, we show here that the N-terminal truncation of 66 amino acids of PEX3 does not abolish the binding to full-length PEX19 *in vitro*. Our *in vitro* binding data are also in agreement with recently reported "two hybrid" data, showing that N-terminally truncated *Pichia pastoris* (Snyder *et al*., 2000; Snyder *et al*., 1999a) and *Saccharomyces cerevisiae* (Götte *et al*., 1998) PEX3 still retains the ability to interact with PEX19. Furthermore, Fransen et al. reported that full-length PEX19 was able to bind to a N-terminally 43 amino acid truncated PEX3 protein in a blot overlay assay (Fransen *et al*., 2001). The N-terminal 40 amino acids of PEX3 have been shown to be sufficient to target a reporter protein to the peroxisome. The targeting information of PEX3 is thus localized in the short N-terminal part of the protein including the first transmembrane region (Soukupova *et al*., 1999). In all targeting signals of PMPs known today, one ore more transmembrane domains are directly integrated (Brosius *et al*., 2001). In human PEX3, only one physical transmembrane region (amino acids 16-33) has been reported (Soukupova *et al*., 1999). One can therefore propose that the region of the N-terminal 40 amino acids of PEX3 harbors the one and only targeting information of the protein. Taken together, these findings support the hypothesis that PEX3 has non-overlapping functional regions that are not directly interconnected: A region containing the peroxisomal targeting information located at the extreme N-terminus of PEX3 and a spatially distinct region essential for binding to the PEX19-domains D1 or D2.

Human PEX19 protein has been reported to be partly farnesylated *in vitro* (Kammerer *et al*., 1997) and *in vivo* (Matsuzono *et al*., 1999). However, the role of farnesylation in peroxisomal biogenesis remains still unclear. Matsuzono et al. assumed that farnesylation of PEX19 is most likely essential for its biological activity because a PEX19 variant harboring a mutation in the farnesylation consensus sequence failed to restore peroxisomal biogenesis in *PEX19*-deficient fibroblasts (Matsuzono *et al*., 1999). On the other hand, Sacksteder et al. reported that PEX19 is functional in peroxisomal biogenesis even in the absence of the farnesyl moiety (Sacksteder *et al*., 2000). In our functional complementation studies we utilized the splice variant *PEX19pΔE8* to express a truncated PEX19 protein lacking the domain D3 which includes the C-terminal farnesylation consensus sequence. We have also previously shown that this variant protein cannot be modified by a farnesyl group *in vitro* (Kammerer *et al*.,

1997). Nevertheless, we observed that expression of this splice variant completely restored peroxisomal membrane synthesis in *PEX19*-deficient fibroblasts (Fig A3-3C and D). We therefore conclude that posttranslational farnesylation of the PEX19 protein is not required for its biological function regarding the induction of peroxisomal membrane synthesis.

Splice variants may display a considerable functional diversity. For example, it has been reported for several genes that different splice variants have different protein–binding partners (Strehler & Zacharias, 2001; Xiong *et al*., 1998). We provide evidence that the splice variants PEX19all, PEX19ΔE2, and PEX19pΔE8 exhibit similar binding-capacity to the peroxisomal ABC-transporters and to full length PEX3. On the other hand, the binding-capacity to a N-terminally truncated PEX3 variant lacking the targeting region is different for PEX19ΔE2 when compared to PEX19all and PEX19pΔE8. The interaction between PEX19ΔE2 and this truncated PEX3 variant is markedly reduced or even absent, whereas PEX19all and PEX19pΔE8 are able to bind to this variant PEX3 protein. Furthermore, *PEX19pΔE8* but not *PEX19ΔE2* is able to induce peroxisomal biogenesis in *PEX19*-deficient fibroblasts.

In conclusion the data presented here demonstrate (i) that the proteins encoded by the PEX19 splice variants *PEX19ΔE2* and *PEX19ΔE8* display a considerable functional diversity as shown by divergent results of *in vitro* protein interaction and functional complementation studies (ii) that farnesylation of PEX19 is not essential for its biological activity and (iii) that PEX19 interacts with PEX3 in a region which is spatially distinct from the peroxisomal targeting region of PEX3. Taken together, this study provides first experimental evidence for the specific biological functions of the different predicted domains of the PEX19 protein known to play a key role in the very early steps of peroxisomal biogenesis.

Acknowledgments

References

The references are listed on pages 38–49.

Appendix 4

Genomic Organization, Expression Analysis, and Chromosomal Localization of the Mouse *PEX3* Gene Encoding a Peroxisomal Assembly Protein

Ania C. Muntau[1], Peter U. Mayerhofer[1], Sabrina Albet[2], Thomas E. Schmid[3], Maurice Bugaut[2], Adelbert A. Roscher[1], and Stefan Kammerer[1]

[1] Dr. von Hauner Children's Hospital, Laboratory of Molecular Biology,
Ludwig-Maximilians-University, Lindwurmstrasse 4, 80337 Munich, Germany
[2] Laboratoire de Biologie Moléculaire et Cellulaire,
Faculté des Sciences Mirande, Dijon, France
[3] GSF – National Research Center for Environment and Health,
Institute of Mammalian Genetics, Neuherberg, Germany

*Contributions to the manuscript: Outline of the project by S.K. and A.A.R.; concept by A.C.M. and **P.U.M.**; library screening by S.K.; cDNA cloning by A.C.M.; FISH analysis by T.E.S.; determination of the genomic structure, cloning of the putative promoter region and expression analysis in mouse tissues by A.C.M. and **P.U.M.**; fenofibrate-treatment of rats and northern blot analysis by S.A. and M.B.; writing by A.C.M. and **P.U.M.**; editorial help by the co-authors*

Abstract

The peroxin Pex3p has been identified as an integral peroxisomal membrane protein in yeast where *PEX3* mutants lack peroxisomal remnant structures. Although not proven in higher organisms, a role of this gene in the early peroxisome biogenesis is suggested. We report here the cDNA cloning and the genomic structure of the mouse *PEX3* gene. The 2-kb cDNA encodes a polypeptide of 372 amino acids (42 kDa). The gene spans a region of 30 kb, contains 12 exons and 11 introns and is located on band A of chromosome 10. The putative promoter region exhibits characteristic housekeeping features. *PEX3* expression was identified in all tissues analyzed, showed the strongest signals in liver and in testis, and could not be induced by fenofibrate. The data presented may be useful for the generation of a mouse model defective in *PEX3* in order to clarify the yet unknown functional impact of disturbances in early peroxisomal membrane assembly.

Peroxisome biogenesis includes peroxisome proliferation, membrane biogenesis and peroxisomal matrix protein import (Subramani, 1997). Proteins involved in the assembly of peroxisomes are encoded by *PEX* genes and are termed peroxins (Distel *et al*., 1996). While at least 23 peroxins have been reported to be essential for peroxisome biogenesis, the exact functions and interactions of only a limited number of these have been determined so far. Data from yeast have suggested that the *PEX3* gene is coding for an integral membrane protein essential for both peroxisomal membrane assembly and membrane protein import (Höhfeld *et al*., 1991; Snyder *et al*., 1999b). In a previous study we cloned and characterized the human *PEX3* cDNA (Kammerer *et al*., 1998). Pex3p has been shown to interact with Pex19p in yeast (Götte *et al*., 1998; Snyder *et al*., 1999a), and in human (Soukupova *et al*., 1999). *Saccharomyces cerevisiae* cells deficient in either Pex3p or Pex19p were reported to lack peroxisomal remnant structures, also called peroxisomal ghosts (Götte *et al*., 1998). These observations and the recent identification of multimeric peroxisomal assembly protein complexes are consistent with the hypothesis that these two proteins are essential players in peroxisomal membrane biogenesis and peroxisomal membrane protein localization (Snyder *et al*., 1999b). However, the precise contribution of these peroxins to the maturation of early peroxisomes and human disease pathogenesis is not yet known. The generation of mice with targeted disruption of early peroxin genes, such as *PEX3,* is expected to deliver more information about biological relevance and function. We report here the cDNA sequence and expression data as well as the analysis of the genomic structure and the chromosomal localization of the mouse *PEX3* gene.

The expressed sequence tag (EST) database dbEST (Boguski *et al*., 1993) was probed with the human *PEX3* cDNA sequence. Four mouse EST clones, m1 (IMAGp998L081096), m2 (IMAGp998H081406), m3 (IMAGp998P072169), and m4 (IMAGp998M232137) were obtained from the Resource Center of the German Human Genome Project (Lehrach, 1990). The longest clone, m1, was completely sequenced and revealed to contain 1511 bp including the 3' portion of the gene. The cDNA was completed by 5' RACE-PCR (Marathon-Ready mouse liver cDNA, Clontech) and showed the following features: a 5' untranslated region of 167 bp followed by an open reading frame of 1116 bp (372 amino acids) and a 3' untranslated sequence of 729 bp. A consensus poly(A) signal was identified 34 bp upstream of the poly(A) at position +2017 relative to the transcription start site. The usage of an alternative poly(A) site in the 3' untranslated region was confirmed by 3' RACE-PCR. Two further poly(A) signals at positions +1341 and +1376 were detected in several clones followed by a poly(A)

tail 16-35 bp downstream. The position of the two alternative poly(A) sites at about 70 and 730 bp downstream of the TGA stop codon is in agreement with the data on the human *PEX3* gene (Kammerer *et al*., 1998). Using the ClustalW program (Thompson *et al*., 1994) from the Baylor College of Medicine, we performed a pairwise alignment of the deduced murine Pex3p with the human Pex3p. These two proteins revealed an overall amino acid identity of 93.8%. The degree of identity to the Pex3 proteins of other species is 22.3% to *Pichia pastoris* (455 amino acids), 20.9% to *Hansenula polymorpha* (457 amino acids), 19.9% to *Saccharomyces cerevisiae* (441 amino acids), and 18.6% to *Kluyveromyces lactis* (483 amino acids). Protein similarity scores were determined using the Align program from EERIE (Nimes, France). A comparative analysis of Pex3 proteins using the TMpred server of the Bioinformatics group at ISREC (Epalinges, Switzerland) predicted two hydrophobic transmembrane regions that are located in the N-terminal half of the protein in all species.


Figure A4-1: Genomic organization of the mouse *PEX3* gene. The gene consists of twelve exons (closed boxes) and eleven introns (solid lines between the exons). Exon sizes in base pairs are indicated above, intron sizes below the horizontal line. The 5' and 3' UTRs are shown as open boxes. *Methods:* Mouse cosmid DNA was prepared using ion exchange column purification (Midiprep Kit, Qiagen). Multiple exon-exon PCR reactions were performed using mcos3 cosmid DNA, mouse genomic DNA from 129/Ola mouse embryonic stem cells or both as a template. The resulting PCR products were sequenced from either end using the amplification primers. The sequence containing the putative promoter region was obtained by long template PCR (Expand Long Template PCR System, Boehringer Mannheim) using adaptor-ligated genomic DNA fragments (Mouse Genome Walker Kit, Clontech) according to the manufacturer's procedure. Two successive PCR reactions were performed using the anchor-specific primer AP1 and a mouse *PEX3*-specific reverse primer (m128, 5'-ACT GTG CCC AGG AAG ATG C-3') and then AP2 combined with a nested reverse primer from the coding region (m81, 5'-CCA CAT TGA TCT CAG CAT CTC C-3'). The obtained PCR products were purified from the gel (QIAquick Gel Extraction Kit, Qiagen), directly sequenced by fluorescent dye terminator technology and separated on an ABI 377 sequencer. EMBL/GeneBank accession numbers: AF152996 and AF162890 through AF162896.

To determine the exon-intron structure of the mouse *PEX3* gene, a 129/Ola mouse genomic DNA cosmid library was screened with a mouse cDNA probe. One positive clone, mcos3, covering about 17 kb of the *PEX3* gene including exon 3 to exon 12 was isolated. To amplify the introns, multiple exon-exon PCR reactions were performed using mcos3 cosmid DNA,

mouse genomic DNA from 129/Ola mouse embryonic stem cells or both as a template. Exons 1 and 2, which were not present on the clone mcos3, were exclusively amplified from mouse genomic DNA. Overlapping fragments spanning the complete coding region were generated and sequenced from either end using the amplification primers in order to get the intron-exon boundaries. Comparison of the obtained genomic sequence with the cDNA sequence revealed that the mouse *PEX3* gene consists of 12 exons and 11 introns (Figure A4-1). The exon sizes range from 44 bp (exon 4) to 166 bp (exon 8). All exon-intron junctions conform to the GT-AG rule (Figure A4-2). Five introns (intron 4, 5, 6, 7, and 9) were fully sequenced and the exon-flanking intronic sequences of all other introns were determined. The approximate sizes of introns not fully sequenced were estimated by agarose gel electrophoresis of corresponding PCR products. The total size of the mouse *PEX3* gene is approximately 30 kb (Figure A4-1).

		_____	Intron	_____	
		5' splice site (donor)		3' splice site (acceptor)	
Mm	CTCGGAG	GTGAGTTGACAACA	---In1---	TTTAATGATTTTAG	GAGTATA
Hs	CTTGGAG	GTGGGTGACAACGT	---In1---	TTTAATGATTGTAG	GAGTATA
Mm	ATGACAG	GTAAGCATGCGCGC	---In2---	CTGTTGAAAAGCAG	TGCTGTC
Hs	ATGACAG	GTAAGACAGGGAGA	---In2---	TGTTTGTATTACAG	TGCTGTC
Mm	AAAGCAG	GTGAAAGCGCACTG	---In3---	ATTTTTTTCTTTAG	GCCTTCA
Hs	AAAACAG	GTAAATGCAAGTTA	---In3---	ATTTTGTTCTTTAG	GCCTTCA
Mm	ATAATAA	GTAAGTCCAAATAT	---In4---	TCTTCTCTCTGAAG	GTTTCAC
Hs	ATAATAA	GTAAGCCTGCATAT	---In4---	TTTTCTCTGTGAAG	GTTTCAC
Mm	TGGCACT	GTAAGTTTAACAGA	---In5---	TTCTGTTTGCACAG	ACCGTTC
Hs	TGGCACT	GTAAGTTTAATAGA	---In5---	TCTGTTTTATACAG	ACAATTC
Mm	GGAGACG	GTAAGATTCCAGTC	---In6---	TTTTTGTTTGATAG	GCCTCAC
Hs	GGAGATG	GTAAGATTCTTATT	---In6---	TTTTTCTTTAATAG	GCCTGAC
Mm	TAGGAAG	GTATGCTATGTCCT	---In7---	TCCTCTATTTCCAG	TGTCTCT
Hs	TAGGAAG	GTAAGGCATTTTTC	---In7---	TTCTCTGTTTCTAG	TGTTTCT
Mm	AGCTCAG	GTACTTAATTCATA	---In8---	TTTTGATTTTACAG	GCCTATG
Hs	AGTGCAG	GTGCTTAATTCATA	---In8---	TTTTAATTCTATAG	GCCTGTG
Mm	TGGAAAG	GTATGTAGAGTGCA	---In9---	CTTTTTTTATCTAG	TCCAGAT
Hs	TGGAAAG	GTATGTATACTTCA	---In9---	CTTACTTTATATAG	CCCAGAT
Mm	TAAACAG	GTAACTTGGAATGT	---In10--	TAATTTGTTTTCAG	TCTGTCC
Hs	TGAATAG	GTAAGATGACATAT	---In10--	TAATGATTTTTCAG	TCTTTCC
Mm	TGTGCAG	GTAAGTGAGAAGCT	---In11--	ATGGTTGTTACCAG	GATCTGC
Hs	TGTTCAG	GTAAGAAGAAAGCT	---In11--	ATCATCTTTGCTAG	GATCTGT

| **Cs** | | GTAAGT | | TTTTTTTTTTNCAG | |
| | | G | | CCCCCCCCCC | |

Figure A4-2: Comparison of the exon-intron boundaries of the mouse and human *PEX3* gene. The consensus sequences (CS) of the 5' and 3' intron splice sites are given below, where N is any nucleotide and, where two nucleotides are given, the one above is more common (Shapiro & Senapathy, 1987).

To characterize the putative promoter region, 2 kb of genomic sequence immediately upstream of the transcriptional start sequence were obtained by long template PCR. Analysis of this 5' flanking sequence for consensus promoter elements was performed using the

Transcription Factor Database (TFD) (Ghosh, 1991) and the Signal Scan server of BIMAS (Prestridge, 1991). As a characteristic finding for housekeeping genes, which are expressed at low levels in essentially all tissues, canonical TATA and CCAAT boxes were not found. The region close to the transcription initiation site was shown to be relatively GC-rich exhibiting a GC content of about 60% from -250 to -1. This sequence contains a putative binding site for the transcription factor Sp1 at -30 to -25, which was found with identical sequence and similar location in the orthologous human gene (Muntau, unpublished). At approximately 1.8 kb upstream of the transcription start site we detected a polymorphic CT repeat. By analyzing several subclones, repeat lengths between 17 and 27 - with the exception of 21 and 22 repeats - were identified. A visual inspection of the promoter region for possible peroxisome proliferator-responsive elements (PPRE) or oleate-responsive elements (ORE) did not reveal motifs that show a strong similarity to the consensus sequences (Karpichev *et al*., 1997; Zhang *et al*., 1992).

Figure A4-3: Chromosomal localization of the mouse *PEX3* gene. Specific hybridization signals were identified on band A of chromosome 10 using fluorescence in situ hybridization of metaphase chromosomes. *Methods:* Metaphase chromosome preparations were obtained from mouse bone marrow cells according to standard procedures. The cosmid clone mcos3 containing about 17 kb of the murine *PEX3* gene, was labeled with biotin-14-dUTP (Life Technologies) by nick-translation method and was detected with streptavidin-Cy3 (Amersham Life Science). Metaphase chromosomes were analyzed under an Axioppgot microscope (Zeiss) and pictures were taken by digitizing the microscopic image with the computer program ISIS3 (Metasystems).

The chromosomal localization of the *PEX3* gene was determined by fluorescence *in situ* hybridization (FISH) analysis. The cosmid clone mcos3 containing about 17 kb of the mouse *PEX3* gene, was labeled with biotin. By hybridization of this probe to mouse metaphase chromosomes, *PEX3* was localized to band A on chromosome 10 (Figure A4-3). This region has syntenic relationship with the human chromosome region 6q23-6q24 where the human *PEX3* gene has been located by FISH analysis (Muntau, unpublished) and by large scale genome sequencing (NCBI, GenBank Accession number AL031320).

Figure A4-4: Expression of the *PEX3* gene in various mouse and rat tissues. A Northern blot of mRNA from several murine tissues was hybridized with the 1.6-kb mouse cDNA probe. A human actin probe was used as control for the loaded amount of RNA. Fragment sizes are indicated on the right. *Methods: PEX3* mRNA expression in various mouse tissues was examined using a BALB/c mouse multiple tissue Northern blot containing 2 μg poly(A)$^+$ mRNA per lane (Clontech). A 1.6-kb cDNA fragment was isolated with *Not*I and *Xho*I from the mouse EST clone m1 and radiolabeled with [α-^{32}P]dATP by random priming method. The blot was hybridized as described elsewhere (Braun *et al*., 1994) and exposed to an X-ray film for 10 days. Signals obtained were compared to those detected by a human actin cDNA probe.

PEX3 mRNA expression in various mouse tissues was examined by Northern blot analysis using a 1.6-kb mouse cDNA as a probe. A human actin probe was used as control for the loaded amount of RNA. The presence of *PEX3*-specific mRNA in all tissues examined with the strongest expression in liver and testis was demonstrated. In heart, brain, spleen, lung, liver, skeletal muscle, and kidney, signals at 1.6 and 2.3 kb were detected with the 2.3-kb signal being predominant in these tissues (Figure A4-4). These fragments seem to be derived from alternative polyadenylation at +1341/1376 and +2017 bp described above. In testis, in addition to the 2.3-kb transcript several shorter fragments were observed with lengths between 1.4 and 1.7 kb. This was the only tissue, in which the shorter transcripts were expressed at a higher intensity. It might be interesting to note that a marked morphological heterogeneity of peroxisomes has been described in cultured mouse testicular Leydig cells (Litwin & Bilinska, 1995). *PEX3* might potentially be involved in the formation of small local networks of interconnected tubular peroxisomes observed in this study.

Pharmacological modification of expression levels of specific peroxins might be a valuable addition to treatment strategies for human peroxisomal biogenesis disorders. Fenofibrate, which was proven to be a potent peroxisomal proliferator in rodents, is a broad-spectrum lipid-lowering agent widely used in patients with coronary heart disease (Packard, 1998). To compare *PEX3* mRNA expression in rats before and after fenofibrate treatment, Northern blot analysis of rat tissues using a human 2.1-kb *PEX3* probe was performed. Signals obtained were compared to those detected with a rat glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) control probe. As a positive control for the effectiveness of the fenofibrate treatment, hybridization with a mouse acyl-CoA oxidase (*AOX*) probe was performed. As in mouse, *PEX3*-specific mRNA in rat was also expressed in all tissues examined. The amount of lower transcript was slightly increased in liver but overall transcripts showed a more even distribution than in mouse (Figure A4-5). The examination of rat testis tissue has still to be performed. The fenofibrate-treatment did not affect the level of *PEX3* mRNA expression indicating that transcription of *PEX3* is not induced by fenofibrate in rats (Figure A4-5). In contrast the level of peroxisomal acyl-CoA oxidase (*AOX*) mRNA used as a marker of peroxisomal proliferation was strongly enhanced in liver, kidney, intestine and heart proving the effectiveness of fenofibrate treatment (Figure A4-5).

Figure A4-5: Northern analysis in various tissues from fenofibrate-treated and untreated rats. Hybridization was performed using the 2.1-kb human *PEX3* cDNA probe. Signals obtained were compared to those detected with a rat glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) control probe. The level of peroxisomal acyl-CoA oxidase *(AOX)* mRNA was used as marker for peroxisomal proliferation. Fragment sizes are indicated on the right. c: untreated, f: fenofibrate-treated rats. *Methods:* Northern blot analysis of rat tissues using a human 2.1-kb *PEX3* probe was performed.as previously described (Albet *et al.*, 1997). Signals obtained were compared to those detected with a rat glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) control probe. As a positive control for the effectiveness of the fenofibrate treatment, hybridization with a mouse acyl-CoA oxidase (*AOX*) probe prepared from a 246-bp coding fragment was performed as described elsewhere (Albet *et al.*, 1997).

Fenofibrate is known to strongly increase the level of peroxisome proliferator activated receptors in rats (Gebel *et al.*, 1992). Interestingly, the mouse promoter does not exhibit canonical peroxisome proliferator-responsive elements. Assuming that this is also the case in rat, this might explain the lack of induction of rat *PEX3* by fenofibrate. It has been reported

previously that fenofibrate strongly induced the expression of two other peroxisomal membrane proteins of the ABC-transporter superfamily, PMP70p and ALDRp, in rat and mouse (Albet *et al*., 1997; Berger *et al*., 1999; Holzinger *et al*., 1998). These data are in agreement with the hypothesis that proteins, which are directly or indirectly involved in peroxisomal metabolism, are pharmacologically inducible, whereas proteins involved in the peroxisomal biogenesis, such as Pex3p, can not be induced. Confirmation of these findings would have important consequences for the development of new treatment strategies.

Based on the findings in yeast, *PEX3* is a candidate gene for human peroxisomal biogenesis disorders. *PEX3* mutations have not been identified so far. Among the considerable number of *PEX* genes, mouse models have only been described for *PEX2*, which encodes a zinc-binding integral membrane protein (Faust & Hatten, 1997), and *PEX5,* which encodes the import receptor for most peroxisomal matrix proteins (Baes *et al*., 1997). However, a mouse model with targeted disruption of one of the *PEX* genes involved in the initial steps of peroxisomal biogenesis is not yet available. The data reported here might contribute to further elucidate the basic aspects of formation and function of peroxisomes and help to develop treatment strategies for peroxisomal biogenesis disorders, which are still leading to early death in affected children.

Acknowledgements

References

The references are listed on pages 38–49.

Appendix 5

The Human *PEX3* Gene Encoding a Peroxisomal Assembly Protein: Genomic Organization, Positional Mapping, and Mutation Analysis in Candidate Phenotypes

Ania C. Muntau,[1] Andreas Holzinger,[1] Peter U. Mayerhofer,[1] Jutta Gärtner,[2] Adelbert A. Roscher,[1] and Stefan Kammerer[1]

[1]Dr. von Hauner Children's Hospital, Laboratory of Molecular Biology,

Ludwig-Maximilians-University, Lindwurmstrasse 4, 80337 Munich, Germany

[2]Department of Pediatrics, Heinrich Heine University Düsseldorf, Moorenstrasse 5,

40225 Düsseldorf, Germany

*Contributions to the manuscript: Outline of the project by A.A.R and S.K.; concept by A.C.M.; FISH analysis by P.L.; genomic mapping by A.H.; southern blot analysis by **P.U.M.**; determination of the genomic structure, sequencing of the putative promoter region, and mutation analysis by S.K.; A.C.M., and **P.U.M.**; writing by A.C.M.; editorial help by the co-authors*

Abstract

In yeast, the peroxin Pex3p was identified as a peroxisomal integral membrane protein that presumably plays a role in the early steps of peroxisomal assembly. In human, defects of peroxins cause peroxisomal biogenesis disorders such as Zellweger syndrome. We previously reported data on the human *PEX3* cDNA and its protein, which in addition to the peroxisomal targeting sequence contains a putative endoplasmic reticulum targeting signal. Here we report the genomic organization, sequencing of the putative promoter region, chromosomal localization, and physical mapping of the human *PEX3* gene. The gene is composed of 12 exons and 11 introns spanning a region of approximately 40 kb. The highly conserved putative promoter region is very GC rich, lacks typical TATA and CCAAT boxes, and contains potential Sp1, AP1, and AP2 binding sites. The gene was localized to chromosome 6q23-24 and D6S279 was identified to be the closest positional marker. As yeast mutants deficient in *PEX3* have been shown to lack peroxisomes as well as any peroxisomal remnant structures, human *PEX3* is a candidate gene for peroxisomal assembly disorders. Mutation analysis of the human *PEX3* gene was therefore performed in fibroblasts from patients suffering from peroxisome biogenesis disorders. Complementation groups 1, 4, 7, 8, and 9 according to the numbering system of Kennedy Krieger Institute were analyzed but no difference to the wild type sequence was detected. *PEX3* mutations were therefore excluded as the molecular basis of the peroxisomal defect in these complementation groups.

Introduction

Peroxisomes are single-membrane-bound organelles present in all eukaryotic cells other than mature erythrocytes (van den Bosch *et al*., 1992). A large variety of metabolic pathways including the production and degradation of hydrogen peroxide, and many reactions that involve lipids have been assigned to the peroxisome (Tolbert, 1981). The biogenesis of functional peroxisomes including peroxisome proliferation, membrane biogenesis and peroxisomal matrix protein import, requires the interaction of numerous proteins, designated peroxins, which are encoded by *PEX* genes (Distel *et al*., 1996). At least 22 peroxins are known so far (Moser, 1999). *PEX* genes have first been identified by genetic analysis of peroxisome-deficient mutants of yeast (Erdmann *et al*., 1989). There is a remarkable degree of homology between man and yeast in respect to the factors involved in peroxisome biogenesis. Human *PEX* genes that are required for peroxisomal assembly have therefore been identified by genetic phenotype-complementation assays of Chinese hamster ovary (CHO) cell mutants and by searching human expressed sequence tag databases using yeast *PEX* gene sequences (Tateishi *et al*., 1997).

Data from yeast suggested that the *PEX3* gene is coding for an integral peroxisomal membrane protein (PMP) essential for both peroxisomal membrane assembly and membrane protein import (Baerends *et al*., 1996; Snyder *et al*., 1999b). Pex3p has been shown to interact with Pex19p in *Saccharomyces cerevisiae* (Götte *et al*., 1998), in *Pichia pastoris* (Snyder *et al*., 1999a), and in human (Soukupova *et al*., 1999). The recent identification of peroxin multimeric protein complexes is consistent with the hypothesis that these two proteins are essential players in peroxisomal membrane biogenesis and PMP localization (Snyder *et al*., 1999b). Both proteins are thought to be involved in the early stages of peroxisomal biogenesis (Götte *et al*., 1998; Kammerer *et al*., 1997; Matsuzono *et al*., 1999).

In general, any defect of a human peroxin is expected to result in a lack of fully functional peroxisomes causing peroxisomal biogenesis disorders (PBD). PBD are associated with four clinical phenotypes: Zellweger syndrome (Zellweger, 1987), neonatal adrenoleukodystrophy (Ulrich *et al*., 1978), infantile Refsum disease (Scotto *et al*., 1982), and rhizomelic chondrodysplasia punctata (Spranger *et al*., 1971). The most important clinical symptoms are progressive neurological dysfunctions, liver disease, and eye abnormalities. Cells from patients with PBD have previously been shown to segregate into at least 12 complementation groups (Shimozawa *et al*., 1998). The number of *PEX* genes in yeast, however, suggests the existence of even more complementation groups. The relationship between the genetic defects and the clinical phenotype is not yet elucidated in detail. It is tempting to speculate that

patients even lacking peroxisomal remnants may suffer from particularly severe forms of the disease. This hypothesis is consistent with the observation of a patient with Zellweger syndrome, the most severe clinical form among peroxisomal disorders, which was shown to be caused by a *PEX19* mutation (Matsuzono *et al.*, 1999). To date, the molecular defects causing PBD in human have been identified in 10 of the 12 complementation groups, proving 10 of the corresponding *PEX* genes to be disease-causing.

In yeast, *PEX3* deficiency leads not only to a lack of functional peroxisomes but also to the absence of peroxisomal remnant structures ("peroxisomal ghosts") (Baerends *et al.*, 1997; Götte *et al.*, 1998; Höhfeld *et al.*, 1991), whereas in most other peroxin deficiencies residual peroxisomal membrane structures can be detected. Based on these findings, *PEX3* is a candidate gene for one of the peroxisomal biogenesis disorders. The corresponding phenotype is unknown so far. Interestingly, fibroblasts of some patients suffering from Zellweger syndrome and belonging to the complementation groups D, J, and G according to the Japanese classification have been shown to lack peroxisomal ghosts. These patient cells are of particular interest as candidate cells bearing a mutation in the *PEX3* gene.

In a previous study we described the full-length cloning of the human *PEX3* cDNA and the characterization of the human Pex3 protein (Kammerer *et al.*, 1998). As prerequisite for the identification of the yet unknown phenotype of *PEX3* deficiency we present here the genomic structure, analysis of the putative promoter region, chromosomal localization, and mapping of the human *PEX3* gene. These data enabled us to design a strategy for *PEX3* mutation analysis by PCR amplification and sequencing of large amplicons from genomic DNA including one or more exons each. We then evaluated fibroblasts from several patients suffering from peroxisomal biogenesis disorders assigned to different complementation groups for the presence of mutations in the human *PEX3* gene.

Material and Methods

Isolation and sequencing of genomic clones

A human DNA library generated with the pCYPAC-2 vector and genomic DNA derived from cultured skin fibroblasts with an average insert size of approximately 100 kb (Ioannou *et al*., 1994) was screened with a 2.1-kb human *PEX3* cDNA probe. This probe was excised with *Sac*I and *Apa*I from the pBlueskript SK⁻ clone EST176494 (GenBank accession number AA305508) which was previously identified by our group (Kammerer *et al*., 1998). The probe was radiolabeled by random priming method using [α-^{32}P]dATP and Klenow enzyme. Several positive clones were isolated by the Screening Service of the Resource Center of the German Human Genome Project (Heidelberg/Berlin) (Lehrach, 1990). The preparation of pCYPAC-2 DNA was performed using ion exchange columns (Qiagen Plasmid Midi Kit) according to the manufacturer´s protocol for P1-derived constructs. Cycle sequencing of pCYPAC-2 clone 1 (LLNLP704A02547Q3) was performed with a rhodamine didesoxy dye terminator kit (ABI/Perkin Elmer) using *PEX3* specific primers and 600 ng DNA. Samples were then precipitated and separated on an ABI 377 sequencer.

Southern blot analysis of genomic clones

7µg of DNA from several pCYPAC-2 clones was digested with different restriction enzymes, separated in a 0.8% agarose gel and transferred to a positively charged nylon membrane. Hybridization with the radiolabeled 2.1-kb cDNA probe described above was performed by a modified method of Church and Gilbert as described elsewhere (Braun *et al*., 1994). The blots were exposed to X-ray films for 10 minutes.

Amplification and sequencing of intron-containing genomic fragments

Exon-exon PCR was performed in order to amplify human *PEX3* introns using the Expand Long Template system (Boehringer Mannheim) and 200 ng of genomic leukocyte DNA or 10 ng of pCYPAC-2 clone 1 DNA, respectively. To estimate intron sizes the PCR products were separated by agarose gel electrophoresis. These products were column-purified using a Qiaquick PCR Purification Kit (Qiagen) and directly sequenced with amplification primers as described above.

Amplification and analysis of the 5' flanking region

The first 700 bp upstream of the transcription start were determined by direct sequencing of pCYPAC-2 clone 1 DNA as template. The region upstream from -700 bp was amplified using a Human Genome Walker Kit (Clontech). For this purpose, two successive PCR reactions using the Expand Long Template system (Boehringer Mannheim) were performed. Products amplified with the AP1 primer and a *PEX3* specific reverse primer (5'R2) were diluted 1:80 and subjected to a second PCR reaction with the AP2 primer and a nested *PEX3* specific reverse primer (5'R3). The PCR products obtained were gel purified using a Qiagen Gel Extraction Kit and directly sequenced with amplification primers.

Fluorescence in situ hybridization (FISH)

Human metaphase cells were prepared from phytohemagglutinin-stimulated peripheral blood lymphocytes according to standard procedures. *In situ* hybridization was performed using DNA from pCYPAC-2 clone 1, which contained the entire human *PEX3* gene. The probe was labeled with biotin-14-dUTP (Life Technologies) by nick-translation and preannealed with Cot-1 DNA (Life Technologies). Detection and visualization was achieved using the avidin-fluorescein isothiocyanate/antiavidin antibody system described elsewhere (Lichter *et al*., 1988; Lichter *et al*., 1990) and chromosomes were identified by staining with 4,6-diamino-2-phenylindole dihydrochloride (DAPI).

Genomic mapping using the CEPH-Généthon YAC library

A high-density robot-spotted filter representing the CEPH-Généthon human genomic YAC library characterized with positional markers (Chumakov *et al*., 1995) was hybridized with a radiolabeled human *PEX3* cDNA probe (Screening Service of the Resource Center of the German Human Genome Project, Heidelberg/Berlin) (Lehrach, 1990). Clones were rescreened by PCR of short fragments with exon 12-specific primers (1164F, 5'-CCC CCA ACA ACT GGA GAA ATG-3' and 1800R, 5'-CAC TTC TGT TTA CAG CAG TCT-3'). Neighboring and potentially overlapping clones were obtained from the Resource Center of the German Human Genome Project and PCR screened with the same oligonucleotide primer combinations.

Mutation analysis of the human *PEX3* gene

200 ng of genomic fibroblast DNA from cultured cells of several PBD patients assigned to the complementation groups 1, 4, 7, 8, and 9 according to the numbering system of Kennedy Krieger Institute were used to amplify the complete coding region with intron-specific oligonucleotide primers (Fig. A5-1 and Table A5-2). Single exons were amplified using *Taq* DNA polymerase (Boehringer Mannheim). For amplification of large fragments containing several exons the Expand Long

Template system (Boehringer Mannheim) was used. The resulting PCR products were column-purified and sequenced with amplification primers, fragments spanning several exons additionally with internal intronic primers. Sequencing reaction and fragment separation was performed as described above.

Table A5-1: Classification of PEX Genes, Assignment to Complementation groups, and Peroxisomal Morphology in Yeast Mutants and Patient Fibroblasts

Yeast gene	Human ortholog identified	Complementation group			Peroxisomal morphology	References
		KKI	Japan	Amsterdam		
PEX1	+	1*	E	2	remnants	(Erdmann *et al*., 1991)
PEX2	+	10	F	5	remnants	(Tamura *et al*., 1998) (Shimozawa *et al*., 1992)
PEX3	+				**no remnants**	(Tsukamoto *et al*., 1991) (Höhfeld *et al*., 1991)
PEX4	-				normal	(Kammerer *et al*., 1998) (Wiebel & Kunau, 1992)
PEX5	+	2		4	remnants	(van der Klei *et al*., 1998) (Dodt *et al*., 1995)
PEX6	+	4*	C	3	remnants	(McCollum *et al*., 1993) (Fukuda *et al*., 1996) (Spong & Subramani,
PEX7	+	11	R	1	normal	(Purdue *et al*., 1997) (Braverman *et al*., 1997) (Marzioch *et al*., 1994) (Motley *et al*., 1997)
PEX8	-				remnants	(Waterham *et al*., 1994)
PEX9	-				remnants	(Eitzen *et al*., 1995)
PEX10	+	7*	B		remnants	(Warren *et al*., 1998) (Okumoto *et al*., 1998) (Tan *et al*., 1995)
PEX11	+				giant	(Abe *et al*., 1998) (Erdmann & Blobel, 1995)
PEX12	+	3			remnants	(Kalish *et al*., 1996) (Okumoto & Fujiki, 1997)
PEX13	+		H		remnants	(Björkman *et al*., 1998) (Elgersma *et al*., 1996) (Toyama *et al*., 1999)
PEX14	+				remnants	(Komori *et al*., 1997) (Shimizu *et al*., 1999)
PEX15	-				remnants	(Elgersma *et al*., 1997)
PEX16	+	9*	D		**no remnants**	(Honsho *et al*., 1998)
PEX17	-				remnants	(Huhse *et al*., 1998)
PEX18	-				normal	(Purdue *et al*., 1998)
PEX19	+		J		**no remnants**	(Kammerer *et al*., 1997) (Matsuzono *et al*., 1999)
PEX20	-				small	(Titorenko *et al*., 1998)
PEX21	-				normal	(Purdue *et al*., 1998)
PEX22	-				remnants	(Koller *et al*., 1999)
Unassigned	-	8*	A	7	remnants	(Shimozawa *et al*., 1998)
Unassigned	-		G		**no remnants**	(Shimozawa *et al*., 1998)

* *PEX3* mutation analysis performed in this study

Results

Determination of the complete exon-intron structure

By screening a human genomic fibroblast library with a 2.1-kb cDNA probe containing the complete coding region of human PEX3, 16 positive clones were identified. The five clones that yielded the strongest signals, clone 1 (LLNLP704A02547Q3), clone 2 (LLNLP704I11520Q3), clone 4 (LLNLP704A041052Q3), clone 7 (LLNLP704K07884Q3), and clone 10 (LLNLP704J22833Q3), were analyzed by PCR testing and Southern blot analysis (data not shown). Clone 2 and clone 7 contained only a part of the gene, whereas clones 1, 4, and 10 proved to contain the entire gene. To determine the genomic organization of the human PEX3 gene, genomic fragments were PCR amplified using cDNA-derived primers and either pCYPAC-2 clone or genomic DNA as template. Overlapping fragments spanning the complete coding region were generated and sequenced. Comparison of the obtained genomic sequence with the cDNA sequence revealed that the human PEX3 gene consists of 12 exons and 11 introns (Fig. A5-1). Exon sizes range from 44 bp to 169 bp. All exon-intron junctions conform to the GT-AG rule. Five introns (intron 4, 5, 6, 7, and 9) were fully sequenced, the exon-flanking intronic sequences of all other introns were determined and deposited with Genbank (AJ009866 to AJ009874). The approximate sizes of introns not fully sequenced were estimated by agarose gel electrophoresis of corresponding PCR products.

Figure A5-1: Genomic organization and strategy for mutation analysis of the human *PEX3* gene. The gene consists of twelve exons (closed boxes) and eleven introns. Exon sizes in base pairs are indicated above, intron sizes below the horizontal line. The 5' and 3' UTRs are shown as open boxes. The solid bars A, B, C1, C2, and D indicate the strategy of PCR amplification of large amplicons from genomic DNA for mutation analysis of the human *PEX3* gene. A: amplification of exon 1; B: amplification of exon 2 and 3; C1: amplification of exon 4 through 9; C2: amplification of exon 10; D: amplification of exon 11 and 12. Filled arrows indicate primers used for amplification and sequencing, empty arrows indicate primers used only for sequencing (see also Table A5-2).

Characterization of the 5' flanking region

The 1.4-kb sequence upstream of the transcription initiation site was analyzed in silico for transcription factor binding sites. The analysis of the 5' flanking sequence for consensus promoter elements was performed using the Transcription Factor Database (TFD) (Ghosh, 1991) for an analysis with the Signal Scan server of BIMAS (Prestridge, 1991). Canonical TATA and CCAAT boxes were not found. The putative promoter sequence is very GC rich and exhibits a GC content of about 69% from -250 to -1 relative to the transcription start site. This sequence contains several predicted binding sites typically observed in GC-rich regions: an Sp1 site at -30 to -25, and three AP2 sites at -75 to -68, -116 to -109, and -221 to -214. Additionally, a putative AP1 site was identified at position -847 to -840. While the Sp1 site is identical in the orthologous mouse gene, the potential AP1 and AP2 binding sites are not highly conserved in mouse (unpublished data).

Cytogenetic localization and mapping of the human *PEX3* gene

The pCYPAC-2 clone 1 containing the complete human *PEX3* gene was used as a probe to hybridize metaphase chromosomes. Twin-spot signals on the long arm of both chromosomes 6 were detected and assigned to chromosome 6q23-24 (Fig. A5-2). Screening of the CEPH Généthon human genomic YAC library with the human 2.1-kb *PEX3* cDNA probe described above resulted in the identification of two clones (930G4 and 930G5) that are part of the contig WC6.15. These clones are overlapping as characterized with positional markers (Whitehead Institute for Biomedical Research/MIT; http://www-genome.wi.mit.edu). *PEX3*-specific fragments were successfully amplified from these clones. These data placed the *PEX3* gene between positional markers CHLC.GATA68F06 and CHLC.GATA41E03. Neighboring and potentially overlapping clones (967H10, 800C7, 748E1, 882D8, 773H6, 764G8, and 798D8) were obtained and PCR tested as described above. Only clone 967H10 proved positive which suggests D6S279 at 145 cM to be the closest positional marker. These results are in accordance with the results of the FISH analysis.

Mutation analysis of the human *PEX3* gene

We analyzed all *PEX3* exons and exon flanking regions of two patients belonging to CG-1 and one patient of CG-4, CG-7, CG-8, and CG-9, respectively. For that purpose, all exons were amplified with flanking intron primers from fibroblast genomic DNA and the resulting

PCR products subjected to cycle sequencing. No difference to the published wild type sequence was detected in all six cell lines analyzed (Kammerer *et al*., 1998).


Figure A5-2: Chromosomal localization of the human *PEX3* gene. Plasmid DNA from pCYPAC-2 clone 1 containing the entire human *PEX3* gene was labeled with biotin-14-dUTP and used as probes for in situ hybridization of metaphase chromosomes. Twin-spot signals at q23-24 on both chromosomes 6 are marked by arrows.

Table A5-2: Primers for Mutation Analysis of the Human *PEX3* Gene

Exon	Primer	5' Sequence 3'	Sense	Fragment length
Exon 1 (A)	5'F3	GAGAGCACAGAACGGGACGA	for	300 bp
	1R	CTCTACATATCCCAGACTAGG	rev	
Exons 2-3 (B)	2F2	GCTAATTTCCTTTTCTTTGGGCC	for	~ 4100 bp
	3R3	GTAGTGCTTAAACAGAAAATGC	rev	
Exons 4-9 (C1)	4F3	CAGAGTTTTCTATTAGATTATCTAG	for	~ 6500 bp
	5R	GAACCTCCTGAGGGAAAGAAC	rev	
	7R	CTCATTAGAATCAAGAAGTCAG	rev	
	8F	ATAGGATGTGTTGTATAGTTTC	for	
	9R	GTCTCAAGTACATTCAACATAC	rev	
Exon 10 (C2)	10F	CAAAGGTAACCACGTTATTACTG	for	303 bp
	10R2	GTTGTTATCTGGAACAAAAAGAC	rev	
Exons 11-12 (D)	11F2	TTCTACAATGGCTATGTATTAC	for	~ 4200 bp
	1255R	GTATAGGTGATTTACCCAGTG	rev	

Discussion

Among the *PEX* genes known to date, *PEX3* is of particular interest because of two observations: its putative implication in the very early stages of peroxisomal biogenesis (Baerends *et al*., 1997) and the involvement of the endoplasmic reticulum (ER) in its targeting (Baerends *et al*., 1996) (Kammerer *et al*., 1998). Recent studies on the interaction of peroxisomal membrane proteins showed that in *P. pastoris* Pex3p is part of a multimeric protein complex that facilitates the insertion of peroxisomal membrane proteins into the peroxisomal membrane (Snyder *et al*., 1999b).

In this report we present the genomic organization of the human *PEX3* gene. The gene is composed of twelve exons encoding a 2.2-kb cDNA and eleven introns. The complete length of the gene is approximately 40 kb. The sequence information presented in this paper has very recently been confirmed by a PAC sequence released by the Human Genome Sequencing Project (Accession number AL031320). As a finding characteristic for housekeeping genes, sequence analysis of the putative promoter region failed to identify TATA and CCAAT boxes. Consensus binding sequences for the cellular transcription factors Sp1, AP1, and AP2, which are thought to regulate RNA polymerase II activity (Faisst & Meyer, 1992), were identified. These promoter characteristics are common in genes with ubiquitous expression and have been described for other *PEX* genes (Björkman *et al*., 1998; Kammerer *et al*., 1997; Purdue *et al*., 1997; Yahraus *et al*., 1996).

By *in situ* fluorescence hybridization, we were able to assign the cytogenetic locus of human *PEX3* to chromosome 6q23-24. *PEX* genes are distributed over the whole genome. Human *PEX6,* for instance, was assigned to chromosome 6p21.1 (Fukuda *et al*., 1996), *PEX1* to chromosome 7q21-22 (Reuber *et al*., 1997), *PEX5* to chromosome 12p13.3 (Dodt *et al*., 1995), *PEX10* to chromosome 8q21.1 (Warren *et al*., 1998), and *PEX19* to chromosome 1q22 (Kammerer *et al*., 1997). Noteworthy is the localization of the human *PEX7* gene encoding the type 2 peroxisome targeting signal (PTS 2) receptor to chromosome 6q22-24 (Braverman *et al*., 1997), which is the same as the one we identified for the human *PEX3* gene. Although the physical distance between the two genes has not been determined so far, there could be a cluster of peroxisomal genes on chromosome 6. The results of FISH analysis in our study were confirmed by screening a human genomic YAC library that identified D6S279 to be the closest positional marker to the human *PEX3* gene on chromosome 6. The mapping data might be used for segregation analysis in patients with Zellweger syndrome to exclude *PEX3* gene defects as underlying cause of the disease.

Twelve complementation groups (CG) are known so far, each of which is probably defined by a distinct gene defect (Table A5-1) (Moser, 1999). Underlying mutations in the corresponding *PEX* genes have been identified in ten of these twelve.

In yeast, disruption of *PEX3* leads to a lack of peroxisomes and remnant peroxisomal structures ("peroxisomal ghosts") (Baerends *et al.*, 1997). It has been hypothesized that peroxisomal ghosts may act as acceptors of matrix proteins in the peroxisomal assembly process supporting the view that peroxisomes can grow by incorporating newly synthesized matrix proteins (Yamasaki *et al.*, 1999). *PEX3* is thus a candidate gene for being involved in one of the subgroups of human peroxisomal biogenesis disorders that have yet to be characterized. So far, *PEX3* has not been assigned to one of the known complementation groups. There is a high probability that human cells with a *PEX3* defect also lack peroxisomal ghosts. We were therefore particularly interested in the analysis of cells from complementation group 9 as fibroblasts from all patients belonging to this complementation group very rarely have peroxisomal ghosts (Shimozawa *et al.*, 1998). We performed mutation analysis of the human *PEX3* gene in fibroblasts from patients belonging to the following complementation groups: CG-1, CG-4, CG-7, CG-8, and CG-9. A strategy of PCR amplification and sequencing of large amplicons from genomic DNA including one or more exons each was used. The sequencing technique employed has repeatedly been proven to be suitable for heterozygote detection. In all complementation groups analyzed so far, no difference to the wild type sequence was detected. This result does not completely exclude a *PEX3* mutation because only exons and exon-intron boundaries were sequenced. Rare promoter or intron mutations cannot be ruled out since *PEX3* cDNA complementation studies were not done. After the completion of our studies, complementation groups CG-1, CG-4, CG-7 and CG-9 have been shown to be caused by defects of *PEX1* (Reuber *et al.*, 1997), *PEX6* (Fukuda *et al.*, 1996), *PEX10* (Warren *et al.*, 1998), and *PEX16* (Honsho *et al.*, 1998), respectively. At present, among the complementation groups analyzed in our study, only for CG-8 the molecular defect has not yet been elucidated.

The most likely reason for our inability to identify a *PEX3* mutation might be the fact that not all known complementation groups were available for mutation analysis. CG-G, for example, is another potential candidate for harboring a *PEX3* mutation, as fibroblasts from patients belonging to this group completely lack peroxisomal ghosts (Shimozawa *et al.*, 1998). Another possible explanation might be that not all PBD patient cell lines have been classified by complementation analysis so far. Patients not yet assigned to a complementation group would therefore not have been available for mutation analysis. Furthermore, it could be

possible that functional mutations in the *PEX3* gene are prenatally lethal and are therefore not represented in the patient cell lines. On the other hand, a patient with Zellweger syndrome, which is considered to be the most severe clinical phenotype lacking all peroxisomal functions, who was assigned to CG-J lacking peroxisomal remnants was recently shown to have a *PEX19* mutation (Matsuzono *et al*., 1999). This observation is consistent with the hypothesis that a phenotype defective in an early peroxin is not necessarily lethal. Therefore it can be expected that a *PEX3* mutation will also result in a viable phenotype.

The human phenotype related to *PEX3* deficiency is still unidentified. The data presented here will be helpful for the generation of a mouse model with targeted mutations in the *PEX3* gene as another approach to elucidate the functional role of *PEX3* in mammals and the clinical consequences arising from defects in this gene.

Acknowledgments

Rerefences

Appendix 6

Defective Peroxisome Membrane Synthesis
Due To Mutations in Human *PEX3* Causes Zellweger Syndrome,
Complementation Group G

Ania C. Muntau,[1] Peter U. Mayerhofer,[1] Barbara C. Paton,[2]

Stefan Kammerer,[3] and Adelbert A. Roscher [1]

A.C.M. and P.U.M. contributed equally to this paper

[1] Dr. von Hauner Children's Hospital, Laboratory of Molecular Biology,

Ludwig-Maximilians-University, Lindwurmstrasse 4, 80337 Munich, Germany

[2] Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide, South Australia 5006

[3] SEQUENOM Inc., 11555 Sorrento Valley Road, San Diego, CA 92121,

United States of America

Contributions to the manuscript: Outline of the project by A.A.R.; concept by A.C.M. and ***P.U.M.****; mutation analysis by A.C.M.; cDNA cloning, immunofluorescence microscopy, functional complementation assays, and in vitro binding assay* ***P.U.M.****; somatic cell-fusion experiments by A.C.M. and* ***P.U.M.****; writing by A.C.M. and* ***P.U.M.****; editorial help by the co-authors*

Abstract

The cerebro-hepato-renal syndrome of Zellweger is a severe congenital disorder associated with defective peroxisomal biogenesis. At least 23 *PEX* genes have been reported to be essential for peroxisome biogenesis in various species indicating the complexity of peroxisomal assembly. Cells from patients with peroxisomal biogenesis disorders have previously been shown to segregate into at least 12 complementation groups. Two patients assigned to complementation group G previously not linked to a specific gene defect were confirmed to display a cellular phenotype characterized by a lack of even residual peroxisomal membrane structures. Here we demonstrate that this complementation group is associated with mutations in the *PEX3* gene encoding an integral peroxisomal membrane protein. Homozygous *PEX3* mutations, each leading to C-terminal truncation of PEX3, were identified in the two patients, who both suffered from a severe Zellweger syndrome phenotype. One of the mutations involved a single nucleotide insertion in exon 7, whereas the other was a single nucleotide substitution eight nucleotides from the normal splice site in the 3' acceptor site of intron 10. Expression of wild type PEX3 in the mutant cell lines restored peroxisomal biogenesis, whereas transfection of mutated *PEX3* cDNA did not. This confirmed that the causative gene had been identified. The observation of peroxisomal formation in the absence of morphologically recognizable peroxisomal membranes challenges the theory that peroxisomes arise exclusively by growth and division from preexisting peroxisomes and establishes *PEX3* as a key factor in early human peroxisome synthesis.

The importance of peroxisomes in mammalian metabolism is illustrated by the existence of severe inherited metabolic diseases caused by the inability to assemble peroxisomes. Among these peroxisomal biogenesis disorders (PBD), Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum's disease represent a continuum of clinical phenotypes (PBD [MIM 601539]), whereas rhizomelic chondrodysplasia punctata (RCDP [MIM 215100]) is characterized by distinct clinical features (Wanders, 1999). Peroxisomes have long been thought to arise exclusively by growth and division of preexisting peroxisomes (Lazarow & Fujiki, 1985) and only recently alternative hypotheses have been proposed (South & Gould, 1999). Proteins required for peroxisomal assembly are termed peroxins and are encoded by *PEX* genes. At least 23 peroxins have been identified in yeast, most of which are conserved among different eukaryotic organisms (Subramani, 1997). In most cases, defects in *PEX* genes lead to a disruption of peroxisomal matrix protein import while various peroxisomal membrane components are synthesized and accumulate in peroxisomal membrane remnants ("ghosts"). *PEX3* and *PEX19* mutants represent an exception to this rule as the corresponding yeast mutants have been shown to lack even these peroxisomal ghosts (Baerends *et al*., 1996; Götte *et al*., 1998). We had previously cloned the human orthologue of *PEX3* (*PEX3* [MIM 603164]) (Kammerer *et al*., 1998). Evidence suggests that human PEX3 is a peroxisomal assembly protein displaying two transmembrane helices in the N-terminal half of the protein. Immunofluorescent microscopy studies indicate that it is an integral membrane protein with its C-terminus exposed to the cytosol and its N-terminus facing the intraorganellar space (Kammerer *et al*., 1998; Soukupova *et al*., 1999). Despite an extensive search, disease causing mutations in the human *PEX3* gene have not been identified so far (Muntau *et al*., 2000b).

In somatic cell fusion experiments, fibroblasts from patients with peroxisomal biogenesis disorders have been shown to segregate into at least 12 complementation groups (CG) (Moser, 1999; Shimozawa *et al*., 1998). In this study we investigated fibroblasts from two patients (PBDG-01 and PBDG-02) previously assigned to CG-G (Gifu University nomenclature) (Poulos *et al*., 1995). CG-G fibroblasts lack peroxisomal ghosts as evidenced by staining with an antibody directed against the human 70-kD peroxisomal membrane protein, PMP70 (Poulos *et al*., 1995; Shimozawa *et al*., 1998) and were therefore excellent candidates for a *PEX3* mutation. To our knowledge CG-G is represented so far by only two patients worldwide and cell lines from both individuals were available for this study.

Figure A6-1: Somatic cell fusion experiments. Fusion of co-cultivated fibroblasts was performed using methods described elsewhere (Roscher *et al*., 1989). Fusion of fibroblasts from patients PBDG-01 and PBDG-02 with fibroblasts from a patient carrying a *PEX19* mutation (PBDJ-01) (Matsuzono *et al*., 1999) restored peroxisomes in the majority of multinucleated cells as demonstrated by a punctate immunofluorescent pattern after staining for catalase. Somatic cell fusion of fibroblasts from patient PBDG-01 with fibroblasts from patient PBDG-02 revealed only diffuse cytosolic staining with anti-catalase antibodies.

The two male infants from unrelated families were born to consanguineous Dutch and Italian parents. Patient 1 (PBDG-01) showed a marked muscular hypotonia at birth. Dysmorphic features included hypertelorism, prominent epicanthic folds, and a high, broad forehead with a round face. Seizures developed on day 1 but were controlled with treatment. His condition deteriorated rapidly and he died at 4 months of age. Patient 2 (PBDG-02) was cyanotic at birth, markedly hypotonic, and lacked deep tendon reflexes. He had a prominent midface and an antimongoloid slant of the palpebral fissures, ocular hypertelorism, small low-set ears, a prominent nose, and a high arched palate. The liver was enlarged. Seizures developed in the first 20 hours. The child required gavage feeding and died at 19 days of age of congestive heart failure. The patient's brother had been similarly affected and died at the age of 15 days. The concentrations of very long-chain fatty acids were elevated in the plasma and fibroblasts of patient 1 and patient 2. In fibroblasts from both patients, the percentage of sedimentable

catalase, the rate of oxidation of pristanic acid, and the activities of alkyl dihydroxyacetone phosphate synthase and dihydroxyacetone phosphate acyl transferase were all reduced (Poulos *et al*., 1995). In summary, the clinical and biochemical features of both patients correspond to a severe Zellweger syndrome phenotype.

By performing somatic cell fusion experiments (fig. A6-1) we showed that fusion of cultured fibroblasts from patient PBDG-01 with cells from patient PBDG-02 did not rescue peroxisomal biogenesis. This confirms that the two cell lines were correctly assigned to the same complementation group and are therefore expected to bear mutations in the same gene. By contrast, fusion of cultured fibroblasts from patients PBDG-01 and PBDG-02 with those from a patient carrying a *PEX19* mutation (PBDJ-01) (Matsuzono *et al*., 1999) restored peroxisomal biogenesis. These results indicate that complementation group G and *PEX19* mutated cell lines can complement each other despite both phenotypes being devoid of detectable preexisting peroxisomal membranes.

When analyzed by immunofluorescent microscopy, both patient cell lines lacked morphologically recognizable PMP-containing peroxisomal membranes ("ghosts"). This was demonstrated by the absence of punctate staining for the peroxisomal membrane protein adrenoleukodystrophy protein (ALDP) (fig. A6-2*C,D*) and the membrane marker protein PMP70 (data not shown). However, these findings do not exclude the possibility that some small peroxisomal vesicles may still exist in the patients' cells. The lack of peroxisomal staining was not accompanied by any detectable staining for these PMPs in the cytoplasm or any other cellular compartment. By contrast, fibroblasts from a Zellweger patient assigned to complementation group E (PBDE), due to the presence of a *PEX1* mutation, displayed peroxisomal ghosts on immunofluorescence (fig. A6-2*B,J*). On Western blot analysis, the PBDE cells contained a similar amount of ALDP as fibroblasts from a healthy control, whereas ALDP was below the detection limit of our assay in the PBDG-01 and PBDG-02 fibroblasts (data not shown). The lack of immunofluorescence for ALDP and PMP70, and the reduced amount of ALDP shown on Western blot analysis, support the hypothesis that these peroxisomal membrane proteins are degraded rather than mislocalized. Analysis of the intracellular localization of another unrelated peroxisomal membrane protein, PEX14, revealed that the fate of this PMP in PBDG differs from that for ALDP and PMP70. Despite the lack of morphologically recognizable peroxisomal membrane staining, the patients' fibroblasts gave an unequivocal signal when using antibodies to PEX14 indicating that this

protein was mislocalized to mitochondria (fig. A6-2*K,L*). This finding is consistent with results from the Western blots, where the abundance of PEX14 in PBDG-01 and PBDG-02 cells was not reduced when compared to cells from a healthy control or a PBDE Zellweger patient (data not shown). Taken together, our data are consistent with the hypothesis that in mutants lacking peroxisomal membranes PMPs are either degraded, as proposed for ALDP and PMP70, or mislocalized, as shown for PEX14. Mitochondrial mislocalization of PEX14 has also been reported in *PEX19* deficient fibroblasts (Sacksteder *et al*., 2000) and a similar mitochondrial mislocalization was observed when either PEX3, PEX12, PEX13, PEX11ß, or ALDP was overexpressed in these *PEX19* deficient cells (Sacksteder *et al*., 2000). In our native *PEX3* deficient cell lines, however, immunofluorescence studies using antibodies to ALDP did not lead to any detectable staining, neither in the peroxisomes nor in the mitochondria, cytoplasm or any other cellular compartment.

As the cell lines of the two patients described above were excellent candidates for a *PEX3* mutation we performed *PEX3* mutation analysis by direct sequencing of genomic fragments using a slight modification of the previously described technique (Muntau *et al*., 2000b). The primer sequences are listed in table A6-1. Patient PBDG-01 exhibited an insertion of a thymine in exon 7 at nucleotide 543 of the coding region (fig. A6-3*B*). This frameshift mutation is expected to result in a truncation of the C-terminal 190 amino acids of the protein (fig. A6-5*A*).

Sequence analysis of patient PBDG-02 did not reveal any exonic mutation. However, we identified a thymine to guanine transversion in the 3' acceptor splice site of intron 10. While the conserved polypyrimidine stretch in the wild type corresponds to the consensus sequence (Padgett *et al*., 1986), the thymine at –8 relative to exon 11 is replaced by a guanine in the patient (fig. A6-3*C*). To determine whether the point mutation interferes with correct splicing, RT-PCR was performed. A single PCR product was obtained missing the complete 97 base pairs of exon 11 (fig. A6-3*D,E*). This exon deletion causes a frameshift with a premature termination after three amino acids predicting a C-terminal truncation of the protein by 56 amino acids. Among the various types of mutations associated with splicing aberrations (Krawczak *et al*., 1992), 3' splice site mutations occur less frequently than 5' splice site mutations and in the majority of cases the invariant AG dinucleotide is involved. Mutations at positions –3 to –14 of the splice site consensus region have rarely been associated with splicing defects, but instances of mutations at position –8 leading to aberrant splicing have already been observed (Beldjord *et al*., 1988). Additional sequencing analysis confirmed that

the *PEX3* intronic change was absent from 50 unrelated healthy individuals (data not shown). For these reasons we conclude that the –8 mutation is the cause of the aberrant splicing in the patient described here.


Figure A6-2: Intracellular localization of peroxisomal membrane proteins in CG-G cell lines. Indirect immunofluorescence microscopy was performed with fibroblasts from a healthy control (*A, E, I, M*), from a Zellweger patient assigned to CG-E (*B, F, J, N*), and from the patients PBDG-01 (*C, G, K, O*), and PBDG-02 (*D, H, L, P*). The cells were stained using rhodamine labelled antibodies to ALDP, a peroxisomal membrane protein (*A-D*), fluorescein labelled antibodies to catalase, a peroxisomal matrix protein (*E-H*), fluorescein labelled antibodies to PEX14, a peroxisomal membrane protein (*I-L*), or the mitochondrial marker MitoTracker (*M-P*). In normal fibroblasts, staining with antibodies to ALDP (*A*), catalase (*E*), and PEX14 (*I*) all yielded a punctate pattern indicating the presence of peroxisomal membranes and intact peroxisomes. Fibroblasts from a Zellweger patient assigned to CG-E (PBDE) were stained with antibodies to the peroxisomal membrane proteins ALDP (*B*) and PEX14 (*J*). Note the colocalization of the punctate patterns indicating the presence of peroxisomal membranes. These membranes presumably are non-functional peroxisomal ghosts. Incubation with anti-catalase antibodies (*F*) resulted in a diffuse cytosolic localization consistent with the absence of intact peroxisomes. In PBDG-01 (*C*) and PBDG-02 (*D*) cells, no ALDP positive particles are visible indicating the complete absence of morphologically detectable peroxisomal membranes. Incubation with anti-catalase antibodies (*G, H*) exhibited a diffuse cytosolic pattern consistent with the absence of intact peroxisomes. Staining the cells using an antibody specific for PEX14 (*K, L*) reveals a mitochondrial pattern as demonstrated by colocalization of PEX14 with MitoTracker (*O, P*).

The mutations identified in patient PBDG-01 and patient PBDG-02 each appeared to be present in a homozygous state, consistent with the consanguineity of both parental couples. Hemizygosity with a deletion of the second allele, however, cannot be excluded as parental DNA was not available.

Figure A6-3: Mutation analyses. *A*, Genomic organization of the human *PEX3* gene. Exons are indicated as boxes. *B*, Exon 7 sequencing results and predicted protein sequences of a wild type control (wt) and the patient PBDG-01. Note the homozygous thymine insertion (arrow). The frameshift causes a premature stop two codons after the insertion. *C*, Genomic sequencing of the exon-intron boundary of a control individual (wt) and patient PBDG-02. Note the homozygous substitution of a thymine by a guanine in the 3' splice site of intron 10 at position –8 (arrow). *D*, PCR amplification of *PEX3* fragments from total RNA of PBDG-02 after synthesis of first strand cDNA by reverse transcription using primer 1255R (see table A6-1 for primer sequences). Amplification of a fragment containing exon 5 to exon 10 using the primers 404F and 873R did not reveal any difference between the control individual (wt) and the patient (PBDG-02). The fragment containing exon 5 to exon 11 amplified using primer 404F and the exon 11 specific primer 957R could not be amplified from the patient's cDNA. Amplification of exon 5 to exon 12 using the primers 404F and 1120R produced an aberrantly sized PCR product from the patient's cDNA. *E*, Sequence analysis of the PCR fragment containing exon 5 to exon 12 showed that the *PEX3* cDNA of the patient PBDG-02 is missing 97 basepairs, which were present in wild type *PEX3* cDNA. The 97-bp deletion corresponds to the sequence of exon 11 and leads to direct fusion of exon 10 to exon 12. Premature termination of the protein is predicted from the frameshift.

The functional impact of the identified mutations was subsequently investigated by complementation studies. Immunofluorescent microscopy analysis of PBDG-01 (fig. A6-4*A to F*) and PBDG-02 (fig. A6-4*G to L*) fibroblasts indicated that both cell lines were lacking intact peroxisomes as demonstrated by diffuse staining with antibodies to catalase (fig. A6-4*B,H*). Five days after transfection of PBDG-01 and PBDG-02 with wild type *PEX3* cDNA, antibodies to ALDP (fig. A6-4*C,I*) and catalase (fig. A6-4*D,J*) showed a punctate pattern in both cell lines demonstrating rescue of organelle formation. We also investigated whether the identified *PEX3* mutations affect the function of the PEX3 protein. This was particularly crucial for the splice site mutation detected in patient PBDG-02. We generated *PEX3* expression vectors for each mutated *PEX3* cDNA. The resulting plasmids pcDNA3-PBDG-01

and pcDNA3-PBDG-02 were transfected into PBDG-01 and PBDG-02 cells, respectively, and the cells were assayed five days later by indirect immunofluorescence. Transfection of the mutated *PEX3* constructs failed to restore peroxisomal biogenesis in the cells (fig. A6-4E,F,K,L). In summary, these results demonstrate that the mutations identified in the *PEX3* gene disrupt the function of PEX3.


Figure A6-4: Functional complementation of patient fibroblasts. In untransfected PBDG-01 (*A, B*) and PBDG-02 cells (*G, H*), no ALDP positive particles were visible (*A, G*). Incubation with anti-catalase antibodies (*B, H*) showed a diffuse cytosolic localization. Five days after transfection with a human *PEX3* cDNA vector (pcDNA3.1/Pex3-Myc-His) (Kammerer *et al*., 1998) punctate patterns for ALDP (*C, I*) and catalase (*D, J*) indicated that these proteins were co-localized at or in restored peroxisomes. To generate the mutated *PEX3* expression vectors pcDNA3-PBDG-01 and pcDNA3-PBDG-02, RT-PCR was performed using the primers 5'F3 and 1255R and the resulting fragments were cloned into pcDNA3. Transfection of the mutant *PEX3* cDNA constructs pcDNA3-PBDG-01 and pcDNA3-PBDG-02 into PBDG-01 (*E, F*) and PBDG-02 cells (*K, L*), respectively, did not lead to restoration of a peroxisomal punctate pattern with either ALDP (*E, K*) or catalase (*F, L*) immunofluorescence. In an additional experiment, transfection efficiency was verified by cotransfection of pcDNA3-PBDG-01 and pcDNA3-PBDG-02 constructs with the green fluorescent protein expression vector pEGFP-N1 (Clontech) as a reporter plasmid (data not shown).

The observation of peroxisomal rescue despite the absence of preexisting peroxisomal membranes is at odds with the favored model of peroxisomal biogenesis where peroxisomes arise exclusively by budding from and/or fission of preexisting peroxisomal vesicles (Lazarow & Fujiki, 1985). Instead, it lends support to the existence of an alternative pathway

of peroxisome biogenesis. There is recent evidence from yeast and human studies that this pathway is likely to involve the interaction of three peroxins, namely PEX3, PEX16, and PEX19 (Sacksteder *et al*., 2000; South & Gould, 1999). In this regard, it is interesting to note that restoration of peroxisomes after expression of *PEX3* in the complementation group G fibroblasts occurred very slowly over several days. The step-wise nature of peroxisome synthesis in mutants deficient in peroxisomal membranes has been observed previously for a *PEX16* deficient cell line (South & Gould, 1999), and a *PEX19* deficient cell line (Matsuzono *et al*., 1999) with PMP-containing vesicles becoming visible first, followed by import of peroxisomal matrix proteins. These findings suggest that peroxisomal membrane vesicles form prior to the import of matrix proteins.

How might the *PEX3* mutations disrupt early peroxisomal biogenesis? The precise role of PEX3 in the complex processes leading to the assembly of peroxisomes has still to be elucidated. If not from preexisting vesicles, peroxisomes may arise from some other endomembranes of the cell (South & Gould, 1999). Although not proven, it has been hypothesized that PEX3 may be sorted to the peroxisome via the endoplasmic reticulum (ER) (Baerends *et al*., 1996). It was therefore proposed that PEX3 mediates the early steps of peroxisome formation from the ER (Baerends *et al*., 1996; Kammerer *et al*., 1998; Kunau & Erdmann, 1998; Titorenko & Rachubinski, 1998) and mutations in the *PEX3* gene could potentially interfere with this process. PEX3 has previously been shown to interact with PEX19 and with PEX16 in yeast (Götte *et al*., 1998) and in humans (Soukupova *et al*., 1999; South & Gould, 1999). A *PEX3* mutation might lead to disruption of the interaction between these early peroxins. In yeast, this protein-protein interplay appears to be a prerequisite for generating pre-peroxisomal structures that can acquire and stabilize newly synthesized PMPs (Hettema *et al*., 2000). Thus, a lack of interaction due to a *PEX3* mutation could disturb peroxisomal assembly by leading to degradation or mislocalization of other PMPs.

To address this question, we performed PEX3 interaction studies to see whether a *PEX3* mutation could lead to a disruption of the interaction between PEX3 and PEX19. For this purpose we performed a pull down assay after *in vitro* translation of wild type *PEX3* cDNA and mutated *PEX3* cDNA from patient PBDG-01. In an *in vitro* binding assay we investigated the ability of wild type PEX3 and the truncated PEX3 protein from patient PBDG-01 to bind to an immobilized GST-PEX19 fusion protein (fig. A6-5*B*). Wild type PEX3 eluted from the GST-PEX19 fusion protein yielded a strong signal indicating that wild type PEX3 binds PEX19. However, no signal was detected when the interaction of mutated PEX3 with PEX19

was analyzed despite using an excess amount of mutated protein compared to the wild type protein. *In vitro* translation of the wild type sequence yielded two proteins of differing molecular weight (fig. A6-5*B,C*). To demonstrate that the molecular weight of the lower band in the PEX3 wild type lanes was a result of the utilization of the internal start codon at position 199 of the coding region, we generated a construct lacking the first start codon and the following 63 bp of the *PEX3* gene (Δ66bp). *In vitro* translation of this construct using the internal start codon yields a protein corresponding to the lower band of wild type PEX3 (fig. A6-5*C*). In summary, results of the *in vitro* binding assays reported here are consistent with the hypothesis that the interaction between mutated PEX3 and PEX19 is markedly reduced or absent. While this does not necessarily reflect the situation *in vivo,* the potential functional impairment might contribute to impaired peroxisomal membrane synthesis in cells from patient PBDG-01.

Figure A6-5: PEX3 *in vitro* binding assays. *A*, Schematic diagram of wild type PEX3 and truncated PEX3 of patient PBDG-01. The mutation in PBDG-01 results in a C-terminally truncated PEX3 protein while predicted transmembrane regions (TM) remain unaffected. *B*, Pull down assays of *in vitro* translated PEX3 using immobilized GST-PEX19 were performed as previously described (Gloeckner *et al*., 2000). The left hand gel was loaded with 10% of the ^{35}S-methionine-labelled PEX3 translation products used as input for the binding assays. To ensure that even weak binding of the mutated PEX3 would be detected, the amount of mutated PEX3 was chosen so that it clearly exceeded the amount of wild type PEX3. Wild type PEX3 (wt) was bound by GST-PEX19, whereas no detectable signal was obtained when the interaction of the mutated PEX3 protein (PBDG-01) with PEX19 was analyzed (central gel). GST alone did not bind to either protein (right hand gel). Several repetitions of the assay yielded similar results. *C*, To demonstrate that the molecular weight of the lower band in the PEX3 wild type lanes is a result of the utilization of the internal start codon at position 199 of the coding region, we generated a construct lacking the first start codon and the following 63 bp of the *PEX3* gene (Δ66bp). *In vitro* translation of this construct using the internal start codon yielded a protein corresponding to the lower band of wild type PEX3.

The molecular and biochemical evidence shown here leaves little doubt that *PEX3* mutations are responsible for Zellweger syndrome in complementation group G patients. Both patients display a very severe Zellweger syndrome phenotype with all tested peroxisomal functions being deficient. A correlation between the severity of the clinical phenotype and biochemical activities such as plasmalogen synthesis (Lazarow & Moser, 1995; Roscher *et al*., 1985) as well as the extent of morphological changes such as the number of residual peroxisomes in tissues (Arias *et al*., 1985) has previously been described for PBD patients. Therefore, it is not surprising that we observed a severe clinical phenotype associated with mutations in the *PEX3* gene, which encodes a protein considered to be important in the very early steps of peroxisomal biogenesis.

We have shown that, by expressing wild type PEX3, intact peroxisomes are formed in the *PEX3* mutant cell lines, which had lacked detectable peroxisomal membrane structures. Similar observations have recently been made for human cells bearing mutations in either *PEX16* or *PEX19* (Matsuzono *et al*., 1999; South & Gould, 1999). The combined data provide evidence for the essential role of these three early peroxins in a pathway for human peroxisome formation that does not require morphologically detectable preexisting peroxisomal structures. Besides supplying the basis for molecular diagnostics, the identification of *PEX3* mutations in the human provides an important model for elucidating a fundamental mechanism in human organelle biosynthesis.

Acknowledgements

Electronic-Database Information

Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim (for PBD [MIM 601539], for RCDP [MIM 215100], for *PEX3* [MIM 603164]).

References

The references are listed on pages 38–49.

Table A6-1: Primers for mutation analysis and RT-PCR of the human *PEX3* gene

Method and Exon	Primer Name[a]	Sequence (5'→3')
Mutation analysis		
Exon 1	5'F3	GAGAGCACAGAACGGGACGA
	1R	CTCTACATATCCCAGACTAGG
Exon 2	2FN	CTGTGTAGAATTTTTGGTACTC
	2RN	CAACCGTCAAACAACTTTAC
Exon 3	3F	GACTCTTGCTAGTTGCTAGC
	3R4	CATTGCCTTGAATGCTTTATGC
Exon 4	4FN	CTGCAGTTATGCTGTGTTGC
	4RN	GAGTCATCCTAATAGAATGC
Exon 5	5F	GGATGGTTCATGATTTTACAC
	5R	CATAGAAATTGTTATCAGG
Exon 6	6F	CCCGTCATTTCAGATCTTG
	6R2	GACAGTGATCAATTCTGTCAG
Exon 7	6F	CCCGTCATTTCAGATCTTG
	7R	GTCACTGGTTTCACTAGAAC
Exon 8	8F	GCAGTTACAGGTGTAAGCAG
	8R3	CTTACCTTTCAAGAGACTCAG
Exon 9	9FN	GTTTCATCATAACCCTGTGC
	9RN	CCGACCATGTTGTTCAAG
Exon 10	10F	CAAAGGTAACCACGTTATTACT
	10R2	GTTGTTATCTGGAACAAAAAG
Exon 11	11FN	GTCCTGTGGGGTCATTTCAG
	11RN	CCTCTCAGCAGAGAATGTAAC
Exon 12	12FN	CTTAGAGCTGAATTCATCGC
	1255R	GTATAGGTGATTTACCCAGTG
RT-PCR		
	404F	AGTACTGTGGCTGT
	957R	GAACTCAGCCATATTGTCTAG
	1062R	GATCTGTCCGTTTACTATAGG
	1120R	GCTCCATTGTCAACAGATC

[a] F: forward; R: reverse

Abbreviations

AAA ATPase	ATPases associated with various cellular activities
ABC transporter	ATP binding cassette transporter
ALD(P)	adrenoleukodystrophy (protein)
ALDR(P)	adrenoleukodystrophy related (protein)
CaaX-box	C-terminal farnesylation consensus sequence
CG(s)	complementation group(s)
CoA	coenzyme A
COP	coat protein complexes
DHAP(AT)	dihydroxyacetonephosphate (acyltransferase)
ER	endoplasmic reticulum
GFP	green fluorescent protein
Graf	GTPase regulator associated with focal adhesion kinase
GST	glutathione-S-transferase
HK33	housekeeping gene encoding a 33kDa protein; now termed *PEX19*
IRD	infantile Refsum disease
MCFAs	medium chain fatty acids
NALD	neonatal adrenoleukodystrophy
NBF	nucleotide binding fold
PAS2	*Pichia pastoris* peroxisome-assembly mutant No. 2, now termed *PEX3*
PAS3	*Saccharomyces cerevisiae* peroxisome-assembly mutant No. 3, now termed *PEX3*
PBDs	peroxisomal biogenesis disorders
PBDG-01/02	Zellweger patients 1/2, assigned to CG-G
PER9	*Hansenula polymorpha* peroxisome-assembly mutant No. 9, now termed *PEX3*
PEX	peroxisomal assembly gene
PEX	peroxisomal assembly protein
PEX3	peroxisomal assembly protein 3
PEX19	peroxisomal assembly protein 19
PEX19ΔE2	*PEX19* splice variant lacking exon 2
PEX19pΔE8	*PEX19* splice variant lacking parts of exon 8
PMP69	69 kDa peroxisomal membrane protein
PMP70	70 kDa peroxisomal membrane protein
PPAR	peroxisome proliferator-activated receptor
PMP(s)	peroxisomal membrane protein(s)
PRNK	PYK2-related non-kinase
PTS	peroxisomal targeting sequence
PXA1/2	*Saccharomyces cerevisiae* peroxisomal ABC-transporter 1/2
PxF	peroxisomal farnesylated protein, now termed PEX19
PYK2	proline-rich tyrosin kinase 2
RCDP	rhizomelic chondrodysplasia punctata
SH3	src-homology domain 3
TM(D)	transmembrane (domain)
TPR	tetratricopeptide
Ub	ubiquitin
VLCFAs	very-long-chain fatty acids
X-ALD	X-linked Adrenoleukodystropy
ZS	Zellweger syndrome

Danksagung

List of Publications

Landgraf P, **Mayerhofer PU**, Polanetz R, Roscher AA, Holzinger A (2003). Targeting of the human adrenoleukodystrophy protein to the peroxisomal membrane by an internal region containing a highly conserved motif. Eur J Cell Biol, accepted.

Mayerhofer PU, Kattenfeld T, Roscher AA, Muntau AC (2002) Two splice variants of human PEX19 exhibit distinct functions in peroxisomal assembly. Biochem Biophys Res Commun 291:1180-6

Holzinger A, Maier EM, Buck C, **Mayerhofer PU**, Kappler M, Haworth JC, Moroz SP, Hadorn HB, Sadler JE, Roscher AA (2002) Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency. Am J Hum Genet 70:20-5

Holzinger A, Roschinger W, Lagler F, **Mayerhofer PU**, Lichtner P, Kattenfeld T, Thuy LP, Nyhan WL, Koch HG, Muntau AC, Roscher AA (2001) Cloning of the human MCCA and MCCB genes and mutations therein reveal the molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency. Hum Mol Genet 10:1299-306

Roerig P, **Mayerhofer PU**, Holzinger A, Gärtner J (2001) Characterization and functional analysis of the nucleotide binding fold in human peroxisomal ATP binding cassette transporters. FEBS Lett 492:66-72.

Muntau AC, **Mayerhofer PU**, Paton BC, Kammerer S, Roscher AA (2000) Defective peroxisome membrane synthesis due To mutations in human PEX3 causes Zellweger syndrome, complementation group G. Am J Hum Genet 67:967-75.

Muntau AC, **Mayerhofer PU**, Albet S, Schmid TE, Bugaut M, Roscher AA, Kammerer S (2000) Genomic organization, expression analysis, and chromosomal localization of the mouse PEX3 gene encoding a peroxisomal assembly protein. Biol Chem 381:337-42.

Muntau AC, Holzinger A, **Mayerhofer PU**, Gärtner J, Roscher AA, Kammerer S (2000) The human PEX3 gene encoding a peroxisomal assembly protein: genomic organization, positional mapping, and mutation analysis in candidate phenotypes. Biochem Biophys Res Commun 268:704-10.

Holzinger A, **Mayerhofer PU**, Berger J, Lichtner P, Kammerer S, Roscher AA (1999) Full length cDNA cloning, promoter sequence, and genomic organization of the human adrenoleukodystrophy related (ALDR) gene functionally redundant to the gene responsible for X-linked adrenoleukodystrophy. Biochem Biophys Res Commun 258:436-42.

Holzinger A, Muntau A, **Mayerhofer PU**, Kammerer S, Albet S, Bugaut M, Roscher AA (1998) The mouse gene encoding the peroxisomal membrane protein 1-like protein (PXMP1-L): cDNA cloning, genomic organization and comparative expression studies. FEBS Lett 433:179-83.

Oral Presentations

Mayerhofer PU, Muntau AC, Paton BC, Kammerer S, and Roscher AA (2001) Defective biogenesis of peroxisomal membranes due to mutations in human *PEX3*. FEBS advanced course: Molecular dynamics of membrane biogenesis; Cargèse, Corsica

Citable Abstracts

Holzinger A, Röschinger W, Lagler F, **Mayerhofer PU**, Kattenfeld T, Le Phuc T, Nyhan WL, Koch HG, Muntau AC, and Roscher AA (2002) The molecular basis of 3-methyl-crotonyl-CoA: carboxylase deficiency. 38th Workshop for Pediatric Research; Göttingen, Germany; Eur J Ped 161:R15

Muntau AC, **Mayerhofer PU**, Paton BC, Kammerer S, and Roscher AA (2001) Defective peroxisomal biogenesis due to mutations in human *PEX3*. 37th Workshop for Pediatric Research; Göttingen, Germany; Eur J Ped 160:R21

Holzinger A, Maier EM, Bück C, **Mayerhofer PU**, Haworth JC, Moroz S, Sadler JE, Roscher AA, and Hadorn H-B (2001) Mutations in the proenteropeptidase gene are the primary cause of congenital enteropeptidase deficiency. 37th Workshop for Pediatric Research; Göttingen, Germany; Eur J Ped 160:R24

Muntau AC, **Mayerhofer PU**, Paton BC, Kammerer S, and Roscher AA (2000) Defective peroxisomal biogenesis due to mutations in human *PEX3*. VIII International Congress of Inborn Errors of Metabolism; Cambridge, UK; J Inherit Metab Dis 23, Suppl. 1: 243

Holzinger A, Maier EM, Bück C, **Mayerhofer PU**, Haworth JC, Moroz S, Sadler JE, Roscher AA, and Hadorn H-B (2000) Identification of mutations in the enteropeptidase gene in congenital enteropeptidase deficiency. World Congress of Pediatric Gastroenterology, Hepatology, and Nutition; Boston; JPGN 31, Suppl. 2: S128

Poster Presentations

Mayerhofer PU, Maier EM, Kattenfeld T, Berger J, Roscher AA, and Holzinger A (2001) No evidence for adrenoleukodystrophy-related protein (ALDRP) acting as modifier gene in a large X-linked adrenoleukodystrophy kindred with various phenotypes. 3rd FEBS Advanced Lecture Course: „ATP-Binding Cassette (ABC) Proteins: From Genetic Disease to Multidrug Resistance"; Gosau, Austria

Landgraf P, **Mayerhofer PU**, Roscher AA, and Holzinger A (2001) Identification of a novel peroxisomal targeting motif in human adrenoleukodystrophy protein (ALDP), conserved in humans and yeast. 3rd FEBS Advanced Lecture Course: „ATP-Binding Cassette (ABC) Proteins: From Genetic Disease to Multidrug Resistance"; Gosau, Austria

Mayerhofer PU, Jarrar S, Holzinger A, and Roscher AA (1999) The subfamily of eukaryotic peroxisomal ABC-transporter proteins: Inventory, specific signatures, identification of prokaryotic orthologs or paralogs and phylogeny. 2nd FEBS Advanced Lecture Course: „ATP-Binding Cassette transporters: From Multidrug Resistance to Genetic Disease"; Gosau, Austria

Landgraf P, **Mayerhofer PU**, Roscher AA, and Holzinger A (1999) An N-terminal region of the human adrenoleukodystrophy protein, a peroxisomal ABC transporter, is sufficient for translocation a reporter fusion protein to the peroxisome. 2nd FEBS Advanced Lecture Course: „ATP-Binding Cassette transporters: From Multidrug Resistance to Genetic Disease"; Gosau, Austria

Gloeckner CJ, **Mayerhofer PU**, Holzinger A, Gerber JK, Kammerer S, Adamski J, and Roscher AA (1999) The human adrenoleukodystrophy protein and related ABC-transporters interact with the farnesylated peroxisomal assembly protein PEX19. 2nd FEBS Advanced Lecture Course: „ATP-Binding Cassette transporters: From Multidrug Resistance to Genetic Disease"; Gosau, Austria

Holzinger A, Maier EM, Muntau AC, **Mayerhofer PU**, Berger J, Molzer B, Bernheimer H, and Roscher AA (1999) Genomic organization and mutational analysis of the human gene encoding the adrenoleukodystrophy-related protein (ALDRP) in adrenoleukodystrophy patients. 2nd FEBS Advanced Lecture Course: „ATP-Binding Cassette transporters: From Multidrug Resistance to Genetic Disease"; Gosau, Austria

Muntau AC, Holzinger A, **Mayerhofer PU**, Kammerer S, Roscher AA (1998) Similarities of the primary structure and the genomic organization between the human adrenoleukodystrophy (ALD) gene and the adrenoleukodystrophy-related (ALDR) gene indicate a recent divergence and point to a similar function. International Symposium, CREST Research Conference. Peroxisome: Biogenesis, function and disease; Fukuoka, Japan

Holzinger A, Muntau AC, **Mayerhofer PU**, Kammerer S, Roscher AA (1998) cDNA cloning, expression, and genomic organization of the mouse PXMP1-L gene. International Symposium, CREST Research Conference. Peroxisome: Biogenesis, function and disease; Fukuoka, Japan

Mayerhofer PU, Bronnenmeier K, and Zverlov V (1997) Characterization of Cellobiohydrolase CbhA, a thermostable multi-domain E1-glycosyl hydrolase from *Clostridium thermocellum*. VAAM-Frühjahrestagung; Hamburg, Germany

Curriculum Vitae

Personal

Name:	Peter Uli Mayerhofer
Date of birth:	28TH June 1971
Place of birth	Munich, Germany
Nationality:	German
Civil status	unmarried
Address:	Isener Str. 8
	85570 Markt Schwaben, Germany
	phone +49-8121-229040

Education and Diplomas

1978 – 1981	Primary School Anzing
1981 – 1990	Franz-Marc Gymnasium Markt Schwaben
	(grammar school with special emphasis on mathematics and science)
June 1990	High School degree: Abitur
1990 – 1991	Military service
1991 – 1997	Study of biology at the Technische Universität (TU) of Munich
	Major subjects: Microbiology, Genetics, Immunology, Biochemistry
	Diploma thesis: "*Biochemische und molekularbiologische Charakterisierung der Cellobiohydrolase CbhA aus Clostridium thermocellum.*"
June 1997	Academic degree: Diplom-Biologe Univ.
Since 1998	Ph.D. thesis at the Department of Clinical Chemistry and Metabolism, Molecular Biology Laboratory, Dr.v. Hauner Children's Hospital, Ludwig-Maximilians University of Munich

Work experience

1995 – 1998	MWG-Biotech (Laboratory assistant: Oligonucleotide-synthesis and quality control)

Teaching

Nov. 1996	Elementary practical student course in microbiology; Department of Microbiology, Technische Universität of Munich
Feb. 1997	Advanced practical student course in microbiology; Department of Microbiology, Technische Universität of Munich